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Since the development of antiretroviral medications in the mid-1990s, treatment of 
human immunodeficiency virus (HIV) infection has improved steadily and HIV is now 
considered a manageable chronic condition with improved quality of life for those who are 
medically adherent. However, medication regimens typically require near perfect adherence to 
be effective and people living with HIV/AIDS (PLWHA) may experience a unique set of 
biopsychosocial barriers that limit or inhibit their ability to be medically adherent. The purpose 
of this study was to examine the influence of biopsychosocial factors and motivational 
interviewing on antiretroviral medication adherence in people living with HIV/AIDS (PLWHA). 
Specifically, this study explored how biopsychosocial barriers (i.e., physical health, mental 
health, substance use, housing, transportation, and employment concerns) and motivational 
interviewing predict antiretroviral medication adherence in PLWHA as measured by patients’ 
CD4 count and HIV viral load. 
This study utilized archival data that was collected between July 2013 and July 2016 at 
the Brody School of Medicine HIV Clinic and captured patients’ biopsychosocial barriers, CD4 
count and HIV viral load. A stratified sample of 210 patients was drawn from the archival data 
for this study. Multiple logistic regression analysis showed that patients’ CD4 count cut scores at 
intake made a significant contribution to the prediction of medication adherence as measured by 
PLWHA CD4 count cut scores at week 21, when controlling for patients’ CD4 count cut scores 
at intake. Comparatively, results showed a statistical significance for the barrier substance use 
when examining antiretroviral medication adherence in PLWHA as measured by patients’ HIV 
viral load cut scores at week 21. Further, a non-significant association between patients’ CD4 cut 
scores at week 21 and patients’ HIV viral load cut scores at week 21 in predicting antiretroviral 
medication adherence was found. The results of this study suggest that patients’ starting CD4 
count and substance use are important components that warrant further research for PLWHA. 
Further, this study has implications for healthcare professionals, counselors, and counselor 
educators related to substance use concerns for this specific population. Future research 
exploring substance use treatment and ARV medication adherence in PLWHA is suggested. 
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CHAPTER ONE: INTRODUCTION 
Introduction 
This chapter provides an introduction for the study investigating the influence of 
biopsychosocial barriers to care and the use of motivational interviewing as a treatment modality 
on antiretroviral medication adherence for people living with human immunodeficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS) in a multidisciplinary medical 
healthcare setting. In this chapter the background for the current study, the statement of the 
problem, the study rationale, the research questions, the study significance, the operational 
definitions, and a brief review of the chapter are provided. 
Background to the Study 
The human immunodeficiency virus (HIV) progressively weakens the immune system by 
attacking the body’s natural defense mechanisms. Further, HIV targets cluster of differentiation 4 
(CD4) white blood cells and uses these cells to replicate and spread throughout the body. Cluster 
of differentiation 4 cells are responsible for protecting the body from illness and individuals 
without HIV have a CD4 count of approximately 500 to 1,200 cells in a given sample of blood 
(HIV.gov, 2017e). Once HIV enters the body, the virus begins to attack and destroy CD4 cells. 
As the number of CD4 cells decrease, the risk of seropositive (i.e., HIV-positive) individuals 
becoming sick from opportunistic infections increases (AVERT.org, 2018a). 
Cluster of differentiation 4 count is also indicative of disease progression and suggests 
that individuals with HIV and a CD4 count below 200 have acquired immunodeficiency 
syndrome (AIDS; HIV.gov, 2017b). Individuals with AIDS have the highest risk of dying from 
an opportunistic infection such as tuberculosis (TB) or pneumonia, especially when antiretroviral 
(ARV) medications are not taken. However, modern advances in HIV prevention and treatment 
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(e.g., rapid HIV testing and antiretroviral medications) have dramatically reduced the amount of 
AIDS-related deaths worldwide. However, HIV and AIDS remain a major public health concern. 
Approximately 17 million people worldwide are unaware of their seropositive status, and many 
more do not have access to HIV testing services (HIV.gov, 2017f; Joint United Nations 
Programme on HIV/AIDS [UNAIDS], 2016). 
Prevalence of HIV/AIDS 
HIV/AIDS Worldwide. Scientists believe the origins of HIV can be traced to Kinshasa, 
Democratic Republic of Congo (AVERT.org, 2018c). Specifically, scientists postulate a 
chimpanzee version of the virus called simian immunodeficiency virus was transmitted through 
contact with contaminated chimpanzee blood when humans hunted these primates for meat 
(Centers for Disease Control and Prevention [CDC], 2018g). Since the discovery of HIV in the 
early 1980s, nearly 78 million individuals have been diagnosed (HIV.gov, 2017f; Information 
Evidence and Research, 2016). As of 2014, over 30 million people have died from AIDS-related 
illnesses (World Health Organization [WHO] & Oatway, 2009). Today, more than 36 million 
people are living with HIV/AIDS worldwide (WHO, 2017). 
HIV/AIDS in the United States. Characteristics of what would later be defined as AIDS 
were first seen in the United States in June of 1981 when rare cases of Pneumocystis carinii 
pneumonia (PCP) were reported for five previously healthy young men in Los Angeles (CDC, 
2001). Further, groups of men in New York and California were being diagnosed with an 
aggressive cancer known as Kaposi’s Sarcoma (HIV.gov, 2016). By the end of 1981, among gay 
men, there was a total of 270 reported cases of severe immune deficiency, of which 121 were 
deceased (HIV.gov, 2016). Since then, more than 650,000 people have died of AIDS-related 
illnesses in the United States (AVERT.org, 2018d). Presently, over one million people are living 
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with HIV in the United States (CDC, 2018d). Nationwide there are approximately 50,000 
individuals who receive a diagnosis of HIV each year (CDC, 2018d). 
Compared to global statistics, the United States represents a small portion of the overall 
HIV/AIDS epidemic (AVERT.org, 2018d). Historically, death rates from epidemics are higher in 
areas that are heavily populated as infectious diseases are able to spread quicker and easier when 
people live in close proximity, and the same is true of HIV/AIDS (Dyson, 2003; Population 
Action International, 2011). Worldwide, HIV/AIDS is highly concentrated in urban areas 
(Dyson, 2003). The United States shows a similar trend as states with more urbanized areas 
report a higher prevalence of HIV/AIDS (CDC, 2018h). However, in the United States, the 
prevalence of HIV/AIDS is geographically concentrated in the Northeast and South, which 
includes over half (n = 26) of the states in the country (CDC, 2018h). By 2010, the estimated 
number of people living with HIV/AIDS (PLWHA) was highest in the South as compared to 
other regions in the United States (CDC, 2018h). Additionally, the South accounts for nearly 
half, (49%), of all new HIV infections in the United States (AVERT.org, 2018d). 
HIV/AIDS in North Carolina. According to the 2010 U.S. Census, North Carolina is 
the 10th most populous state in the nation as well as one of the most rapidly growing states 
(North Carolina Department of Health and Human Services [NCDHHS], 2012). North Carolina 
reports having more than 29,000 people diagnosed and living with HIV with nearly five percent 
of these being newly diagnosed cases (NCDHHS, 2017). Furthermore, in 2013 North Carolina 
ranked ninth in the United States for the highest number of HIV diagnoses with more than 1,500 
cases (CDC, 2017a). While geographical location underscores the breadth of the HIV/AIDS 
epidemic, there are certain individuals who are disproportionally affected by HIV/AIDS when 
compared to their counterparts. 
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Special Populations 
Human immunodeficiency virus affects individuals across all sociodemographics. 
However, certain populations are identified as high-risk groups. For instance, a significant 
portion of PLWHA reside in low- to middle-income countries (UNAIDS, 2017). According to 
the World Health Organization (2016), an estimated 2 million of HIV cases are new diagnoses, 
which includes more than 220,000 children aged 15 years old or younger. The sub-Saharan 
African region represents the majority of newly diagnosed HIV cases with close to 26 million 
people living with HIV (WHO, 2017). 
Women, Pregnant Women, and Children. Women, particularly young women and 
adolescent girls, have a disproportionately higher risk of HIV infection than men (AVERT.org, 
2018e). Worldwide, women represent 17.4 million of those living with HIV, with the majority 
(80%) living in the sub-Saharan African region (WHO, 2016b; AVERT.org, 2018e). 
Explanations for these global trends include: (a) lack of education, (b) lack of access to 
healthcare, (c) lack of access to HIV testing and counseling, (d) gender inequality, and (e) 
intimate partner violence (AVERT.org, 2018e).  
In the United States, approximately 25% of people living with HIV are women (CDC, 
2018f). Similarly, women account for 22% of new HIV diagnoses in North Carolina (NCDHHS, 
2016). Women of color, particularly African American and Hispanic/Latina, disproportionally 
represent the majority of women living with HIV in the United States (CDC, 2018f). 
Explanations for trends in the United States parallel the socio-economic and institutional barriers 
seen globally (Henry J. Kaiser Family Foundation, 2014). 
Mother-to-child transmission of HIV occurs when a seropositive mother passes the HIV 
infection to her child during pregnancy, labor, delivery, or through breastfeeding (AIDSInfo, 
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2017). Globally, 1.8 million children (15-years-old and younger) are living with HIV after 
becoming infected by seropositive mothers (HIV.gov, 2017f). Again, most of these children live 
in sub-Saharan Africa (HIV.gov, 2017f).  
In the United States, 73% of children diagnosed with HIV in 2014 acquired the infection 
by mother-to-child transmission (CDC, 2018i). In North Carolina, roughly 400 women of child-
bearing age are diagnosed with HIV (NCDHHS, 2012). In 2007, North Carolina implemented 
preventative measures that required HIV testing for pregnant women at the first prenatal visit and 
in the third trimester, which helps reduce the likelihood of perinatal HIV transmissions 
(NCDHHS, 2012). In 2014, there were no reported cases of mother-to-child transmission of HIV 
(NCDHHS, 2016). 
Gay, Bisexual, and Men Who Report Having Sex with Men (MSM). Gay, bisexual, 
and men who report having sex with men (MSM) continue to experience the greatest prevalence 
of HIV (HIV.gov, 2017g). In 2014, this subpopulation represented an estimated 83% of new HIV 
diagnoses among all males age 13 and older in the United States (CDC, 2018e). One explanation 
for this rate is that approximately 1 in 7 of men falling into this category are unaware of their 
seropositive status (CDC, 2018e). Additionally, African American and Hispanic/Latino gay, 
bisexual or MSM represent a disproportionate number of seropositive individuals (CDC, 2018d). 
For the state of North Carolina, 79% of new diagnoses were among gay, bisexual, and 
MSM adult/adolescent males (NCDHHS, 2012). Most individuals comprising this subpopulation 
acquire HIV through unprotected anal sex with an HIV-positive individual (CDC, 2018e). 
Unprotected anal sex, particularly receptive anal sex, is the riskiest type of sexual behavior 
responsible for the transmission of HIV (HIV.gov, 2017c).  
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Minorities. As previously discussed, individuals of color have higher rates of HIV 
infection in the United States. For example, Hispanics/Latinos represent approximately 17% of 
the total United States population; however, this group accounts for roughly 24% of all new HIV 
diagnoses (CDC, 2018a). Contributing factors of higher HIV prevalence rates in Hispanic/Latino 
communities include: (a) higher rates of other sexually transmitted illnesses (STIs), (b) cultural 
barriers (e.g., stigma, discrimination, language barriers), and (c) structural barriers (e.g., poverty, 
limited access to healthcare, and lower educational level; CDC, 2018a). Specifically, this group 
represents more than 8% of new HIV diagnoses in North Carolina (National Latino AIDS 
Awareness Day, n.d.). 
When compared to other races and ethnicities, African Americans/Blacks represents the 
highest proportion of new HIV diagnoses and persons living with HIV, despite representing only 
12% of the U.S. population (AVERT.org, 2018d; Henry J. Kaiser Family Foundation, 2017). 
Additionally, this population disproportionally represent the largest group of individuals ever 
diagnosed with AIDS (CDC, 2018d). One explanation for this trend is African Americans 
typically have sex with partners of the same racial/ethnic community, which increases the 
likelihood of acquiring the HIV infection with each new sexual partner (CDC, 2018d). In North 
Carolina, the prevalence of African Americans living with HIV is 6.9 times higher for males and 
14.4 times higher for females when compared to their Caucasian counterparts (AIDSVu.org, 
n.d.). 
Age Differences. Similar to trends seen in gender, sexual orientation, and minority status, 
HIV/AIDS is not evenly distributed among age groups. For instance, 670,000 adolescents and 
young people ages 15 to 24 worldwide were newly infected with HIV in 2015 (United Nations 
International Children’s Emergency Fund, 2016). Adolescent girls and young women, 
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particularly those in southern Africa, are disproportionally affected with this group representing 
390,000 cases of new HIV infections in 2015 (UNAIDS, 2016).  
In the United States, 2014 data suggests youth ages 13 to 24 represent 1 in 5 new HIV 
diagnoses (American Foundation for AIDS Research, 2017). Of the United States youth 
diagnosed with HIV, 80% identify as gay/bisexual males with the majority (55%) being 
gay/bisexual African Americans males (CDC, 2018c). Factors contributing to high prevalence 
rates for this age group include lack of sex education, low rates of condom use during sexual 
intercourse, low rates of STI testing, and increased stigma around HIV (CDC, 2018c). 
Due to the advent and use of antiretroviral medications to treat HIV, individuals with 
HIV/AIDS are living longer (AVERT.org, 2018b). Globally, 17% of PLWHA are 50 years of 
age and over, with rates higher in high-income countries that utilize ART to treat HIV 
(UNAIDS, 2016). Interestingly, men account for a higher proportion of PLWHA, despite their 
naturally higher mortality rates (UNAIDS, 2016). Older adults (people age 50 and over) account 
for 17% of new HIV diagnoses (CDC, 2018b). Furthermore, 40% of people in this age group are 
diagnosed with AIDS, suggesting the diagnosis occurs later in the course of their infection 
(CDC, 2018b). One explanation for these trends include the lack of knowledge about HIV of 
older adults compared to their younger counterparts (UNAIDS, 2016). Many older adults are 
sexually active and have the same risk factors for STIs; however, healthcare professionals are 
less likely to discuss sexual activity with this population (CDC, 2018b).  
Worldwide the risk of HIV infection often peaks in adulthood (UNAIDS, 2016). This 
trend is especially true among men, where half of new infections occur in men age 30 to 49 
(UNAIDS, 2016). In 2015, individuals age 25 to 49 represented 60% of the diagnoses of HIV 
infection in the US (CDC, 2017a). As a global trend, rates of new HIV infections have plateaued 
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following a decade of steady decreases for adults aged 25 to 49 (UNAIDS, 2016). This trend is 
attributed to a lack of comprehensive HIV prevention and treatment programs that address 
biopsychosocial barriers such as access to healthcare, gender equality, or stigma of HIV 
(UNAIDS, 2016).  
HIV/AIDS and the Cost to Society 
As previously discussed, many people living with HIV or at risk for HIV lack access to 
prevention, treatment, and continued care (UNAIDS, 2017; HIV.gov, 2017f). Additionally, 
problems arise when the number of individuals in need of HIV treatment services exceeds the 
number of resources available. One report estimates a nine-billion-dollar gap in need versus 
resources to provide HIV treatment (UNAIDS, 2017). Furthermore, there has been a decline in 
donor funding at the global level for HIV/AIDS (AVERT.org, 2017; Henry J. Kaiser Family 
Foundation, 2016). In 2015, funding for global HIV needs decreased by 8% when compared to 
funding provided the previous year (AVERT.org, 2017). In response, many countries are relying 
on governments for domestic funding sources. However, low- and middle-income countries 
where HIV prevalence is the highest, still rely heavily on the support of international donors 
(AVERT.org, 2017). Comparatively, the United States has experienced an increase in federal 
funding in response to the rising financial demands for HIV/AIDS. In 2017, the United States 
appropriated $27.5 billion of an estimated $34 billion budget for domestic HIV efforts (Henry J. 
Kaiser Family Foundation, 2016). Interestingly, in the United States the smallest allocation (3%) 
of overall federal funding budget is for prevention efforts (Henry J. Kaiser Family Foundation, 
2016). 
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HIV/AIDS and Antiretroviral Drugs and Therapies 
Despite HIV prevalence and the cost to society, global and national efforts have increased 
the number of PLWHA receiving HIV/AIDS treatment (CDC, 2017a). According to the CDC 
(2017a) the incidence of new HIV infections in the United States has remained relatively stable 
over the past few years. This is due in large part to the advancements in medications, specifically 
antiretroviral (ARV) drugs, used to treat HIV/AIDS.  
After discovering rare cases of Pneumocystis carinii pneumonia (PCP) and Kaposi’s 
Sarcoma in 1981, scientists began researching ways to cure, what would later be known as HIV 
(HIV.gov, 2016). Though currently no cure exists, researchers have developed a host of ARV 
medications that treat the biological and physical symptoms associated with HIV infection. In 
1986, the first clinical trial of an ARV begins with zidovudine or AZT (Bartlett, 2006). One year 
later, the United States Food and Drug Administration (FDA) approved AZT for the treatment of 
HIV/AIDS (HIV.gov, 2016). Since then, numerous gains were made, which have led to a decline 
in morbidity rates. One such advent is the highly active antiretroviral therapy or HAART, where 
multiple ARV medications are combined to create therapeutic treatment for HIV/AIDS 
(Palmisano & Vella, 2011). Today, more than 25 antiretroviral medications are FDA approved 
and used in the treatment of HIV (AIDSInfo, 2018). 
Antiretroviral medications fall into one of six drug classes and are categorized by the 
mechanisms involved to fight HIV (AIDSInfo, 2018). These six classes include: (a) non-
nucleoside reverse transcriptase inhibitors (NNRTIs); (b) Nucleoside reverse transcriptase 
inhibitors (NRTIs); (c) Protease inhibitors (PIs); (d) Fusion inhibitors (FIs); (e) CCR5 
antagonists (CCR5s or entry inhibitors); and (f) Integrase strand transfer inhibitors (INSTIs; 
AIDSInfo, 2018). While the specific mechanisms are beyond the scope of this discussion, the 
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key takeaway is that each class of drugs works to inhibit the ability of the virus to replicate (U.S. 
Department of Veterans Affairs, 2016). Most of these medications are available in tablet or 
capsule form and several classes can be combined to form multi-class drug combinations (U.S. 
Department of Veterans Affairs, 2016). The United States Department of Health and Human 
Services provides a guideline on the use of ARV with adults and adolescents. Individuals 
initiating antiretroviral therapy (ART) typically begin with three ARVs from at least two 
different drug classes (AIDSInfo, 2018). The most common ART regimen includes the use of 
two NRTIs combined with either an INSTI, an NNRTI, or a pharmacokinetic-enhanced PI 
(AIDSInfo, 2018). Specific benefits associated with the use of ART includes obtaining and 
sustaining viral load suppression, increasing duration and quality of life, restoring and 
maintaining immunologic functioning, and reducing the transmission of HIV (AVERT.org, 
2018b; AIDSInfo, 2018). Failure to adhere to an ART regimen, can reduce the expression of 
benefits, and can lead to negative health effects including having more side effects from ARV 
medications (HIV.gov, 2017a).  
While the ART regimen helps manage the long-term effects of HIV/AIDS, individuals 
may experience adverse (side) effects soon after starting medications (Herrmann et al., 2013; 
Portillo, Holzemer, & Chou, 2007). As with all medicines, some individuals taking ARVs 
experience adverse side effects that may further deter medication adherence. Common adverse 
effects include but not limited to anemia, diarrhea, fatigue, rash, weight loss, as well as nausea 
and vomiting (Reust, 2011; HIV.gov, 2017a). Some individuals may experience more long-term 
adverse effects resulting in additional diagnoses such as insulin resistance, lipid abnormalities, 
and lactic acidosis (HIV.gov, 2017a). 
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There are also drug interactions to consider when using ARVs. Specifically, healthcare 
providers must consider how each drug will affect the other drug’s therapeutic effect (AIDSInfo, 
2018). Examples of medications that have drug interactions with ARVs are cardiac medications 
(e.g., warfarin), psychiatric medications (e.g., Ativan), and anticonvulsants (Reust, 2011). 
Individuals with multiple diagnoses that are treated with medications (e.g., HIV, hypertension, 
and epilepsy) may have more complex medication regimens as they work with their healthcare 
providers to reduce contraindications and adverse effects. 
Typically, adverse medication side effects usually subside after a brief adjustment period, 
which will vary depending on the individual (HIV.gov, 2017a). However, these adverse effects 
and drug interactions may further complicate individuals’ ability to maintain medication 
adherence. Further, ART is a lifelong treatment that requires behavioral changes (e.g., taking 
medications at the same time daily, monitoring and organizing medications) to sustain 
effectiveness (HIV.gov, 2017a). Failure to adhere or stopping treatment suddenly can negatively 
impact individuals’ health and may lead to the development of drug-resistant strands of HIV 
(HIV.gov, 2017a). Finally, there are biopsychosocial challenges that threaten individuals’ ability 
to maintain medication adherence. 
Biopsychosocial Threats to Antiretroviral Medication Adherence  
The following information introduces common biopsychosocial threats to medication 
adherence PLWHA may experience. Specifically, this section explores medical (i.e., physical 
health), mental health, substance use, housing, transportation, and employment concerns.  
Medical. One of the salient challenges PLWHA face relates to physical health concerns. 
People living with HIV/AIDS may experience an array of symptoms depending on where they 
are in disease progression (Portillo et al., 2007). Physical symptoms of PLWHA vary from the 
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primary acute, to chronic asymptomatic, and finally to the severe immune comprised known as 
the acquired immunodeficiency syndrome (AIDS) stage. Some undiagnosed individuals are 
asymptomatic for years and seek medical attention only after severe and persistent, flu-like 
symptoms emerge (Evangelisto, 1996; CDC, 2018g). Other physical symptoms PLWHA may 
experience include pain, fever, constant fatigue, and chronic diarrhea (Evangelisto, 1996; Portillo 
et al., 2007). Research suggests that PLWHA may also encounter neurocognitive changes that 
can result in attention deficits, learning or memory difficulties, and impaired executive and 
motor function (Thames et al., 2012). Individuals that progress to the AIDS stage may encounter 
additional symptoms originating from opportunistic infections such as pneumonia (Portillo et al., 
2007).  
Physical health challenges may be more complicated for marginalized groups (e.g., 
racial/ethnic minorities). As previously discussed, African Americans disproportionately 
represent nearly half of all new HIV diagnoses in the United States (Sankar, Neufeld, Berry, & 
Luborsky, 2011). Additionally, the rate of new HIV infections among Hispanic/Latino is more 
than double for men and nearly four times for women than that of their Caucasian counterparts 
(Robinson, Sanders, & Boyd, 2012). Research suggests that stigma and other social factors such 
as poverty and social inequality contribute to HIV disparities (Buot et al., 2014; Earnshaw, 
Bogart, Dovidio, & Williams, 2013). 
Mental Health. Research shows a high prevalence of mental illness among PLWHA 
(Galvan, Burnam, & Bing, 2003; Whetten et al., 2005). Bing et al. (2001) suggest that prevalence 
rates of depression for PLWHA are two to three times higher than that of the general population. 
Untreated depression can result in suicidal ideations, suicide attempts, and completed acts of 
suicide. Mental health may also be affected by the introduction of HIV/AIDS-related stigma. 
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HIV/AIDS-related stigma is due to the belief that PLWHA are solely responsible for their 
current condition (Hermann et al., 2013). One such example in popular culture is Charlie Sheen, 
who went public regarding his seropositive status. Many people blame Sheen for his status and 
refer to previous behaviors of drug use and promiscuity as explanations for possible exposure 
(Kim, 2015). HIV/AIDS-related stigma can also be internalized. Earnshaw and Chaudoir (2009) 
found that stigma affects PLWHA differently than those without HIV/AIDS. Specifically, 
internalized stigma increases stress, which in turn increases HIV-related symptoms and reduces 
mental health and social supports (Kalichman et al., 2009).  
Substance Use. Many PLWHA may have substance use issues that predate their 
HIV/AIDS diagnosis (Pettinati, O’Brien, & Dundon, 2013; Whetten, Reif, Whetten, & Murphy-
McMillan, 2008). Prevalence rates for substance use among PLWHA vary depending on one’s 
definition, but generally, substance issues are believed to be high (Galvan et al., 2003; Bing et 
al., 2001). As a subpopulation, individuals whose primary means of drug use is intravenous 
injection have higher prevalence rates than those who use substances orally, smoking or inhaling 
(Bing et al., 2001). Additionally, PLWHA with a dual diagnosis of mental health and substance 
use disorders have a lower likelihood of obtaining and taking antiretroviral medication (Whetten 
et al., 2008).  
Housing. Research suggests that individuals who lack stable housing or are homeless 
have higher rates of health concerns, including HIV (Milloy, Marshall, Montaner, & Wood, 
2012). Specifically, PLWHA who are homeless or reside in marginal living conditions are more 
likely to delay initiation of HIV care as well as maintaining access to care (HIV.gov, 2017b). 
Furthermore, the prevalence of HIV for individuals who are homeless/marginally-housed is 
estimated to be five to ten times higher when compared to individuals who have stable housing 
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conditions (Milloy et al., 2012). United States housing experts suggest approximately half of 
PLWHA will need some form of housing assistance at some point after diagnosis (Nussbam, 
2010). This barrier may be particularly true for PLWHA in the Southern region of the United 
States where HIV prevalence is higher (Reif, Golin, & Smith, 2005). The Housing Opportunities 
for Persons with AIDS (HOPWA) program is a federally funded initiative designed to help 
PLWHA address housing needs (U.S. Department of Housing and Urban Development, n.d.). 
Unfortunately, these programs have a limited reach and as Bennett (2010) points out, a housing 
need gap still exists for many individuals, particularly those in the South. 
Transportation. Lack of reliable transportation is another barrier to medication 
adherence for PLWHA. Individuals with HIV/AIDS require regular visits to their primary 
healthcare provider, HIV care provider (if different from primary healthcare provider), and 
dentist (HIV.gov, 2017d). Transportation may be particularly problematic for individuals 
residing in rural areas who commute to the closest town or city to receive services (Ford & 
Spicer, 2012). Additionally, individuals who require wheelchair assistance or a medical transport 
may experience additional barriers when accessing care, as transportation options may be more 
limited due to the nature of their needs (Ford & Spicer, 2012). Furthermore, transportation is 
linked to other barriers to care (e.g., unemployment, unstable housing) suggesting a multifaceted 
challenge to medication adherence (Pellowski, 2013).  
Employment. Another area of financial stability involves employment. Additionally, as 
ART helps PLWHA live longer, there is an increased need to secure employment. Employment 
has many benefits including income, social support, structure and helps PLWHA develop a sense 
of purpose (Basavaraj, Navya, & Rashmi, 2010). A major employment consideration is that of 
health benefits and how these benefits may affect PLWHA’s ability to obtain necessary 
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treatment and medications (Dahlbeck & Lease, 2010). People living with HIV/AIDs may also 
struggle with deciding on whether to disclose their seropositive status to employers and co-
workers. This can become important when PLWHA require a flexible work schedule as they 
may have frequent doctor visits or miss work because of adverse side effects of new medications 
(Dahlbeck & Lease, 2010).  
Addressing Biopsychosocial Threats to Antiretroviral Medication Adherence 
Given the factors associated with antiretroviral medication adherence success and failure, 
PLWHA require a continuum of care to support their ART adherence efforts (AIDSInfo, 2018). 
In response to this need, the National HIV/AIDS Strategy for the United States was developed. 
First introduced in 2010, the five-year National HIV/AIDS Strategy for the United States was 
designed to improve the response to the HIV epidemic (Health Resources and Services 
Administration [HRSA], 2016). In July 2015, these strategies were updated to 2020 and 
identified four primary goals: 1) reduce new HIV infections; 2) increase access to care and 
optimize health outcomes for people living with HIV; 3) reduce HIV-related health disparities 
and health inequities; and 4) achieve a more coordinated national response to the HIV epidemic 
(HRSA, 2016).  
Specifically, goal two identifies a sub-goal to “support comprehensive, coordinated 
patient-centered care for people living with HIV, including addressing HIV-related co-occurring 
conditions and challenges meeting basic needs, such as housing” (The Office of National AIDS 
Policy, 2015). One way to accomplish this goal is through case management. Case management 
entails a client-centered approach that facilitates access to and utilization of an array of 
biopsychosocial supports (Brennan-Ing et al., 2016). For PLWHA, case management can serve 
as a bridge that connects individuals to both HIV and non-HIV related resources (Brennan-Ing et 
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al., 2016). Ultimately, the goal of case management is to encourage and support the independent 
functioning (autonomy) of individuals (New York State Department of Health AIDS Institute, 
2006).  
While a number of HIV case management models exists, the literature supports the 
effectiveness of a strengths-based model (Gardner et al., 2005; Craw et al., 2008, Hoffman et al., 
2017). A strengths-based case management approach allows individuals to identify internal 
strengths and apply these to obtain needed resources (Gardner et al., 2005). HIV specific case 
management sessions focus on establishing a relationship between the case manager and client, 
encouraging regular contact with HIV medical care provider, as well as identifying ways to 
overcome biopsychosocial barriers that hinder access to health care (Ko, Liu, Lai, Pai, & Ko, 
2013). Additionally, using a strengths-based case management model, case managers assist 
individuals in “attaining client-specific goals by self-determination” (Ko et al., 2013, p. 392). 
Theoretical Rationale 
A source of support for PLWHA is a non-judgmental, patient-provider relationship that 
uses motivational approaches to influence positively medication adherence (AIDSInfo, 2018). 
Motivational interviewing is a non-confrontational, client-centered, treatment modality used to 
help individuals make behavioral changes (Rollnick & Miller, 1995). This modality can be 
incorporated into case management establish a foundation of trust and collaboration between 
case manager and client, particularly during the assessment phase (Tahan & Sminkey, 2012). 
Additionally, motivational interviewing has empirical support for its effectiveness in increasing 
motivation with implications of improving medication adherence (Hill & Kavookjian, 2012; 
DiIorio, Resnicow, McDonnell, Soet, McCarty, & Yeager, 2003; Thrasher et al., 2006). 
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Self-determination theory (SDT) is an empirically based theory that explores the 
interplay among motivation, fulfillment of basic human needs and overall wellbeing (Deci & 
Ryan, 1985a). This theory purports people have an innate tendency toward personal development 
and growth, which is achieved along a continuum of autonomy (Deci & Ryan, 1985a). Self-
determination theory introduces a meta-theory that identifies three assumptions related to the 
organismic nature of the theory. Additionally, SDT includes six mini-theories that elaborate on 
the basic human needs and types of motivation. Chapter Two provides a more in-depth 
discussion of SDT and motivational interviewing. 
Statement of the Problem 
Since the development of antiretroviral therapies (ART) in the mid-1990s, treatment of 
HIV infection has improved steadily (AIDSInfo, 2018). With the advent and use of ART, HIV is 
now considered a manageable chronic condition (AIDSInfo, 2018). Continued improvements in 
ARV medications have improved the quality of life and longevity for PLWHA (Basavaraj et al., 
2010; Herrmann et al., 2013). However, most HIV/AIDS medication regimens require near-
perfect (> 95%) adherence in order to be effective (Thames et al., 2012). Furthermore, failure to 
follow adherence recommendations can lead to additional health issues such as the transmission 
of antiretroviral-resistant strands of the virus to sexual partners (Thrasher et al., 2006). 
Nevertheless, less than one-third of PLWHA in the United States have viral load suppression 
(AIDSInfo, 2018).  
A number of factors have been identified as predictors of adherence to ARVs. 
Specifically, patient variables (e.g., those mentioned in threats to medication adherence), clinical 
setting, and the patient-provider relationship, have all be identified as contributing factors to 
adherence (Machtinger & Bangsberg, 2006). As stated previously, a continuum of care is needed 
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to support the individual needs of PLWHA. Providing a continuum of care for PLWHA can be 
accomplished through the use of a multidisciplinary care model (Broeckaert & Challacombe, 
2015). Research suggests PLWHA who obtain additional services (e.g., behavioral health 
services, case management) are up to three times more likely to remain in care than clients who 
do not obtain additional needed services (Broeckaert & Challacombe, 2015). Furthermore, there 
is clinical research that supports the inclusion of a pharmacist as a part of the multidisciplinary 
team to treat PLWHA (Broeckaert & Challacombe, 2015). Finally, fostering non-judgmental and 
supportive patient-provider relationship with the use of motivational strategies can positively 
influence medication adherence for PLWHA taking ARVs (AIDSInfo, 2018). This study 
explores the influence of motivational interviewing as a treatment modality in a multidisciplinary 
HIV/AIDS clinic focused on medication adherence as well as case management of 
biopsychosocial challenges to improve overall medication adherence for PLWHA. 
Research Questions 
This study addressed the following research questions: 
(a) How do biopsychosocial barriers (i.e., physical health, mental health, substance use, 
housing, transportation, and employment) and motivational interviewing predict antiretroviral 
medication adherence in people living with human immunodeficiency virus and acquired 
immune deficiency syndrome as measured by patients’ CD4 count cut score at week 21? 
(b) How do biopsychosocial barriers (i.e., physical health, mental health, substance use, 
housing, transportation, and employment) and motivational interviewing predict antiretroviral 
medication adherence in people living with human immunodeficiency virus and acquired 
immune deficiency syndrome as measured by patients’ HIV viral load cut score at week 21? 
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(c) Is there a statistically significant relationship between patients’ CD4 cut scores at 
week 21 and patients’ HIV viral load cut scores at week 21 in predicting antiretroviral 
medication adherence? 
Definition of Terms 
The following is an alphabetical list of terms relevant to the study.  
1. Acquired Immunodeficiency Syndrome (AIDS). The final stage of HIV infection and is 
signified by a weakened immune system unable to fight off opportunistic infections or cancers. 
2. Antiretroviral (ARV) drugs. The specific medicines designed to treat HIV infection (WHO, 
2013).  
3. Antiretroviral therapy (ART). The use of three or more ARV medicines taken in combination 
to achieve viral suppression. Synonyms are combination ART and highly active ART (HAART; 
WHO, 2013).  
4. Biopsychosocial approach and barriers. An approach which “systematically considers 
biological, psychological, and social factors and their complex interactions in understanding 
health, illness, and health care delivery” (Engel, n.d., para 2). 
5. CD4 cell (T-cell). A type of white blood cell that plays a major role in protecting the body 
from infection. 
6. CD4 count. A lab test that measures the number of CD4 cells in a sample of blood and serves 
as a predictor of HIV progression. The CD4 count of an HIV negative individual in good health 
ranges from 500 cells/mm3 to 1,600 cells/mm3 (HIV.gov, 2017e).  
7. Case management. A “collaborative process of assessment, planning, facilitation, care 
coordination, evaluation, and advocacy for options and services to meet an individual’s and 
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family’s comprehensive health needs through communication and available resources to promote 
quality, cost-effective outcomes” (Case Management Society of America, 2016, para 1) 
8. Human Immunodeficiency Virus (HIV). A virus that affect specific cells of the immune 
system, called CD4 (T-cells), and if left untreated can lead to Acquired Immunodeficiency 
Syndrome (AVERT.org, 2018a). 
9. Medication adherence. Biological markers (CD4 counts, viral load) were used to measure 
medication adherence. Participants CD4 counts and viral load were measured at intake and again 
at week 21 and dichotomized for this study. The dichotomized CD4 counts cut-off scores were: 
≥500 cells/mm3 (1 – immunocompetent) or <500 cells/mm3 (0 – immunocompromised). The 
dichotomized HIV viral loads cut-off scores were: ≥1,000 copies/mL of blood (1 – virologically 
unsuppressed) or <1,000 copies/mL of blood (0 – virologically suppressed). 
9. Motivational interviewing. “A collaborative, goal-oriented style of communication with 
particular attention to the language of change. It is designed to strengthen personal motivation 
for and commitment to a specific goal by eliciting and exploring the person’s own reasons for 
change within an atmosphere of acceptance and compassion” (Miller & Rollnick, 2013).  
10. Viral load. The amount of HIV in a sample of blood. High viral loads indicate that more 
copies of the virus exist in the body and the immune system is not fighting HIV as well 
(HIV.gov, 2017e). 
11. Viral load test. A lab test that measures the number of HIV virus participles, or copies, in a 
milliliter of blood (HIV.gov, 2017e). A viral load test helps monitor the disease, guide treatment, 
and predict disease progression (Vajpayee & Mohan, 2011).  
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12. Viral load suppression. A very low viral load of less than 200 copies per milliliter of blood. 
Individuals with viral load suppression have a significantly reduced likelihood of transmitting 
HIV (HIV.gov, 2017e). 
Justification and Significance of the Study 
The purpose of this study was to explore the influence of biopsychosocial barriers and 
motivational interviewing on antiretroviral medication adherence to improve medication 
adherence for PLWHA. 
Justification 
Literature supports the success of ART for the management of HIV as a chronic illness 
(Palmisano & Vella, 2011). However, research also suggests ART’s effectiveness is contingent 
on a strict medication adherence regimen (HIV.gov, 2017a). To foster medication adherence 
with this population, research encourages the use of non-judgmental, motivational strategies by 
members of a multidisciplinary team. Optimal treatment outcomes (e.g., undetectable viral loads 
of <20 copies/mL and increased CD4 counts of >500 cells/mm3) are linked to medication 
adherence with case management to address biopsychosocial concerns that may pose as barriers 
to HIV/AIDS care (Broeckaert & Challacombe, 2015).  
Significance  
The significance of this study crosscut multiple areas for PLWHA and in the field of 
counseling. Specifically, the information could lend to treatment implications for PLWHA that 
improves their overall wellbeing. Additionally, this study could have training implications for 
use of motivational interviewing with PLWHA at the counselor and counselor education level. 
Finally, the results of this study expand the current body of research on the use of motivational 
interviewing with PLWHA in nontraditional counseling settings. 
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Chapter Summary 
This chapter presented an introduction for the study investigating the influence of 
biopsychosocial barriers as well as the use of motivational interviewing on antiretroviral 
medication adherence for people living with human immunodeficiency virus/acquired immune 
deficiency syndrome (HIV/AIDS) in a multidisciplinary medical healthcare setting. Additionally, 
Chapter One highlighted the prevalence of HIV/AIDS as well as the biopsychosocial of HIV on 
individuals and the community at large. Finally, this chapter provided the statement of the 
problem, research questions, operational definitions, and the study’s significance at multiple 
levels. Chapter Two begins with a discussion of biopsychosocial barriers to medication 
adherence. Chapter Two also provides a review of Motivational Interviewing and Self-
Determination Theory as well as introduce the relevant empirical research related to motivational 
interviewing and medication adherence for PLWHA. 
 
 
CHAPTER TWO: LITERATURE REVIEW 
Introduction 
The previous chapter discussed the use of motivational interviewing as a treatment 
modality to increase antiretroviral medication adherence for people living with human 
immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). Chapter Two 
begins by identifying biopsychosocial barriers that may influence adherence to antiretroviral 
medications for people living with HIV/AIDS (PLWHA). This chapter also contains an 
extensive review of motivational interviewing and self-determination theory, the theoretical 
framework for this study. A review of the literature concerning the application of motivational 
interviewing to improve medication adherence for PLWHA is also discussed. 
Biopsychosocial Barriers to Antiretroviral Medication Adherence 
Achieving adherence to antiretroviral medications (ARVs) is a critical determinant of 
positive long-term health outcomes for PLWHA. However, there are many factors such medical 
(i.e., physical health), social, and the patient-provider relationship, that influence adherence to 
ARVs (AIDSInfo, 2018). Furthermore, non-adherence is often a consequence of individuals 
experiencing one or more biopsychosocial barrier (e.g., gender-specific concerns, age, minority 
status; AIDSInfo, 2018).  
Biopsychosocial barriers can be categorized as either individual or systemic. Barriers at 
the individual level reflect socioeconomic and psychosocial factors such as physical health 
comorbidity, mental health, or substance use concerns (Wawrzyniak et al., 2015). Larger, 
systemic level barriers are those that reflect HIV care systems and include things such as lack of 
transportation, employment status and unstable housing (Wawrzyniak et al., 2015; Colasanti, 
Stahl, Farber, del Rio, & Armstrong, 2017). Individual and systemic barriers can affect retention 
24 
in care for PLWHA. Retention is associated with higher rates of viral suppression as well as 
antiretroviral prescriptions and as a result, PLWHA experience fewer hospitalizations, AIDS-
related illnesses, and have lower mortality rates (Colasanti et al., 2017). Though separate health 
behaviors, retention and medication adherence are interrelated (Holtzman, Brady, & Yehia, 
2015). Specifically, retention in care increases the likelihood PLWHA are prescribed ARVs. 
Furthermore, retention and medication adherence share similar barriers that may affect HIV 
outcomes (e.g., CD4+ count and viral suppression; Holtzman et al., 2015).  
Wawrzyniak et al. (2015) examined how individual and systemic barriers are associated 
with clinic attendance and virologic suppression in PLWHA. Participants (n = 444) were 
recruited from an HIV outpatient clinic in Miami-Dade County, Florida. Participants were 
categorized into one of three categories (regular, irregular, or non-attender) based on their 
number of clinic visits during a one-year period. The final sample consisted of 187 regular 
attenders, 191 irregular attenders, and 66 non-attenders with 80% of the sample representing 
African Americans and 60% of the sample earning less than $10,000 annually (Wawrzyniak et 
al., 2015). 
Participants were administered a questionnaire that captured both individual and systemic 
barriers. Specifically, individual barriers were captured using the Center for Epidemiologic 
Studies Depressive Scale (depression); Life Chaos Scale (stability and predictability); 12-Item 
Short Form Health Survey (perceived health status); Medical Outcomes Study HIV Health Survey 
(quality of life); MOS Social Support Survey (social support); ACTG Adherence Questionnaire 
(medication adherence); Household Food Insecurity Access Scale (food insecurity); Addiction 
Severity Index Lite (drug use); as well as caregiving responsibilities. Systemic barriers (e.g., 
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patient-provider relationship, transportation issues), as well as demographic information (e.g., 
race/ethnicity, gender, education, income), were also collected (Wawrzyniak et al., 2015).  
For each measure, barriers were categorized as either being present or absent. Continuous 
scales and categorical measures with more than one category were dichotomized. Additionally, 
participants’ most recent HIV-1 viral load and CD4 counts were obtained from participants’ 
medical records. Participants with a viral load of <20 copies per milliliters (mL) were classified 
as undetectable (i.e., virologically suppressed).  
Differences between the three attendance groups were compared using ANOVA for 
continuous variables and Chi-square test for categorical measures. Wawrzyniak et al. (2015) 
found that non-attenders were more likely to indicate recent drug use and a lack of money to 
cover medical care and other expenses. At the systemic level, non-attenders were less likely to 
communicate with their HIV care provider and more likely to have transportation issues. 
Wawrzyniak et al. (2015) also compared participants who were virologically suppressed 
(undetectable) to those who were not. Participants who were detectable expressed higher rates of 
depressive symptoms, chaos, recent substance use as well as an overall lower quality of life 
when compared to participants who were undetectable. Additionally, participants who were 
detectable reported a statistically significant lower rate of medication adherence.  
Furthermore, this study explored syndemic barriers. Syndemic refers to the synergistic 
effect of two or more conditions that contributes to the excess burden of disease (Wilson et al., 
2014). Wawrzyniak et al. (2015) found a significant difference between groups in the number of 
individual and systemic-level barriers. Specifically, participants in the non-attenders group had 
significantly more individual-level barriers when compared to regular attenders and significantly 
more systemic-level barriers when compared to regular and irregular attenders. Additionally, 
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participants who were detectable had significantly more individual-level barriers than those who 
were undetectable. 
Both individual and systemic-level barriers were associated were suboptimal clinic 
attendance and viral suppression. However, this study was not without limitations. One 
limitation is that individuals who refused to participate were not included in the study which 
introduces bias, particularly between the regular and irregular attender groups (Wawrzyniak et 
al., 2015). Additionally, this study was conducted at a clinic where patients represent a lower 
socioeconomic status. This population may inherently have more barriers when compared to 
individuals with a higher socioeconomic status limiting the interpretation of the study’s results 
(Wawrzyniak et al., 2015). Though these study limitations exist, this study supports the idea that 
“co-occurring barriers to HIV medical care are additively associated with poorer retention in 
HIV care and increased viral loads…” (Wawrzyniak et al., 2015, p. 9).  
In a similar study, Colasanti and colleagues (2017) used an exploratory study to assess 
individual and structural level barriers that affected retention in care for PLWHA. Participants (n 
= 59) were recruited from one of the largest HIV clinics in the southeastern United States that 
serves predominately minority and socioeconomically disadvantaged individuals. Participants 
were defined as either being continuously retained (attended two scheduled HIV provider visits 
during a 12-month period, n = 32) or unretained (n = 27). Participants grouped into the 
unretained category attended at least one HIV provider visit with a gap of at least seven months 
since their last visit and met one of the following criteria: gap of at least three months for ART, 
single re-enrollment visit during the 12-month period before current gap in care, or history of 
prior gaps (at least 12 months) since initial engagement in care.  
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Participants completed a survey tool that captured demographic information such as 
primary language, gender, race/ethnicity, sexual orientation and highest level of education. The 
survey also included the following scales and screeners: General Self-Efficacy Scale (self-
efficacy); Multidimensional Scale of Perceived Social Support (perceived social support); 
Connor-Davidson Resilience Scale, 2 item (resilience); The NIDA Quick Screen (substance use); 
Alcohol Use Disorder Identification Test (alcohol use); and the Patient Health Questionnaire 
(depression). Finally, the survey asked about unmet needs (e.g., mental health/substance use 
treatment, food), transportation, health insurance status, financial and housing stability (Colasanti 
et al., 2017).  
Colasanti et al. (2017) obtained current HIV-1 RNA level (i.e., viral load) and CD4 
counts from participants’ medical records. This study used a cutoff of <200 copies/mL to 
determine whether participants were virologically suppressed (yes/no). CD4 counts were 
recorded as cells/microliter. Using Chi-square and Mann-Whiney U tests to compare groups, 
differences were found between individuals engaged actively in HIV care versus those that were 
not. Specifically, Colasanti et al. (2017) study reported a higher prevalence of depression and 
alcohol/drug use among unretained participants. Participants in the unretained group also 
reported having more unmet needs (mental health/substance use treatment, housing, financial 
assistance, benefits, food, transportation) when compared to the continuously retained 
participants. Furthermore, unretained participants reported more financial instability (92.6% vs. 
46.9% of continuously retained) and were more likely to not have money to address basic needs 
such as a food or housing (Colasanti et al., 2017). 
One limitation of this study was the small sample size which limits the ability to 
determine the potential additive effects of individual and structural risks factors on retention. 
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Additionally, participants in the unretained group are subject to selection bias because they were 
recruited during re-engagement in care (Colasanti et al., 2017). These participants may not 
reflect the barriers and needs of individuals who are out of care completely. Despite these 
limitations, the study by Colasanti et al. (2017) underscores the need to have a model that 
predicts which patients may have poor retention rates based on individual and structural barriers 
to care. 
Based on the literature introduced in Chapter One and above, the current study explored 
the following six factors: medical (i.e., physical health), mental health, substance use, housing, 
transportation, and employment concerns. Specifically, the current study explored how these 
biopsychosocial barriers predict antiretroviral medication adherence in PLWHA. The next 
section introduces self-determination theory as meta-theory, the six mini-theories of self-
determination theory as well as the extensions and limitations of the theory.  
Self-Determination Theory 
Motivations explain behaviors and reasons to act. Popularized by Edward Deci and 
Richard Ryan (1985), self-determination theory (SDT) is an empirically based theory that 
conceptualizes the fulfillment of the basic human needs and the role of motivation as it relates to 
overall wellbeing. Specifically, SDT introduces an intersection between the concepts of innate 
intrinsic drives and needs as well as extrinsic influences such as external rewards or punishments 
(Kessler, 2013). Self-determination theory provides a meta-theory that describes an organismic 
approach to conceptualizing human motivation along with six mini-theories that further explicate 
intrinsic and extrinsic motivation. 
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Self-Determination Theory’s Meta-Theory 
Self-determination theory is an organismic theory that assumes a holistic perspective and 
explains humans’ active nature and innate tendency towards growth (Brown & Ryan, 2004). 
Notable examples of organismic theories include Kurt Goldstein’s (1939) organismic 
psychology, Jean Piaget’s (1952) theory of cognitive development, and Fritz Perls’ (Perls, 
Hefferline, & Goodman, 1951) Gestalt therapy. 
Underpinning the organismic nature of SDT are three main assumptions. The first claims 
that individuals are not passive agents situated within their environment (Deci & Ryan, 1985a). 
Individuals do not just react to influences; instead, they are able to proactively respond to and act 
on intrinsic or extrinsic forces (Deci & Vansteenkiste, 2004). Autonomy or self-determination, is 
a fundamental concept of SDT that describes individuals’ ability to “act in a volitional manner” 
(Soenens & Vansteenkiste, 2010). Self-determination theory assumes individuals take an active 
role in their lives and participate in different activities that satisfy needs, encourage curiosity, and 
facilitate growth (Vansteenkiste, Williams, & Resnicow, 2012). Intrinsic motivation is one such 
example that demonstrates individuals’ propensity to engage actively in pursuits they find 
inherently stimulating to facilitate growth (Deci & Ryan, 1985a). 
The second assumption of SDT is that individuals naturally desire to grow, develop, and 
function in an integrated manner (Deci & Vansteenkiste, 2004). Drawing from organismic 
theory, SDT supposes that individuals have the capacity to obtain higher levels functioning 
(Sheldon, Williams, & Joiner, 2003b). This inherent tendency to strive for higher levels of 
functioning is an organismic theory concept known as the organismic valuing process. The 
organismic valuing process describes a universal human experience responsible for greater well-
being caused by humans’ social environment that supports opportunities for growth (Brown & 
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Ryan, 2004; Sheldon, Arndt, & Houser-Marko, 2003a). Organismic theory also posits that 
humans inherently know what they need in order to achieve optimal levels of well-being (Brown 
& Ryan, 2004). Again, the social environment plays an instrumental role in supporting or 
weakening humans’ ability to fulfill psychological needs (Vallerand, Pelletier, & Koestner, 2008; 
Brown & Ryan, 2004).  
Finally, the third assumption SDT suggests is that growth tendencies do not occur 
spontaneously; rather, they necessitate the continuous support from social environments 
(Vansteenkiste & Ryan, 2013). Specifically, SDT proposes that social environments should 
facilitate the fulfillment of three basic needs: (a) competence, (b) autonomy, and (c) 
psychological relatedness (Deci & Ryan, 2000). Thus, optimal wellbeing occurs when these 
three needs are satisfied. Conversely, individuals who are unable to fulfill these needs tend to 
have negative biopsychosocial outcomes (Deci & Vansteenkiste, 2004). 
An Overview of Self-Determination Theory’s Mini-Theories 
The six mini-theories – Cognitive Evaluation Theory, Organismic Integration Theory, 
Causality Orientations Theory, Basic Psychological Needs Theory, Goal Content Theory, and 
Relationships Motivation Theory – represents the formal theory of SDT. These mini-theories 
combine decades of research that explain human motivation and personality (Vansteenkiste, 
Niemiec & Soenens, 2010). For parsimony, a review of the mini theories’ concepts relevant to 
the present study is provided. For a comprehensive discussion, see Ryan and Deci’s (2017) latest 
book called Self-Determination Theory: Basic Psychological Needs in Motivation, Development, 
and Wellness.  
Cognitive Evaluation Theory. The cognitive evaluation theory (CET) involves intrinsic 
motivation and specifies the social contexts in which it is influenced (Deci & Ryan, 1985a). 
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Intrinsic motivation describes an inherent drive to participate in activities of interest that afford 
opportunities to master challenges (Deci & Ryan, 1985b). The CET outlines three propositions 
that further describes how intrinsic motivation works. The first proposition suggests that 
individuals have a need to be self-determining or autonomous (Deci & Ryan, 1985a). Deci and 
Ryan (1980) conceptualize this need as individuals’ perceived locus of causality. To expand, the 
perceived locus of causality asks from where (intrinsically or extrinsically) motivations are 
originating. Additionally, this proposition suggests that the presence of external rewards such as 
money reduces or undermines intrinsic motivation (Deci, 1975). 
Deci and Ryan’s (1980, 1985a) second proposition suggests that individuals need to feel 
competent. Essentially, changes in individuals’ perception of their levels of competence can 
influence their intrinsic motivation (Deci & Ryan, 1980). Factors that typically increase 
individuals’ perceived competence include feedback, praise, and self-determination regarding the 
chosen activity (Deci & Ryan, 1980). Likewise, individuals experience perceived incompetence 
when they encounter a task that they cannot master (Deci & Ryan, 1985a). In short, a greater 
perceived competence enhances intrinsic motivation, while perceived incompetence decreases 
intrinsic motivation (Deci & Ryan, 1985a). 
The third proposition of the CET considers the social context of events and introduces 
three aspects, informational, controlling, and amotivating, that are relevant to the “initiation and 
regulation of behavior” (Deci & Ryan, 1985b, p. 111). Informational aspects of social 
environments promote self-determined functioning by providing individuals with choices. This 
aspect enhances intrinsic motivation by fostering an internal perceived locus of causality as well 
as increasing perceived competence (Deci & Ryan, 2002). Comparatively, controlling aspects of 
social environments create an external perceived locus of causality due to pressures that 
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prescribe individuals’ actions, thoughts, and emotions. Because controlling aspects promote 
control-determined functioning, intrinsic motivation is undermined (Deci & Ryan, 1985a). Last, 
amotivating aspects produce a decrease in functioning through perceived incompetence, thus 
undercutting intrinsic motivation and supporting amotivation (Deci & Ryan, 1985a).  
Finally, CET suggests that autonomy and competence work together. Specifically, a 
perception of competence must be accompanied by a sense of self-determination (autonomy) to 
increase or maintain intrinsic motivation (Deci & Ryan, 2000). In sum, CET provides a 
framework that identifies two specific processes, perceived locus of causality and perceived 
competence that can either undermine or enhance intrinsic motivation.  
Organismic Integration Theory. The second mini-theory, organismic integration theory 
(OIT), focuses on extrinsic motivation and the different forms it can assume. Extrinsic 
motivation involves an external motivator and typically serves a purpose (e.g., obtaining 
rewards, avoiding punishments; Kessler, 2013). Organismic integration theory categorizes the 
different forms of regulation within extrinsic motivation as external, introjected, internalization, 
and integrated regulation. Each of these regulations differ on associated processes and perceived 
locus of control (Niemiec & Ryan, 2009). The details of the different forms of regulation are 
explained in detail later in the chapter. 
Causality Orientations Theory. The causality orientations theory (COT) explains 
individuals’ “motivational orientations toward the social world” (Deci & Ryan, 2002, p. 21). 
Deci and Ryan (1985) present three types of causality orientations – autonomy, control, and 
impersonal – that describe individuals’ differences in interpreting or regulating behaviors. 
Simply put, individuals have a primary way in which they initiate or regulate behaviors 
(Deponte, 2004). Causality orientations lie on a continuum of self-determination (Deponte, 
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2004). However, Deci and Ryan (1985b, 1985a), conceptualized each orientation as a separate 
entity that individuals gravitated towards based on their interpretations of initiating or regulating 
behaviors. Causality orientations are learned and cultivated in early childhood. Specifically, the 
environment parents and caretakers provide for their children typically determines how 
individuals develop their causality orientation (Deci & Ryan, 1985a). 
An autonomous orientation occurs when individuals’ choices are based on their interests 
and awareness of psychological needs (Deci & Ryan, 1985a). Individuals with an autonomous 
orientation perceive their behaviors as self-initiated and feel a sense of responsibility for their 
development (Deponte, 2004; Koestner & Zuckerman, 1994). Further, they view initiating or 
regulating events as informational given that these events support their autonomous choices 
(Deci & Ryan, 1985b). In short, individuals with this orientation are more likely to be 
intrinsically motivated and feel that their needs for autonomy and competence are supported with 
minimal to no external rewards (Deci & Ryan, 1985b).  
Individuals with a control orientation perceive rewards as the primary control for their 
choices (Deci & Ryan, 1985b). Control-oriented individuals may feel pressure from their 
environments and are influenced by feelings of guilt, shame, social norms, or cultural values 
(Deci & Ryan, 1985a; Olesen, Thomsen, Schnieber, & Tønnesvang, 2010). When this orientation 
type is dominant, individuals behave in a way that is socially acceptable and extrinsic rewards 
have a more salient role in determining actions (Deci & Ryan, 1985b). Additionally, individuals 
with a control orientation are more likely to view initiating or regulating events as controlling 
(Deci & Ryan, 1985a). 
Finally, the impersonal orientation originates when individuals’ perceive themselves as 
incompetent (Deci & Ryan, 1985a). Individuals develop a sense of helplessness because of a 
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perceived lack of control over internal or external forces (Deponte, 2004). Furthermore, these 
individuals perceive initiating or regulating behaviors as amotivated and are more likely to be 
amotivated themselves (Deci & Ryan, 1985b; Deci & Ryan, 1985a). Specifically, impersonal 
oriented individuals may experience more apprehension about encountering new events and may 
become depressed about their inability to master current challenges (Deci & Ryan, 1985b).  
Basic Psychological Needs Theory. The concept of need satisfaction is explained using 
the basic psychological needs theory (BPNT). This theory clarifies the relationship between 
individuals’ psychological needs and their well-being (Gunnell, Crocker, Wilson, Mack, & 
Zumbo, 2013). Needs are innate, motivating forces that directly affect well-being (Deci & Ryan, 
2002). Well-being describes individuals’ ability to be fully functioning (Deci & Ryan, 2002). 
The BPNT identifies three basic psychological needs – autonomy, competence, and relatedness – 
that are culturally universal and essential for “human thriving” (Chen et al., 2015, p. 217). 
Specifically, SDT defines needs as “innate psychological nutriments that are essential for 
ongoing psychological growth, integrity, and well-being,” (Deci & Ryan, 2000, p. 29).  
Autonomy refers to the feeling of being in control of one’s behaviors (Gunnell et al., 
2013). Self-determination theory posits that fulfilling the need of autonomy promotes better 
overall psychological well-being in individuals (Wichmann, 2011). Additionally, attending to 
this need increases individuals’ ability to better regulate ways in which they behave, think, and 
feel (Deci & Ryan, 2000). Furthermore, supporting autonomous behaviors increases the 
likelihood of integrated regulation occurring (Deci & Ryan, 2000). Competence entails being 
able to effectively deal with one’s environment (Visser, 2010; Kessler, 2013). Autonomy 
involves experiencing novel and challenging activities and being able to master them 
successfully (Kessler, 2013).  
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Like autonomy, competence is integral to the process of internalization (Ryan, Patrick, 
Deci, & Williams, 2008). Competence also plays a role in the integration process, in that 
individuals sustain/maintain behaviors they now value as important (Ryan et al., 2008). Finally, 
relatedness describes individuals’ felt sense of connection and belonging to others (Visser, 
2010). Satisfaction in the need for relatedness encourages internalization of certain values, which 
in turn increases motivation (Niemeic & Ryan, 2009). Collectively, these three factors have 
predictive value in determining the overall wellbeing of individuals as their presence is 
indicative of fulfillment of needs. Failing to address any or all of these needs can lead to a 
decrease in self-motivation (Visser, 2010). 
The BPNT also identifies three parallel social environments that either support or thwart 
the needs of autonomy, competence, and relatedness. Autonomy-supportive environments 
encourage autonomy in comparison to environments that are controlling. Environments that 
provide structure fulfills the need of competence in contrast to social contexts that are chaotic. 
Finally, social contexts that offer warmth and responsiveness, rather than cold and neglectful, 
support the need of relatedness (Vansteenkiste et al., 2010).  
Self-determination theory suggests the more basic psychological needs met, the higher 
optimal functioning individuals experience (Deci & Ryan, 2002). Therefore, if any of these three 
needs are thwarted, individuals can experience threats to their overall well-being. Initially, 
individuals keep pursuing need fulfillment despite repeated experiences of need thwarting 
(Vansteenkiste et al., 2010). Over time, individuals tend to develop maladaptive ways of coping 
when any one of their basic needs are repeatedly thwarted (Deci & Ryan, 2000). Specifically, 
individuals may adopt need substitutes such as material success or social approval, which have 
short-lived effects and fail to satisfy basic psychological needs (Vansteenkiste et al., 2010).  
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Goal Contents Theory. Goal contents theory (GCT) explains how content goals can lead 
to differential outcomes that affect overall wellbeing of individuals (Gunnell, Crocker, Mack, 
Wilson, & Zumbo, 2014). Goals focus on the expectations individuals anticipate in response to 
their participation in activities (Gunnell et al., 2014). Specifically, GCT distinguishes between 
intrinsic goals and extrinsic goals. Content of intrinsic goals include, personal growth, affiliation, 
and community contribution (Deci & Ryan, 2000). Intrinsic goals fulfill individuals’ personal 
interests and generally lead to basic need satisfaction (Sebire, Standage, & Vansteenkiste, 2009; 
Vansteenkiste, Lens, & Deci, 2006).  
Comparatively, extrinsic goals such as recognition and financial success are pursued to 
obtain external indicators of worth (Gunnell et al., 2014). Additionally, extrinsic goals do not 
originate from individuals’ personal interests neither do extrinsic goals contribute to individuals’ 
development (Sebire et al., 2009). Furthermore, GCT posits that the content of goals are 
predictors of behaviors and overall wellbeing with intrinsic goal contents offering more positive 
outcomes such as increased self-determination motivation and overall better wellbeing (Gunnell 
et al., 2014). 
Relationships Motivation Theory. The sixth mini-theory, relationships motivation 
theory (RMT) addresses the concept of relatedness. As previously mentioned, the desire to feel 
connected to others is a basic psychological need that, if unfulfilled, can have detrimental effects 
on individuals. As a result of this fundamental need, individuals actively seek out others to 
experience a sense of belonging (Deci & Ryan, 2014). However, RMT acknowledges that not all 
social interactions result in meaningful exchanges between individuals (Deci & Ryan, 2014).  
To explain this phenomenon, RMT suggests that relatedness alone is not sufficient to 
produce high-quality relationships (Hadden, Rodriguez, Knee, & Porter, 2015). The quality of 
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relationships increases when people concurrently experience satisfaction in their needs for 
autonomy and competence (Deci & Ryan, 2014). To expand, relationship autonomy describes an 
intrinsic desire to be involved in relationships rather than feeling coerced (Hadden et al., 2015).  
Another concept of RMT is autonomy support, which refers to the “extent to which one 
feels that his or her relationship allows him or her to act and choose freely” (Hadden et al., 2015, 
p. 361). Generally, higher quality relationships are seen as having relationship autonomy (i.e., a 
genuine desire to be in relationships) and autonomy support (Deci & Ryan, 2014). 
Additionally, RMT identifies competence support, the extent to which relationships 
“promotes a sense of efficacy and ability” (Hadden et al., 2015, p. 361). Individuals need to feel 
they are useful and contribute positively to relationships. Furthermore, this mini-theory 
underscores the element of mutuality in relationships. In essence, both partners in a relationship 
provide satisfaction of basic psychological needs for the other partner (Deci & Ryan, 2014). 
Mutuality leads to more satisfying relationships for both individuals involved. In sum, the 
highest quality personal relationships are those that support satisfaction for the needs of 
autonomy, competency, and relatedness. 
Extensions of Self-Determination Theory 
Autonomy and Antiretroviral Medication Adherence. The treatment of chronic 
illnesses, like HIV, require long-term pharmacotherapy (i.e., the use of medication(s) to treat 
illness; Brown & Bussell, 2011). However, one of the barriers to chronic illness treatment is 
medication adherence. Research suggests individuals typically take about half of their prescribed 
medications (Brown & Bussell, 2011). Furthermore, research highlights that individuals take less 
than the amount necessary for effectiveness if medication regimens are two weeks or more 
(Dwyer, Levy, & Menander, 1986).  
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Williams, Rodin, Ryan, Grolnick, and Deci (1998) explored long-term medication 
adherence in a study grounded in the application of SDT. Specifically, William and colleagues 
(1998) were interested in the relationship between long-term medication and patients’ 
perceptions of their healthcare providers’ autonomy support. The hypothesis was that patients’ 
medication adherence would be explained by patients’ autonomous motivation. 
 Participants were 126 adults (75% women) from central North Carolina who were taking 
at least one prescribed medication. Additionally, participants had taken their prescribed 
medication for the past month and planned to continue taking medications for another month. 
Participants completed a structured 1-hour interview regarding their health status, medication 
regimen, relationship with medical provider, and adherence to medication regimen. Additionally, 
participants provided subjective ratings of their medication adherence. Finally, a pill count of the 
medication was performed at the initial interview as well as two weeks later during a self-report 
telephone interview (Williams et al., 1998).  
Overall, participants rated themselves as relatively healthy with low severity health 
concerns. Using correlation, logistic regression, and LISERL analyses, Williams et al. (1998) 
found support for the self-determination model of autonomous motivation to increase medication 
adherence. One limitation of this study is the use of a cross-sectional design, which captures a 
specific point in time and may not accurately reflect participants’ long-term medication 
adherence. A second limitation was the use of self-report measures to assess for medication 
adherence. While self-report measures offer quick and inexpensive methods to assess adherence, 
these measures are subjective and may not reflect actual pill-taking behavior. Additionally, the 
sample itself provides a limitation to this study in that those interviewed may not represent the 
general population. Finally, there may be valuable information regarding long-term medication 
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adherence missing from individuals who decide not to participate in this study (Williams et al., 
1998).  
Despite these limitations, a notable strength of this study is Williams et al. (1998) 
supported their initial hypothesis regarding the importance of autonomous motivation and 
perceived autonomy support from medical providers. Additionally, this study found a correlation 
between perceived barriers to adherence and autonomous motivation. Specifically, individuals 
who felt more autonomous had fewer perceived barriers to adherence (Williams et al., 1998). 
Furthermore, the authors stress the incorporation of interventions that focus on strengthening 
patients’ perceived autonomy in their health-related decisions. The purposed study seeks to 
evaluate motivational interviewing effectiveness in supporting participants’ autonomy and 
medication adherence.   
Lynam et al. (2009) further explain the role of autonomous motivation and its prediction 
of antiretroviral therapy (ART) adherence. Using a randomized, controlled trial of ART 
medication adherence, 189 participants were recruited from five clinics that provided HIV 
medical care. To measure adherence, participants received a Mediation Events Monitoring 
System (MEMS®) bottle, an electronic system that measures bottle cap openings. An 
assumption of this system is that each bottle opening of a least five seconds signifies that 
medication is being taken. After one week, data from MEMS® prescription bottles were 
downloaded and used to measure ART adherence (Lynam et al., 2009). 
Path analysis suggests autonomous motivation is associated with ART adherence for 
PLWHA (Lynam et al., 2009). Once again, this supports the importance healthcare providers 
fostering autonomy in their work with PLWHA. However, autonomy is not the only basic need 
to address when considering medication adherence for PLWHA. Lynam et al. (2009) highlighted 
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that autonomous motivation is mediated by self-efficacy, a concept related to competence. The 
next study introduces the concept of competence to the discussion regarding HIV medication 
adherence. 
Autonomy, Competence, and Antiretroviral Medication Adherence. Chapter one 
introduced the effectiveness of ART for managing HIV and reducing the transmission of the 
virus to uninfected partners. Effective ART requires a near-perfect adherence rate and some 
individuals are unable to adhere adequately to their medication regimens. Furthermore, 
individuals on ART can experience a host of biopsychosocial barriers that contribute to poor 
medication adherence. Kennedy, Goggin, and Nollen (2004) built on the work of Williams et al. 
(1998) and explored the interplay between the SDT principles of autonomy support, autonomous 
motivation, and competence to ART adherence.  
Participants for this study lived in a large Midwestern city and were recruited from four 
clinics providing HIV medical services. Eligible participants were 18-years-old or older, on ART 
for at least four months, and independently responsible for taking their medications. A total of 
201 participants formed the study sample (85% male, 1% transgender, 55% Caucasian, average 
age of 40). Participants were given five questionnaires regarding background information, 
perceived autonomy support (Health Care Climate Questionnaire), perceived autonomous 
motivation (Treatment Self-Regulation Questionnaire), perceived competence (single item from 
the Perceived Competence Scale), psychological distress (Profile of Mood States), and current 
symptoms (Signs and Symptoms Checklist for Persons with HIV Disease). Additionally, self-
reported adherence over the past 3 days was assessed via a structured interview. Finally, for a 
small subsample of participants (n = 40), pharmacy refill logs were used to support the validity 
of self-reported adherence (Kennedy et al., 2004).   
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Statistical analysis revealed that autonomy support predicted autonomous motivation for 
medication adherence (Kennedy et al., 2004). Additionally, perceived competence was the 
strongest direct predictor of adherence and collectively, these three principles resulted in greater 
ART adherence. Interestingly, autonomous motivation was not directly related to adherence 
(Kennedy et al., 2004). This bolsters the argument that an identified or integrated form of 
extrinsic motivation, rather than intrinsic, may be driving behavioral changes in individuals. 
Furthermore, this study reports statistical support of a reoccurring theme for PLWHA regarding 
psychological distress being a barrier to medication adherence.  
One limitation of this study is that all measures were self-report, a form of data collection 
subject to ability to recall, bias, and social desirability. Additionally, this study relied on a 
convenience sample of voluntary HIV-positive individuals. While the sample does represent 
individuals from four different clinics, the sample may not adequately reflect the larger 
population of PLWHA, including those out of care (Kennedy et al., 2004). Despite these 
limitations, this study provides the groundwork for SDT’s principles of autonomy and 
competence as related to ART medication adherence. The next study explores the interplay 
between what SDT identifies as humans’ basic psychological needs – autonomy, competence, 
and relatedness. 
Basic Psychological Needs and Antiretroviral Medication Adherence. Sikkema and 
Kelly (1996) suggest that PLWHA who take an active and collaborative role in planning their 
treatment with healthcare provider often feel empowered and have more positive attitudes toward 
HIV medication adherence. Quinlivan et al. (2013) suggest individuals who are aware of their 
HIV-positive status and engage in care use ART more effectively. Quinlivan et al. (2013) apply 
SDT’s basic needs (i.e., autonomy, competence, and relatedness) to the adoption of healthcare 
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behaviors by women of color following an HIV diagnosis. Specifically, this study focuses on the 
three basic needs during HIV testing, entry into and engagement in HIV care.  
Study participants were recruited from an academic Infectious Diseases clinic in North 
Carolina. Participants were mostly African-American women (88%), older than 40-years-old 
(70%), and had an HIV diagnosis for more than six years (87%). Using qualitative interviews, 30 
HIV-positive women of color were asked to describe their experiences with the HIV care system 
at various stages (i.e., the HIV Continuum of Care: testing, entry into care, engagement in care). 
Transcripts from focus groups and individual interviews were reviewed and expressions 
reflecting the SDT basic needs were identified. For example, phrases such as “I feel like giving 
up” or “I chose to…” reflect autonomy related concepts.  
Quinlivan et al. (2013) found that the particular needs were important at different points 
in the HIV Continuum of Care. For instance, during the testing phase, participants demonstrated 
a need for competence in obtaining knowledge about their diagnosis. Furthermore, relatedness 
became more important as participants become increasingly engaged with the healthcare system. 
Finally, autonomy may be absent immediately following diagnosis but develops in tandem with 
relatedness and competence as participants remained in care for HIV treatment (Quinlivan et al., 
2013).  
Quinlivan and colleagues (2013) findings highlight that HIV-positive women of color 
readily expressed the need for autonomy, competence, and relatedness as they participated in the 
HIV system of care. The authors suggest this informs the appropriateness of interventions with 
respects to progress along the HIV Continuum of Care. Additionally, Quinlivan et al. (2013) 
report that motivation was present in 92% of the responses when discussing facilitators and 
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barrier to care. This implies motivation itself plays an important role in individuals’ decision to 
engage and remain in care.  
While the results of this study contribute to the literature regarding self-determination 
theory, motivation, and HIV medication adherence, the study itself is not without limitations. 
Specifically, this study only included women who were currently engaged in care and may not 
capture the experiences of those who are out of care. Additionally, this study used self-report 
data and required participants to reflect on their experiences making this study limited by time 
(i.e., how well they recall experiences; Quinlivan et al., 2013).  
Limitations of Self-Determination Theory 
While SDT provides a prescriptive model on how to motivate others, there are some 
limitations of this theory (Vansteenkiste & Sheldon, 2006). First, SDT was originally developed 
as a way to study intrinsic motivation and early studies focused on educational settings (Patrick 
& Williams, 2012). More specifically, early applications of SDT focused on the relationship 
between motivation and educational outcomes (e.g., do students with more intrinsic motivation 
perform better than those who are more extrinsically motivated; Deci, Vallerand, Pelletier, & 
Ryan, 1991; Vallerand et al., 1992). While SDT has been applied to numerous educational and 
work settings, there is limited applications to therapeutic counseling settings (Vansteenkiste & 
Sheldon, 2006).  
Secondly, this theory assumes that individuals take an active role in their lives and 
possess the ability to decide whether they participate in different activities (Vansteenkiste et al., 
2012). However, this assumption may not apply to everyone as some individuals face constant 
environmental pressures that influence their decision-making abilities (Vansteenkiste & Sheldon, 
2006). Specifically, PLWHA may face a number of individual- and systemic-level barriers that 
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inhibit their ability to fulfill the needs of autonomy, competence, and relatedness. PLWHA may 
be unable to attend to these psychological needs and instead focus on addressing basic human 
needs such as housing. As a result, these individuals may be more likely to experience 
amotivation and have less than optimal overall functioning (Vansteenkiste & Sheldon, 2006).  
Systems of HIV care are encouraged to establish interventions that address multiple 
barriers to help increase engagement in care (Wawrzyniak et al., 2015). One effective 
intervention is strengths-based case management (Hoffman et al., 2017). Through this model, 
individuals can engage in skill-building to address multiple individual-level barriers to care while 
being assisted by a case manager to address larger, system-level barriers (Wawrzyniak et al., 
2015). Motivational interviewing is a treatment modality that can be incorporated into case 
management to facilitate the assessment phase of treatment and establish a supportive and 
collaborative patient-provider relationship to foster engagement in HIV care (Tahan & Sminkey, 
2012). The next section introduces the clinical approach of motivational interviewing and 
provides examples of its utility to facilitate behavioral changes related to health including ARV 
medication adherence. 
Motivational Interviewing 
Motivational interviewing is a client-centered, clinical approach that helps individuals 
explore and address ambivalence about behavioral changes (Miller & Rollnick, 1991). The 
concept of motivational interviewing evolved from experience in the treatment of problem 
drinkers and was first described by Miller (1983). Though atheoretical in nature, motivational 
interviewing is grounded in the works of Carl Roger’s person-centered psychotherapy (Rogers, 
1959). Motivational interviewing combines the warmth and empathy of person-center 
psychotherapy with specific techniques such as reflective listening and development of 
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discrepancy (Treasure, 2004). Additionally, this person-centered approach allows interviewers to 
arrange “conversations so that people talk themselves into change based on their own values and 
interest” (Miller & Rollnick, 2013, p. 4). Specifically, motivational interviewing utilizes a 
collaborative approach that elicits clients’ motivations for behavioral changes, which are then 
reinforced by “strengthening a person’s own motivation and commitment to change” (Miller & 
Rollnick, 2013, p. 12).  
Motivational interviewing assumes that people have a desire to change. However, most 
people experience ambivalence about making desired changes (Miller & Rollnick, 2013). 
Ambivalence is a feeling in which individuals feel two, often competing, ways about a matter 
(Douaihy, Kelly, & Gold, 2015). Ambivalence is a normal part of the process regarding 
behavioral change (Douaihy et al., 2015). Additionally, unresolved ambivalence can serve as a 
barrier to change (Wagner & Ingersoll, 2012). As a result of ambivalence, individuals may 
engage in two kinds of talk, change talk and sustain talk. Change talk refers to individuals’ 
statements in favor of change(s); comparatively, sustain talk describes individuals’ statements in 
favor of maintaining current behaviors (Miller & Rollnick, 2013).  
In response to client change talk or sustain talk, counselors can respond from three core 
communication styles that lie on a continuum (i.e., directing to guiding to following; Miller & 
Rollnick, 2013). A directing communication style places the counselor in the expert role by 
offering advice or instruction (Douaihy et al., 2015; Miller & Rollnick, 2013). Counselors may 
unintentionally assume this communication style when responding to clients from the righting 
reflex. The righting reflex occurs when counselors desire to “fix” areas of concerns for clients 
(Miller & Rollnick, 2013). Motivational interviewing stresses the need for counselors to refrain 
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from responding to the righting reflex as this relies on the use of the unhelpful directing 
communication style (Douaihy et al., 2015).   
Representing the opposite end of the continuum is the following communication style 
which mimics the person-centered approach to counseling (Douaihy et al., 2015). Specifically, 
counselors using this style seek to understand clients and refrain from imposing their own 
thoughts or opinions on clients (Miller & Rollnick, 2013). Finally, the guiding communication 
style is a combination of the two poles, having a balance between being a supportive listener and 
serving as the expert when needed (Douaihy et al., 2015). While all three styles are useful in 
different situations, motivational interviewing relies primarily on a guiding communication style 
as a means facilitate conversations to explore and address ambivalence (Miller & Rollnick, 
2013). 
Spirit of Motivational Interviewing 
Motivational interviewing identifies four interrelated elements that comprise the spirit of 
motivational interviewing: (a) partnership, (b) acceptance, (c) compassion, and (e) evocation 
(PACE) (Miller & Rollnick, 2013).  
Partnership. In motivational interviewing, the therapeutic relationship is a partnership 
that involves a respectful collaboration between counselors and clients (Wagner & Ingersoll, 
2012). Clients are placed in the expert role concerning their lives which establishes a positive 
working relationship between clients and counselors (Miller & Rollnick, 2013). Furthermore, 
counselors’ primary goal is to understand clients’ experiences and perspectives and facilitate 
conversations supportive of behavioral changes (Wagner & Ingersoll, 2012). 
Acceptance. Acceptance is an attitude assumed by counselors that respects what clients 
bring to encounters (Douaihy et al., 2015). Acceptance does not imply that counselors agree with 
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the choices clients’ make. Instead, acceptance incorporates four aspects – absolute worth, 
accurate empathy, autonomy support, and affirmation – that in turn facilitates change (Wagner & 
Ingersoll, 2012). Absolute worth suggests counselors accept the value of clients as human beings 
(Douaihy et al., 2015). In essence, this aspect is similar to the counseling concept of 
unconditional positive regard towards clients. The contrasting view of absolute worth is one of 
judgment, which prevents individuals’ ability to engage in behavioral changes (Miller & 
Rollnick, 2013). 
Accurate empathy describes how counselors assume a genuine interest in learning and 
understanding the ways in which clients perceive their world (Douaihy et al., 2015). Doing so 
allows counselors to validate clients’ unique experiences/perspectives and ultimately increase 
clients’ awareness of themselves (Wagner & Ingersoll, 2012). Miller and Rollnick (2013) point 
out that the “opposite of empathy is the imposition of one’s own perspective, perhaps with the 
assumption that the other’s views are irrelevant or misguided” (p. 18). The practice of 
motivational interviewing underscores the need to avoid dismissing clients’ experiences 
regardless of counselors’ perceived significance (Douaihy et al., 2015). 
Acceptance also involves respecting clients’ right to autonomy. Autonomy affords clients 
with the ability to self-determine (i.e., make choices; Douaihy et al., 2015). Additionally, 
autonomy acknowledges that counselors cannot make clients change their behaviors (Wagner & 
Ingersoll, 2012). Finally, affirmations recognize clients’ strengths and efforts rather than 
focusing on perceived weaknesses (Miller & Rollnick, 2013). Affirmations highlight clients’ 
resiliency and build momentum upon what is working well for them (Douaihy et al., 2015; 
Wagner & Ingersoll, 2012). 
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Compassion. Miller and Rollnick (2013) describe compassion as “a deliberate 
commitment to pursue the welfare and best interests of the other” (p. 20). Compassion is not 
merely an emotional response; rather counselors who exhibit compassion intentionally place the 
clients’ perspectives and welfare ahead of their own (Wagner & Ingersoll, 2012). Motivational 
interviewing discourages its use as a treatment modality for the pursuit of self-interest and 
suggests that doing so in a breach of professional ethics (Miller & Rollnick, 2013; Wagner & 
Ingersoll, 2012). 
Evocation. Lastly, the spirit of motivational interviewing is evocative, in that counselors 
assist clients in exploring how their own experiences and perspectives influence motivation to 
change. Counselors refrain from imposing their opinions and instead use a collaborative 
approach to build upon clients’ intrinsic motivation to elicit behavioral changes (Douaihy et al., 
2015). The motivational interviewing approach is different from traditional medical interviews 
that rely heavily on closed questions and directive communication. The next section explores the 
utility of motivational interviewing to elicit behavioral changes in a health-related context. 
Motivational Interviewing and Behavioral Changes Related to Health 
Originally developed to help individuals with alcohol use concerns, motivational 
interviewing has evolved into a treatment modality with a wide range of applications including 
behavioral changes for issues such as depression (Brody, 2009), dieting (Britt & Blampied, 
2010) and medication adherence (Salvo & Cannon-Breland, 2015). Motivational interviewing is 
also a useful tool in working with individuals with chronic conditions such as hypertension and 
diabetes (Zeligman & Robinson, 2014). Furthermore, there is a body of research that explores 
the influence motivational interviewing has on medication adherence in PLWHA (DiIorio et al., 
2003; DiIorio et al., 2008; Krummenacher, Cavassini, Bugnon, & Schneider, 2011; Murphy, 
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Greenwell, & Hoffman, 2002a; Safren et al., 2001). These studies are discussed in detail later in 
this chapter.  
Central to motivational interviewing is the OARS counseling approach (Miller & Moyers, 
2006). The OARS acronym suggests counselors use: open-ended questions, affirmations, 
reflections or reflective listening, and summaries; doing so, facilitates a healthy therapeutic 
alliance between clients and counselors (Miller & Moyers, 2006). When working with PLWHA, 
counselors ask open-ended questions to explore thoughts and barriers to medication adherence 
(Zeligman & Robinson, 2014). For example, a counselor may use the following question to 
discover adherence concerns, “What types of things prevent you from taking your medications as 
prescribed?” Affirmations can be used to support clients’ willingness to share personal 
information. Sharing medication adherence information can be difficult if the lack of adherence 
is perceived as a failure (Zeligman & Robinson, 2014). Counselors can affirm clients’ strength to 
discuss adherence concerns by making statements such as “I appreciate that you are willing to 
share with me some concerns you are having. I recognize this may have taken a lot of courage to 
share this information with me.”  
Using reflections affords clients the opportunity to explore any ambivalence regarding 
the topic of adherence and to discuss their motivations for change (Zeligman & Robinson, 2014). 
Counselors may choose to reflect the emotional aspects of adherence to create a greater impact. 
For instance, a counselor may state, “You feel angry about the inconvenience of having to take 
medications daily while your family does not share this experience.” Finally, concluding sessions 
with summaries allows the counselor to point out any discrepancies between clients’ goals and 
current behaviors (Zeligman & Robinson, 2014). Additionally, summaries can be used to 
highlight any changes counselors have noticed over the course of their work with clients. Using 
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the OARS counseling approach and incorporating the spirit and principles of motivational 
interviewing (discussed later in the chapter) into therapeutic work with clients can help increase 
medication adherence for PLWHA. 
Miller and Rollnick (2009) report motivational interviewing is not: (a) based on the 
transtheoretical model of change; (b) a decisional balance process; (c) a form of cognitive-
behavioral therapy or client-centered therapy; (d) a technique for tricking individuals into doing 
something; (e) easy to learn; (f) practice as usual; or (g) a comprehensive approach to treatment 
(Miller & Rollnick, 2009). Of most importance to the present study is motivational 
interviewing’s lack of a theoretical framework, which makes motivational interviewing difficult 
to empirically study (Miller & Rollnick, 2009). However, research proposes a possible union 
between motivational interviewing and the empirically based theory known as self-determination 
theory, a concept explored later in the chapter (Markland, Ryan, Tobin, & Rollnick, 2005; Miller 
& Rollnick, 2012; Vansteenkiste & Sheldon, 2006).  
Motivational Interviewing and Antiretroviral Medication Adherence 
Coinciding with the advent of ARVs was the development of strategies that helped 
PLWHA with medication adherence. Again, the effectiveness of ART relies on a high (95%) 
adherence rate as well as maintaining this level adherence over long periods of time. Individuals 
may have trouble maintaining adherence to HIV medications. Thus, researchers have explored 
ways to improve medication adherence to ART. 
Safren et al. (2001) compared two minimal-treatment interventions to increase adherence 
for individuals that had difficulty with HIV medication adherence. Specifically, Safren et al. 
(2001) evaluated two intervention approaches: (a) Life-Steps, a single-session intervention 
combining cognitive-behavioral, motivational interviewing, and problem-solving strategies; and 
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(b) self-monitoring involving the use of a pill diary and an adherence questionnaire. 
Additionally, this study examined specific psychosocial predictors of adherence. Specific 
psychosocial variables included depression, satisfaction with social support (SSQ), punishment 
beliefs about HIV infection, adherence self-efficacy, frequency of alcohol use, and frequency of 
other substances (Safren et al., 2001).  
Participants were recruited from a community health center that served individuals who 
identify as LGBTQ and HIV-positive. A total of 140 participants were selected for inclusion in 
this study, and 84 (76 men) of the participants were included in the psychosocial predictors 
component of the study. The remaining 56 (49 men) individuals from the original sample 
participated in the intervention portion of the study only. Participants completed self-report 
measures at the initial visit and were asked to return twice at 2 and 12 weeks intervals (Safren et 
al., 2001).  
 Safren et al. (2001) found statistically significant relationships between baseline 
adherence and the psychosocial factors of depression, SSQ, punishment beliefs, and adherence 
self-efficacy. These findings lend support to the inclusion of psychosocial variables in the 
present study as they highlight potential barriers to medication adherence. Additionally, 
participants in the Life-Steps intervention demonstrated faster improvement in adherence when 
compared to those in the self-monitoring group (Safren et al., 2001). These results suggest that 
client-centered interventions such as motivational interviewing can be useful for individuals who 
are experiencing medication adherence concerns. 
While the Safren et al. (2001) work yields valuable information to the present study some 
limitations are noted. One limitation is that HIV medication adherence was based on self-report. 
The use of self-report lends itself to potential bias and recall error. Additionally, this study 
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utilizes a small sample size, which limited the statistical power to detect differences between 
groups (Safren et al., 2001).  
In a similar study, Murphy, Lu, Martin, Hoffman, and Marelich (2002b) performed a 
pilot trial which incorporated a multicomponent intervention to improve medication adherence 
for HIV-positive individuals. Participants included 33 HIV-positive individuals with medication 
adherence concerns. Further, participants were assigned to a standard care condition or the 
intervention condition. The intervention included: (a) behavioral strategies, (b) patient 
information, (c) social support and (d) an alternating series of five group and individual sessions 
over the span of seven weeks. Assessments were completed at the initial visit, at post-
intervention (seven to eight weeks after baseline), and 3 months post-intervention. Participants 
were assessed on the following domains: (a) self-report adherence, (b) coping strategies for 
adherence, (c) social support, (d) mental health, (e) depression, (f) health-related anxiety, (g) 
adherence efficacy, and (h) outcome expectancies (Murphy et al., 2002b). 
Like the Safren et al. (2001) findings, participants in the intervention group who received 
behavioral strategies, showed an increase in medication adherence when compared to 
participants in the standard care group (Murphy et al., 2002b). Additionally, those in the 
intervention group had higher self-efficacy in patient-physician communication, social support, 
and acceptance of the need for taking medication despite barriers. These findings support the 
need for a client-centered approach that offers relatedness (patient-physician communication and 
social support) and autonomy (acceptance of the need for taking medications). As in Safren et al. 
(2001) study, a limitation of Murphy et al. (2002b) study was the small sample size. Despite both 
studies limitations, the works of Safren et al. (2001) and Murphy et al. (2002b) begin the 
discussion of incorporating a client-centered, behavioral intervention that includes psychosocial 
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barriers to improve ART medication adherence for PLWHA. The current study explored the 
influence of biopsychosocial barriers on medication adherence. Specifically, this study examined 
the influence of medical (i.e., physical health), mental health, substance use, housing, 
transportation, and employment concerns. 
In another pilot study, DiIorio et al. (2003) used motivational interviewing to “foster and 
support medication adherence among individuals who are starting or changing HAART” (p. 55). 
A total of 20 participants were recruited for this study; each participant was randomly assigned 
to either the intervention or control group. Study measures included the use of the UCSF 
Adherence Questionnaire, the Antiretroviral General Adherence Scale, and two items asking 
how often in the past two weeks and 30 days had individuals missed taking their medications. 
Participants completed pre-and post-assessments concerning medication adherence. 
Additionally, participants in the intervention group completed three motivational interviewing 
sessions with a nurse counselor prior to their follow-up assessment (DiIorio et al., 2003).  
Overall, participants in the intervention group had higher self-reported adherence when 
compared to those in the control group. However, the sample size for this study was small, 
limiting the use and interpretation of the results. Additionally, unlike Safren et al. (2001) and 
Murphy et al. (2002b) studies, participants in this study reported adherence to their medication 
regimens at baseline (DiIorio et al., 2003). Having a sample of individuals who have trouble with 
medication adherence would have strengthens the applications of this study. Another limitation 
was the reliance on self-report measures of medication adherence (DiIorio et al., 2003). Again, 
self-report measures are subject to concerns related to bias and recall. These limitations, 
however, were addressed in DiIorio et al. (2008) follow-up randomized controlled study. The 
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current study utilized a larger sample size as well as incorporated objective measures of 
medication adherence (i.e., CD4 cell count and HIV viral load). 
In the follow-up study by DiIorio et al. (2008), a total of 247 participants were recruited 
from an HIV/AIDS clinic to complete a baseline assessment. Participants were either prescribed 
ART for the first time or changing their medications. All participants were given a MEMS® cap 
to track use of one ART medication in their regimen. To establish a baseline for participants, 
adherence data was collected for three-weeks using the MEMS® cap. Following the three-week 
baseline measurement, participants were randomly assigned to either the intervention (n = 125) 
or control group.  
The intervention consisted of five, individual motivational interviewing sessions provided 
by registered nurses over a three-month period. Participants in the control condition received 
treatment as usual and were provided adherence education by three nurse educators. All 
participants were asked to return monthly to download MEMS® cap data. In addition to 
MEMS®, medical records of participants were reviewed for viral load and CD4 counts. Finally, 
at 3-, 6-, and 12-months, participants completed a questionnaire as well as face-to-face 
interviews regarding medication adherence (DiIorio et al., 2008).  
For this study, 11 nurses were trained in the use of motivational interviewing in a 24-hour 
introductory model. Additionally, nurses completed periodic booster sessions to help reinforce 
motivational interviewing techniques and their use. Nurses recorded motivational interviewing 
tapes, which were then coded for fidelity using a structured coding form. If needed, nurses were 
provided with individualized training to improve their motivational interviewing skills. Overall, 
though, the nurses in this study were adherent to motivational interviewing skills during the 
motivational interviewing sessions (DiIorio et al., 2008).  
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The results of this study suggest that participants in the motivational interviewing 
intervention group were taking their ART medications as prescribed (i.e., in dose and on time; 
DiIorio et al., 2008). These findings support the use of motivational interviewing in increasing 
medication adherence to ART medications. One important finding of this study is that all study 
participants demonstrated some general improvement in their viral load and CD4 counts over the 
course of the study (DiIorio et al., 2008). This may imply some overall improvement in viral 
load and CD4 counts for individuals engaged in HIV treatment. A limitation of this study is that 
the researchers did not limit participants to those who reported experiencing difficulties in ART 
adherence (DiIorio et al., 2008). Dilorio et al. (2008) suggests that doing so may have limited 
their ability to “fully test the usefulness of motivational interviewing in promoting behavioral 
change” (p. 282). The current study included staff trained in the use of motivational interviewing 
with follow-up training and supervision. The final study in this review explores the use of 
motivational interviewing with individuals who have difficulty with HIV medication adherence. 
Krummenacher and colleagues’ (2011) study expands the body of literature on using 
motivational interviewing to improve ART medication adherence with PLWHA. In this 
retrospective study, Krummenacher et al. (2011) analyzed an interdisciplinary HIV-adherence 
program that combined motivational interviewing strategies as well as electronic drug 
monitoring (EDM). For this study, EDM was captured using MEMS® caps. Additionally, this 
study captured participants’ socio-demographics, clinical characteristics (e.g., ART naïve versus 
experience, type of ART medication), viral load, and CD4 cell count (Krummenacher et al., 
2011).  
One hundred and four patients (59% women, 42% black) were included in the study, of 
which 80 individuals were ART-experienced (prior use of ART medications; Krummenacher et 
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al., 2011). Interventions were provided by pharmacists who used organized, semi-structured 
motivational interviews incorporating four axes: (a) cognitive intervention (e.g., beliefs, 
knowledge); (b) motivational intervention (e.g., readiness to engage in treatment); (c) behavioral 
intervention (e.g., daily medication regimen); and (d) affective and social intervention (e.g., 
feelings towards medication adherence, support persons).  
Unlike the other studies mentioned in this review, this study lacked randomization of 
participants in intervention versus control groups (Krummenacher et al., 2011). This limits the 
interpretation of how the HIV-adherence program influences medication adherence. Despite this 
limitation, this study offers some important insights. One unique component of this study is the 
following of HIV medication adherence over a 13-month period and tracking adherence rates 
over time (Krummenacher et al., 2011). Doing so allowed the researchers to track variability in 
medication adherence over time. One important finding was that over time there was a decline in 
execution (i.e., daily intake). This implies that individuals may need long-term support to 
maintain medication adherence. Given this information, the current study followed medication 
adherence over time. Additionally, the current study focused on individuals who were having 
difficulty with medication adherence. Finally, this study uses data collected during routine 
clinical activities providing results from a real-world perspective, like the current study. 
Motivational Interviewing and Self-Determination Theory Conceptual Overlaps 
While self-determination theory offers an empirically supported information concerning 
human motivation, this theory lacks a systematic way of implementing the tenants of SDT into 
practice. Comparatively, motivational interviewing is a specific treatment modality that is 
atheoretical in nature (Miller & Rollnick, 2009). Research suggests that when integrated, SDT 
can offer the theoretical framework that motivational interviewing lacks while concurrently, 
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motivational interviewing can provide a practical application of SDT principles concerning 
motivating therapeutic change (Markland et al., 2005; Vansteenkiste & Sheldon, 2006; 
Vansteenkiste, et al., 2012). 
Vansteenkiste and Sheldon (2006) suggest motivational interviewing and SDT were 
developed as a dissatisfaction with existing frameworks that “de-emphasize the phenomenology 
of the individual (p. 65). Specifically, motivational interviewing was a response to counseling 
approaches that encouraged the use of confrontation such as DiCicco, Unterberger and Mack’s 
(1978) alcoholism intervention strategy. Similarly, early SDT studies provided an alternative 
view to B.F. Skinner’s (1974) operant conditioning and use of positive reinforcement (e.g., 
rewards; Vansteenkiste and Sheldon 2006). Self-determination theory, instead, highlights the 
potential undermining effects of external motivations in the form of rewards (Deci & Ryan, 
1985a). 
Both motivational interviewing and SDT believe that people are capable of making 
changes in their lives (Vansteenkiste & Sheldon, 2006). Further, both theories conceptualize 
humans as active and growth-oriented organisms that have a natural propensity to improve and 
having internal resources to do so (Vansteenkiste & Sheldon, 2006). Additionally, when using 
motivational interviewing counselors encourage and support autonomy, guide the changes 
process, and accept individuals’ worldview (Miller & Rollnick, 2013; Deci & Ryan, 1985b).  
The Role of Satisfying Basic Psychological Needs 
Self-determination theory identified three basic psychological needs – autonomy, 
competence, and relatedness – individuals need for overall wellbeing. As previously discussed, 
the spirit of motivational interviewing has four elements (i.e., partnership, acceptance, 
compassion, and evocation). Additionally, motivational interviewing has four key principles: (a) 
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express empathy, (b) support self-efficacy, (c) roll with resistance, and (d) develop discrepancy 
(Miller & Rollnick, 2002). As Vansteenkiste and Sheldon (2006) suggest, motivational 
interviewing’s four key components can be conceptualized in terms of SDT’s three basic 
psychological needs.  
The first principle, expressing empathy, encourages counselors to engage in perspective 
taking and see “the world through the eyes of the client” (Crowe & Parmenter, 2012, p. 127). 
Using empathy, counselors avoid assuming the expert role and acknowledge the importance of 
clients’ points of view and feelings. Counselors are able to express empathy by using reflective 
listening as a means to demonstrate an understanding of PLWHAs’ worldview (Treasure, 2004). 
This concept aligns with SDT’s need for relatedness, in that a collaborative relationship is 
established in healthy therapeutic relationships (Vansteenkiste & Sheldon, 2006).  
Another principle of motivational interviewing is to support self-efficacy. The intent of 
supporting self-efficacy is to enhance individuals’ self-confidence that change is possible 
(Treasure, 2004). Counselors support self-efficacy by demonstrating the belief in PLWHAs’ 
ability to make behavioral changes (Crowe & Parmenter, 2012). Supporting self-efficacy likely 
satisfies individuals’ need for competence and increases the likelihood of behavioral changes 
occurring (Vansteenkiste & Sheldon, 2006). 
Rolling with resistance is another key principle of motivational interviewing. Moyers and 
Rollnick (2002) conceptualize resistance as “the product of an interaction between the therapist 
and the client” (p. 187). Counselors are encouraged to “sidestep” confrontation that may arise 
from reacting to resistance and instead respond with empathy (Treasure, 2004). Resistance 
becomes problematic when counselors impose their perspectives on individuals, limiting their 
perceived freedom of choice (Crowe & Parmenter, 2012). As such, this principle aligns with 
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PLWHAs’ need for autonomy to make and act upon choices including medication adherence 
(Vansteenkiste & Sheldon, 2006).  
Finally, developing discrepancy helps individuals identify incongruities between their 
current behaviors and their desired goals or values (Moyers & Rollnick, 2002). Exploring 
discrepancy with PLWHA facilitates the process of change (Crow & Parmenter, 2012). From an 
SDT-perspective, this principle also supports clients’ need for autonomy to make changes that 
better align their behavior and values (Vansteenkiste & Sheldon, 2006). In short, the four key 
principles of motivational interviewing have conceptual overlap with SDT’s three basic 
psychological needs in that these principles support the satisfaction of needs. 
The Concept of Motivation as Applied to Medication Adherence in People Living with 
HIV/AIDS 
As mentioned earlier, intrinsic motivation is an inherent desire to participate in activities 
individuals find interesting (Deci & Ryan, 1985a). Deci and Ryan (1980) define intrinsic 
motivation, as “…behaviors that are motivated by the underlying need for competence and self-
determination” (p. 42). A functional definition of intrinsic motivation encompasses individual 
freedom of choice and internal locus of control. More specifically, individuals demonstrate a 
willingness to engage in activities in which they find value (Kessler, 2013). 
Motivational interviewing purports increasing intrinsic motivation to change (Miller & 
Rollnick, 2002). However, given the definition of intrinsic motivation as well as the concept of 
autonomy, which suggests counselors cannot make clients change their behaviors, an increase in 
individuals’ intrinsic motivation may not be what is occurring (Wagner & Ingersoll, 2012). From 
an SDT-perspective, motivational interviewing likely facilitates an identified or integrated form 
of extrinsic motivation (Vansteenkiste & Sheldon, 2006). The following discussion describes 
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different forms of regulation within extrinsic motivation identified in the organismic integration 
mini-theory and provides examples of the current population of study. Figure 2.1 is included to 
provide a visual representation of these concepts. 
Figure 2.1 
The Self-Determination Continuum 
 
Amotivation. The state in which individuals lack cause to act is amotivation (Deci & 
Ryan, 2000). In essence, amotivation is an absence of motivation and represents one end of the 
motivational continuum. Ryan (1995) states “People are amotivated when they do not see action 
as either (a) reliably connected with outcomes (as in helplessness) or (b) viable given perceived 
incompetence or lack of environmental supports” (p. 407). For example, PLWHA may be 
focused on barriers such as housing or employment and not see the connection between taking 
ART. Additionally, individuals may express no desire to take medication if they cannot readily 
identify the health benefits. Other reasons include disinterest in the activity, inability to complete 
tasks, and irrelevance of the activity to individuals (Deci & Ryan, 2000).  
External regulation. External regulation occurs when motivation is contingent upon 
individuals receiving positive reinforcement (e.g., rewards) or avoiding punishments (e.g., 
negative consequences) from an outside source (Kessler, 2013). When rewarded, individuals 
with external regulation perform well. However, if the reward is removed or punishment occurs 



















medications) when incentives such bus passes are provided. However, PLWHA who lack 
reliable transportation may lose interest in achieving treatment goals when incentives are no 
longer available. 
Introjected regulation. According to the organismic integration theory, introjected 
regulation manifests from internal processes (Deci & Ryan, 2000). Specifically, the preservation 
of self-worth and the avoidance of negative feelings drive individuals’ behaviors (Nicholls, 
1984). Therefore, barriers to medication adherence such as mental health concerns (e.g., anxiety 
or depression) and substance use issues may exacerbate negative feelings (i.e., guilt, shame, 
embarrassment, or anxiety) leading to decreased feelings of self-worth and resistance to 
medication adherence.  
Identification regulation. Unlike, introjected regulation, identification regulation 
originates due to the need for competence (Beasley & Garn, 2013). That is, behaviors are not due 
to reward-seeking behavior, avoidance of punishment, sublimation of negative emotions, or 
enjoyment and pleasure (Beasley & Garn, 2013). Instead, motivation occurs when individuals 
are able to connect with the personal importance of a behavior and perceive behaviors as their 
own (Deci & Ryan, 2000). Consequently, individuals may experience competing priorities 
between their choices and that of their healthcare providers. For example, patients may prioritize 
environmental stability (e.g., stable housing and employment) over medication adherence. 
Integrated regulation. Individuals display integrated regulation once they assimilate the 
values derived from identification regulation into their self-concepts (Deci & Ryan, 2000; 
Kessler, 2013). Integrated regulation is also the most autonomous version of extrinsic motivation 
(Kessler, 2013). Additionally, integrated regulation share characteristics of intrinsic motivation 
but remains an extrinsic form of motivation because motivations to engage in behaviors do not 
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originate from the self as in intrinsic motivation (McLachlan, Spray, & Hagger, 2011). 
Integration happens when behaviors are congruent with individuals’ values and personal needs 
(Deci & Ryan, 2000). For example, individuals take their medications regularly because doing so 
aligns with their personal belief system regarding health and wellbeing. Most importantly, these 
individuals do not feel any negative feelings associated with their decisions. However, if an 
individual’s physical health is compromised and attending to medical concerns (e.g., taking 
medications, keeping appointments) becomes too difficult, this too can pose a barrier to 
medication adherence. 
It is important to note that neither the continuum nor the subtypes of extrinsic motivation 
represent a linear track through which individuals’ progress. For example, a person can express 
amotivation and remain there even when rewards or punishments are introduced (Deci & Ryan, 
2000). Additionally, individuals may begin an activity out of obligation (e.g., leading HIV peer 
support groups) and continue to do so because they enjoy the activity (e.g., helping others). In 
sum, motivational interviewing does not influence individuals’ intrinsic motivation; rather 
motivational interviewing works to promote the internalization of the most autonomous form of 
extrinsic motivation (i.e., integrated).  
Conclusions from Reviews 
The collective research reviewed in chapters one and two suggests that antiretroviral 
therapy (ART) is effective in reducing morbidity and mortality from HIV and AIDS-related 
concerns as well as decreasing the transmission of HIV to uninfected individuals. However, ART 
regimens typically require a near perfect adherence to be effective. Individuals with HIV/AIDS 
may experience a unique set of biopsychosocial barriers that limit or inhibit their ability to take 
ART as prescribed. A host of research supports the use of motivational interviewing in a variety 
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of clinical settings to increase HIV medication adherence. Additionally, the literature identifies 
many of the biopsychosocial barriers that impede medication adherence. However, few studies 
have explored the use of motivational interviewing to increase medication adherence while 
simultaneously addressing barriers to adherence. The present study explores the intersection of a 
multidisciplinary team utilizing motivational interviewing strategies and techniques while 
concurrently addressing the biopsychosocial barriers that may inhibit medication adherence.  
Chapter Summary 
This chapter provided a discussion of common biopsychosocial barriers to antiretroviral 
medication adherence and identified those barriers used in the current study. Additionally, 
Chapter Two offered a review of motivational interviewing and self-determination theory as well 
as introduced the relevant empirical research related to motivational interviewing and medication 
adherence for PLWHA. Chapter Three introduces research design, population, sample, data 
analysis as well as the materials and instrumentation for this study. 
 
 
CHAPTER THREE: METHODS 
Introduction 
This chapter provides an overview of the methods for the study investigating the 
influence of biopsychosocial factors and motivational interviewing on antiretroviral medication 
adherence for people living with human immunodeficiency virus (HIV) and acquired immune 
deficiency syndrome (AIDS) in a multidisciplinary medical healthcare setting. In this chapter the 
research questions, population, sample, research design, as well as the materials and 
instrumentation are provided. Additionally, this chapter presents multiple logistic regression, the 
statistical analysis used to examine the data. Finally, the ethical considerations of the study are 
discussed. 
Research Questions 
This study examined the influence of biopsychosocial factors and motivational 
interviewing on antiretroviral medication adherence in people living with HIV/AIDS (PLWHA). 
This study addressed the following research questions: 
(a) How do biopsychosocial barriers (i.e., physical health, mental health, substance use, 
housing, transportation, and employment) and motivational interviewing predict antiretroviral 
medication adherence in people living with human immunodeficiency virus and acquired 
immune deficiency syndrome as measured by patients’ CD4 count cut score at week 21? 
(b) How do biopsychosocial barriers (i.e., physical health, mental health, substance use, 
housing, transportation, and employment) and motivational interviewing predict antiretroviral 
medication adherence in people living with human immunodeficiency virus and acquired 
immune deficiency syndrome as measured by patients’ HIV viral load cut score at week 21? 
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(c) Is there a statistically significant relationship between patients’ CD4 cut score at week 
21 and patients’ HIV viral load cut score at week 21 in predicting antiretroviral medication 
adherence? 
Population and Sample 
The population of this study included individuals who were clinically diagnosed with 
HIV/AIDS. The sample included residents of eastern North Carolina (ENC) who were clinically 
diagnosed with HIV/AIDS and receiving HIV/AIDS treatment from East Carolina University – 
Brody School of Medicine HIV Clinic. Patients were eligible for study inclusion if they were: a 
resident of Eastern North Carolina, clinically diagnosed with HIV/AIDS, eligible for outpatient 
treatment services at the ECU BSOMHIV Clinic, currently receiving HIV/AIDS treatment from 
the ECU BSOMHIV Clinic, 18 years old or older, currently living, not currently incarcerated, 
and psychiatrically stable. Patients were ineligible for study inclusion if they were: not or no 
longer a resident of Eastern North Carolina, not clinically diagnosed with HIV/AIDS, not 
eligible for outpatient treatment services at the ECU BSOMHIV Clinic, currently receiving 
treatment from the ECU BSOMHIV Clinic for a single health condition other than HIV/AIDS 
(e.g., Hepatitis C only), younger than 18 years old, currently deceased, currently incarcerated, 
and psychiatrically unstable. Patients chosen to be in the sample were assumed to be 
representative of the population, strengthening external validity. 
A stratified sample of 210 patients was drawn from the archival data for this study. 
Stratified sampling is a form of probability sampling that consists of subgroups, or strata (Ary, 
Jacobs, Sorensen, & Razavieh, 2010). The strata for this study included the years before, during, 
and after the implementation of motivational interviewing at the BSOMHIV Clinic. The three 
strata of this study were: Strata 1: August 2013 – July 2014, Strata 2: August 2014 – July 2015, 
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and Strata 3: August 2015 – July 2016. A random sample of equal size (n = 70) was chosen from 
each stratum. The rationale for using a stratified, random sampling was to study the differences 
that might exist between subgroups of the study’s population (Ary et al., 2010). Using stratified 
sampling ensures representation of different strata when compared to simple random sampling 
because it reduces the likelihood that certain strata may by chance be under- or overrepresented 
in the sample. 
Research Design 
This study was a secondary analysis of clinical data routinely collected through a health 
behavior questionnaire at a multidisciplinary HIV treatment clinic in eastern North Carolina. 
Specifically, this study was interested in comparing patients’ antiretroviral (ARV) medication 
adherence before and after an organizational adoption of motivational interviewing to help 
identify biopsychosocial barriers to and increase motivation for ARV treatment adherence. 
Procedures – Motivational Interviewing Training 
The study utilized data collected from a Ryan White – Part D Supplemental grant-funded 
project instituted by the East Carolina University (ECU) – Brody School of Medicine HIV 
Program. This project, known as Project CARE, was developed to train clinic staff involved in 
treatment adherence in the use of motivational interviewing techniques (MIT). The intended goal 
of this project was to teach clinic staff how to integrate MIT into daily interactions with patients, 
to identify biopsychosocial barriers, and to increase patient motivation for ARV medication 
adherence. 
From August 2014 to June 2015, motivational interviewing trainings were provided on-
site at the Brody School of Medicine HIV (BSOMHIV) Clinic. Trainings were facilitated by two 
Motivational Interviewing Network of Trainers (MINT) certified trainers from ECU’s 
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Department of Addictions and Rehabilitation Studies. A variety of team members from the 
BSOMHIV Clinic (e.g., medical case coordinators, behavioral health specialist, medication 
adherence clinical pharmacist, nurses) were trained over a one-year span. For this study, only the 
data from the medical case coordinators was examined because they were responsible for 
administering the Annual Risk Assessment Screening Tool (described below). Medical Case-
Coordinator had a bachelor degree in social work or psychology. 
The training module for the CARE program included a traditional two-day, introduction 
to motivational interviewing components to develop proficiency in the use of motivational 
interviewing skills. Team members also participated in Learning Community groups, which were 
designed to provide continuous learning, skill building, and coaching facilitated by the two 
certified trainers (Appendix A). For the Learning Communities, the two certified trainers 
identified two team members to co-lead each session. The two designated team members 
demonstrated proficiency in the use of motivational interviewing following the two-day 
introductory course. 
Additionally, team members submitted monthly recordings of interactions with clients 
that were later coded for motivational interviewing skill proficiency. Motivational interviewing 
skill proficiency of clinic staff was assessed using the Motivational Interviewing Treatment 
Integrity (MITI) 3.0 coding system. Tapes were coded by a doctoral student who was trained by 
the two Motivational Interviewing Network of Trainers (MINT) certified trainers from ECU’s 
Department of Addictions and Rehabilitation Studies. Individualized motivational interviewing 
proficiency feedback was provided to team members and areas of deficiency were remediated 
one-on-one with team members and team leads. 
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Procedures – Data and Data Collection 
Archival data is defined as “data that have already been collected by an agency or 
organization and are in their records or archives” (Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2017, “Data Collection Methods: Pros and Cons,” para. 1). Benefits 
of using archival data includes low cost, large sample sizes, and good to moderate validity 
(Anglin, Reid, Short, Zachary, & Rutherford, 2017; SAMHSA, 2017). Another advantage of 
using archival data is the availability of longitudinal data (Shultz, Hoffman, & Rieter-Palmon, 
2005). This study utilized archival data of patients’ CD4 count and HIV viral load to examine the 
influence of biopsychosocial factors and motivational interviewing on antiretroviral medication 
adherence in PLWHA. 
The data used was collected between July 2013 and July 2016 at the BSOMHIV Clinic. 
Data for analysis was obtained from patients’ electronic health records through retrospective 
chart reviews and entered into SPSS software package version 24 with identifying information 
removed. Figure 3.1 outlines the Treatment as Usual Procedure, which describes the typical 
progression of patients starting at the intake process, to medication initiation, and finally to 
medication adherence. For the purpose of this study, specific variables of interest for analysis 
included: patients’ biopsychosocial factors captured by the Annual Risk Assessment Screening 
Tool at intake (Week 1) and patients’ CD4 count and HIV viral load captured at 21 weeks post-
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Materials and Instrumentation 
Treatment as usual included the administration of the Annual Risk and Assessment 
Screening Tool (Appendix B) and the collection of patients’ current viral load and CD4 count at 
intake. Twenty-one weeks post intake, patients’ viral load and CD4 count were reexamined to 
compare medication adherence over time.  
Annual Risk Assessment Screening Tool 
The Annual Risk Assessment Screening Tool is a multidimensional screener utilized by 
medical case coordinators (MCCs) during participants’ initial intake session. This tool addresses 
the following domains: (a) basic demographic information (e.g., gender, race, age), (b) Ryan 
White/ADAP Eligibility, (c) Health Education, (d) Medical Care Coordination, and (e) 
Behavioral Health Services. 
Ryan White/ADAP Eligibility. The Ryan White/ADAP Eligibility section captures 
information regarding the Ryan White application, current insurance type, annual income, 
primary care services for HIV, and current housing situation (i.e., stable, unstable, or unknown). 
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Health Education. The Health Education section begins with the highest level of 
education achieved. This question is followed by a brief self-report literacy assessment. 
Participants rated themselves on how well they believe they read and write (1 = not very well to 
5 = very well). Participants are then instructed to identify seven medical terms (menopause, 
antibiotics, exercise, jaundice, rectal, anemia, and behavior) using the Rapid Estimate of Adult 
Literacy in Medicine-Short Form (REALM-SF). The REALM-SF is a 7-item tool that measures 
health literacy based on word recognition of the aforementioned medical terms (Arozullah et al., 
2007).  
Medical Care Coordination. The Medical Care Coordination section explores the 
domains of intimate partner violence, HIV diagnosis history, medication adherence history, and 
barriers to care. Specific barriers to care of interest in this study include: (a) medical (i.e., 
physical health), (b) mental health, (c) substance use and co-morbid concerns, (d) lack of 
housing, (e) lack of transportation, and (f) lack of employment/underemployment. 
Behavioral Health Services. The Behavioral Health Services section assesses patients’ 
mental health and substance use concerns. Specifically, this section incorporates the Patient 
Health Questionnaire for Depression and Anxiety (PHQ-4; Löwe et al., 2010), the Drug Abuse 
Screening Test (DAST-10; National Institute on Drug Abuse [NIDA], n.d.; Evren et al., 2013), 
and the Fagerström Test of Nicotine Dependence (Korte, Capron, Zvolensky, & Schmidt, 2013). 
These screeners are used by medical case managers to determine whether patients may require 
behavioral health services for co-morbid mental health and/or substance use concerns. 
CD4 Count 
The CD4 T lymphocyte (CD4) cell count is one of the two markers used to detect 
patients’ response to antiretroviral treatment (AIDSInfo, 2018). In general, the CD4 count of 
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seronegative individuals in good health ranges from 500 cells/mm3 to 1,600 cells/mm3. 
Monitoring patients’ CD4 count is important because it is an indicator of overall immune 
function in PLWHA (HIV.gov, 2017e). Additionally, this laboratory test is the strongest 
predictor of HIV disease progression (AIDSInfo, 2018). For instance, one of the qualifications 
for a diagnosis of stage 3 of HIV infection (AIDS) in PLWHA is a CD4 count of fewer than 200 
cells/mm3 (HIV.gov, 2017e). In monitoring patients’ immunologic response to ART, patients 
who adhere to their medication regimens have an increase in CD4 count from 50 to 150 
cells/mm3 during the first year, with the most significant changes occurring within the first 3 
months of treatment (AIDSInfo, 2018). In this study, CD4 counts with a count of >500 
cells/mm3 will reflect antiretroviral medication adherence. 
Viral Load 
Viral load testing is an objective measure that uses a blood sample to determine the 
number of HIV viral copies in a sample of blood (WHO, 2013). Viral load testing is the gold 
standard used to determine the effectiveness of antiretroviral medications for PLWHA 
(UNAIDS, 2016). Generally, a score of 400 copies or less of HIV viral load per milliliter of 
blood sampled is desired (Holstad, DiIorio, & McCarty, 2011). At this cutoff, viral levels are 
considered suppressed, which means there is an insignificant amount of viral copies of HIV in 
the blood (UNAIDS, 2016). PLWHA who are considered virologically suppressed have a low 
risk of transmitting the virus and typically have high medication adherence rates. Due to the 
objective nature of this test, HIV viral load has high reliability and validity. However, there is no 
set cut point for viral load as clinics establish different standards for suppressed viral loads 
(Holstad et al, 2011). For example, the BSOMHIV Clinic’s set cut point for viral load is < 20. 
However, this study chose to use the World Health Organization’s threshold of 1,000 copies/mL 
72 
to be inclusive of global, national, and BSOMHIV clinic’s standards (WHO, 2016a). For this 
study, HIV viral loads <1,000 copies/mL will indicate antiretroviral medication adherence.  
Statistical Analyses 
For this study, data was analyzed using the statistical software package, SPSS version 24. 
Descriptive statistics such as skewness, standard deviation, and range for the sample, predictor 
variables, and outcome variables are provided. Correlation between predictors was analyzed to 
determine if multicollinearity had an effect on analysis results. 
Two multiple logistic regression analyses were used to determine how biopsychosocial 
barriers and motivational interviewing predict antiretroviral medication adherence in PLWHA as 
measured by patients’ CD4 count and HIV viral load. Multiple logistic regression is used to 
analyze data in which there are two or more predictor variables that determined the outcome 
(Moore, McCabe, Craig, 2009). For this study, individual predictor variables were categorical 
and included: physical health (comorbidity or no comorbidity), mental health (comorbidity or no 
comorbidity), substance use (comorbidity or no comorbidity), housing (stable or unstable), 
transportation (reliable or unreliable), and employment (employed or unemployed). These 
predictors were used in both multiple logistic regression analyses. Motivational interviewing 
(before program implementation or after program implementation) was an additional predictor 
variable for both multiple logistic regression analyses. Finally, to control for differences in 
patients’ intake CD4 count and viral load cut scores, a second multiple logistic regression model 
will be performed adding patients’ CD4 count cut scores and patients’ viral load cut scores, 
respectively. An α = 0.05 was used to determine statistical significance for all tests, which is 
reported as a customary alpha level for social science research (Witte & Witte, 1997). 
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In logistic regression, the outcome variable is dichotomously coded as either 1 (e.g., true, 
present, success) or 0 (e.g., false, absent, failure; Moore et al., 2009). Dichotomous cut-off scores 
for this study aligned with global, national, and BSOMHIV Clinic’s standards. Specifically, 
dichotomous CD4 counts cut-off scores were: ≥500 cells/mm3 (1 – immunocompetent) or <500 
cells/mm3 (0 – immunocompromised). Dichotomous HIV viral loads cut-off scores were: >1,000 
copies/mL of blood (1 – virologically unsuppressed) or <1,000 copies/mL of blood (0 – 
virologically suppressed).  
Because multiple logistic regression uses maximum likelihood estimation, larger sample 
sizes are needed in comparison to multiple regression that uses ordinary least squares. One rule 
of thumb suggests having a minimum of 20 cases per independent variable after controlling for 
missing data (Garson, 2016). Given the seven independent variables in this study (i.e., physical 
health, mental health, substance use, housing, transportation, employment, and motivational 
interviewing), a minimum of 140 patients was needed to meet the recommendations for sample 
size in multiple logistic regression analyses. Because the presence of small or empty cells may 
cause the model to become unstable and in turn affect interpretation, the sample size was 
increased to 210. Crosstabs were conducted to assure all cell frequencies were ≥ 1 and 80% or 
more of cells are > 5 (Garson, 2016). 
The Hosmer-Lemeshow (H-L) goodness of fit test is the recommended test to determine 
the overall fit of multiple logistic regression models. The H-L goodness of fit tests divides 
responses into approximately ten equal groups based on predicted probabilities. This test then 
computes a chi-square from the number of observations and expected events (i.e., frequencies) 
from which a probability (p) value is computed from the chi-square distribution. This p-value 
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tests the fit of the logistic model (Garson, 2016). A non-significant finding (i.e., p > .05) suggests 
the model adequately fits the data.  
A chi-square test for independence was used to determine if there was a statistically 
significant relationship between antiretroviral medication adherence predicted by patients’ CD4 
count and antiretroviral medication adherence predication by patients’ HIV viral load. Chi-
square tests is used to determine whether there is a significant association between two variables.  
Ethical Considerations 
Ethics are a key element in counseling research and should be considered throughout the 
research process. While an array of ethical codes exists for counselors (e.g., American 
Counseling Association Code of Ethics, National Board for Certified Counselors), six basic 
moral principles: autonomy, nonmaleficence, beneficence, justice, fidelity, and veracity, 
underscore the considerations for this study (Corey, Corey, & Callanan, 2011). Particularly, the 
rights and welfare of the individuals participating in research are of great concern. Historically 
there have been instances in which research studies have neglected these principles (e.g., 
Tuskegee syphilis studies; Gil & Bob, 1999) and have caused immeasurable harm to participants.  
Certain steps were taken to ensure participants’ rights and welfare. Prior to statistical 
analysis, this study underwent approval by the ECU’s Institutional Review Board (Appendix C) 
to ensure the rights of human research participants were protected. Additionally, this study did 
not exclude individuals based on any demographic variables such as race, gender, or sexual 
orientation allowing for, though not guaranteeing, a diverse sample.  
To ensure patient privacy and meet ethical considerations, all electronic data was 
encrypted and saved in a designated departmental Piratedrive on a computer protected with a 
password. Retrospective chart reviews were performed under the direct supervision of the 
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BSOMHIV Clinic’s HIPAA administrator and Clinical Data Analyst. Data collected during 
retrospective chart reviews was coded and transformed into aggregate data. Any data collected 
during retrospective chart reviews was stored on a password-protected computer and saved on 
Internal Medicine - Infectious Diseases & International Travel Health departmental Piratedrive. 
This computer was in a locked office at Internal Medicine - Infectious Diseases & International 
Travel Health, Doctor's Park 6A Room 161. The BSOMHIV Clinic’s HIPAA administrator, 
Clinical Data Analyst, and the principal investigator for this study were the only ones with access 
to this data set. 
Prior to data analysis, records were stripped of all 18 personal identifiers related to 
protected health information. Patients’ data was de-identified by representing each patient with a 
unique 9-digit code containing letters (capital and lowercase), numbers, and the “+” symbol. 
Additionally, data was analyzed at the group level rather than the individual level. Analyzed data 
was stored on a password-protected computer and saved on the Department of Addictions and 
Rehabilitation Studies departmental Piratedrive. This computer was in a locked office in the 
College of Allied Health Sciences, Room 4425C. All analyzed data will be stored for 6 years 
after the completion of the study. The research team for this study will be the only ones with 
access to the data. 
Chapter Summary 
This chapter introduced the research design, population, sample, as well as the materials 
and instrumentation that were used in this study. Additionally, this chapter discussed the 
statistical analyses and described the ethical considerations of the study. Chapter Four provides 
descriptive statistics and a detailed summary of the results of the statistical analyses used in this 
study. 
 
CHAPTER FOUR: RESULTS 
Introduction 
This chapter describes the results of the statistical analyses used in this study. A 
description of the sampling procedures including data cleaning is provided. Descriptive data 
describes the overall sample characteristics. Additionally, analyses for each research question is 
provided and discussed. Finally, a summary of the results concludes this chapter. 
Sampling Procedures 
A total of 627 patient records were identified for study inclusion based on patients’ date 
of intake. Of these, 218 patients were excluded from the study for one or more of the following 
reasons: (a) not or no longer being a resident of eastern North Carolina, (b) not having a 
diagnosed with HIV/AIDS, (c) not being eligible for outpatient treatment services at the ECU 
BSOMHIV Clinic, (d) currently receiving treatment from the ECU BSOMHIV Clinic for a 
single health condition other than HIV/AIDS (e.g., Hepatitis C only), (e) being younger than 18 
years old, and (f) being incarcerated, psychiatrically unstable or deceased,. Of the remaining 409 
patients, a stratified sample of 70 patients was collected from each of the three strata: Strata 1 – 
Year 1 (August 2013 – July 2014); Strata 2 – Year 2 (August 2014 – July 2015); Strata 3 – Year 
3 (August 2015 – July 2016). After performing stratified sampling the total sample size was N = 
210.  
Data Cleaning 
Data cleaning was conducted to obtain the appropriate sample for analysis. After 
sampling 70 patients from within each stratum (i.e., Year 1, Year 2, and Year 3), the total sample 
size was N = 210. Using SPSS, frequency analysis was performed for each variable to detect 
missing values. Frequencies revealed unequal cell sizes, which were problematic when 
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comparing groups before and after the implementation of the BSOMHIV Clinic’s motivational 
interviewing program. Specifically, the Year 1 stratum had 46 records with multiple missing 
values, resulting in unequal cell sizes. Missing values were excluded from the study because 
these values can affect study results. To address this concern, a second random sample of n = 50 
patient records was collected from the Year 1 strata to create equal groups. Additional 
procedures were performed to exclude cases with redundant CD4 counts and viral load. The 
final, usable sample for this study was comprised of 168 patients. 
Descriptive Data 
Sample Characteristics  
This section provides a description of the sample. Demographic data of patients are 
summarized in Table 1. The sample consisted of adults, age 18 to 75 years, who were receiving 
HIV/AIDS-related treatment services at the BSOMHIV Clinic. Of the 168 patient records in the 
sample, the average age was 39.48 (SD = 13.25). For gender, 128 (76.2%) of the sample 
identified as male and 40 (23.8%) identified as female. The distribution of ethnicity was 
predominately patients who identified as African American (n = 125; 74.4%). The remaining 
25.6 percent of the sample represented patients who identified as White (non-Hispanic; n = 30; 
17.9%), Hispanic (n = 11; 6.5%), Asian (n = 1; 0.6%), or more than one ethnicity (n = 1; 0.6%). 
Finally, the sample was grouped based on two diagnosis status – newly diagnosed (positive 
diagnosis of HIV/AIDS within the past two months) or previously diagnosed. For this sample, 
41.7 percent (n = 70) were identified as previously diagnosed while the remaining 58.3 percent 




Demographics of the Sample 
Demographic Variable M (SD) n (%) 
































Descriptive Statistics for Variables 
Descriptive statistics for predictor and outcome variables are provided. Correlations 
between predictors were analyzed to determine if multicollinearity had an effect on results. 
Predictor variables. Table 2 summarizes the frequency for each of the seven predictor 
variables. Predictor variables were categorical and included: (a) physical health (comorbidity or 
no comorbidity), (b) mental health (comorbidity or no comorbidity), (c) substance use 
(comorbidity or no comorbidity), (e) housing (stable or unstable), (f) transportation (reliable or 
unreliable), (g) employment (employed or unemployed), and (h) motivational interviewing 
(before program implementation or after program implementation). The majority of patients did 
not indicate physical health (89.3%), mental health (76.2%), substance use (88.7%), housing 
(89.3%), transportation (80.4%), or employment (83.3%) as a biopsychosocial barrier to 
HIV/AIDS care. In terms of motivational interviewing, 45.8 percent (n = 77) of the sample were 
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patients who completed intake prior to the implementation of the motivational interviewing 
program while the remaining 54.2 percent (n = 91) were completed intake after the motivational 
interviewing program was implemented. 
Table 2 
Descriptive Statistics of Predictor Variables 
Predictor Variable n (%) 





































Program Implementation  
Motivational Interviewing   
Before implementation  77 (45.8%) 
After implementation 91 (54.2%) 
 
Checking model assumptions – multicollinearity. One of the assumptions for multiple 
logistic regression is there should be no high correlations (multicollinearity) among predictors. 
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The phi coefficient measures the degree of association between two binary variables (Tabachnick 
& Fidell, 2013). Correlation between predictors was analyzed to determine if multicollinearity 
had an effect on the analysis. Table 2 provides the phi correlation matrix with the seven predictor 
variables. There was a statistically significant correlation at α = .05 (2-tailed) for the following 
variable pairs – mental health and physical health, housing and employment. There was a 
statistically significant correlation at α = .01 (2-tailed) for the following variable pairs – mental 
health and substance use, transportation and housing. Though statistically significant, these four 
pairs have relatively low correlation coefficients. Further, Tabachnick and Fidell (2013) suggest 
that correlation coefficients less than 0.90 meet assumptions for multiple logistic regression. As 
such, it is assumed that there is little to no multicollinearity among predictors and model 
assumptions are met for this study. 
Table 3 
Phi Correlation Matrix of Predictor Variables 
 PH MH SU HO TR EM MI  
PH 
       
MH .168*       
SU .059 .242**      
HO -.058 .123 -.002     
TR .071 .075 .060 .265**    
EM -.052 -.063 -.008 .155* .020   
MI  -.029 .037 -.011 -.029 .094 -.069  
Notes. *. Correlation is significant at the 0.05 level (2-tailed). **. Correlation is significant at the 
0.01 level (2-tailed). PH = physical health. MH = mental health. SU = substance use. HO = 
housing. TR = transportation. EM = employment. MI = motivational interviewing intervention. 
 
Outcome variables. Patients’ CD4 count cut scores at week 21 and HIV viral load cut 
scores at week 21 were the outcome variables. Table 4 summarizes the frequency for the 
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biological markers at intake and at week 21. Outcome variables were dichotomized for the 
logistic regression analysis. Specifically, dichotomous CD4 counts cut scores were: ≥500 
cells/mm3 (1 – immunocompetent) or <500 cells/mm3 (0 – immunocompromised). Between 
intake and week 21, the number of immunocompromised patients decreased from n = 115 
(68.5%) to n = 97 (57.7%). Additionally, the number of immunocompetent patients in the sample 
increased from n = 53 (31.5%) to n = 71 (42.3%). This suggests that more patients became 
immunocompetent between their intake session and at 21 weeks post-intake. 
Dichotomous HIV viral loads cut scores were: ≥1,000 copies/mL of blood (1 – 
virologically unsuppressed) or <1,000 copies/mL of blood (0 – virologically suppressed). At 
intake, 75.6 percent (n = 127) of the sample were virologically unsuppressed and expressed HIV 
viral loads greater than 1,000 copies/mL of blood. Comparatively, only 8.3 percent (n = 14) of 
the sample was virologically unsuppressed at week 21. This suggests that more patients became 
virologically suppressed between their intake session and at 21 weeks post-intake. 
Table 4 
Descriptive Statistics of Outcome Variables as Cut Scores 
Outcome Variable n (%) 
CD4 at Intake 
499 and below (immunocompromised) 




CD4 at Week 21 
499 and below (immunocompromised) 




Viral Load at Intake 
≥ 1,000 (virologically unsuppressed) 




Viral Load at Week 21   
≥ 1,000 (virologically unsuppressed) 14 (8.3%) 
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999 and below (virologically suppressed) 154 (91.7%) 
Notes. For CD4: 499 and below reflects immunocompromised patients; ≥ 500 reflects 
immunocompetent patients. For viral load: ≥ 1,000 reflects patients who are 
virologically unsuppressed; 999 and below reflects patients who are virologically 
suppressed. 
 
Checking model assumptions – normality. Multiple logistic regression does not assume 
predictor variables are normally distributed. However, biological data is often skewed and 
heavy-tailed (Santos, Loschi, & Arellano-Valle, 2013). Skewness measures the degree and 
direction of asymmetry, which can indicate the presence of extreme scores (Ary et al., 2010). 
Because the outcome variables in this study are biological in nature, skew statistics were run and 
are discussed. Table 5 summarizes the mean, standard deviation, and skewness for patients’ CD4 
count and HIV viral load at intake and week 21. Both outcome variables at intake and at week 21 
show a positive skew. Specifically, the skewness of the data shows a slightly positive skew for 
CD4 at intake (0.64) and at week 21 (0.96). The skewness statistic shows a largely positive skew 
(11.32) for viral load at intake and a positive skew (9.28) for viral load at week 21. Positive skew 
for HIV viral load indicate that patients have lower viral loads, have reached or are close to being 
virologically suppressed, and are demonstrating medication adherence.   
Table 5 
Descriptive Statistics of CD4 and Viral Load 
Outcome Variable Mean  Std. Deviation Skewness 
CD4 (Intake) 358.32 292.97 0.64 
CD4 (Week 21) 471.13 344.90 0.96 
Viral Load (Intake) 174763.92 800416.50 11.32 
Viral Load (Week 21) 5662.51 38539.72 9.28 
 
Examining biopsychosocial barriers and biological markers together. Table 6 
provides the percent of patients falling into either the immunocompromised or 
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immunocompetent category for CD4 count cut score or the virologically unsuppressed or 
virologically suppressed category for HIV viral load score at intake. For CD4 count cut score at 
intake, the majority of patients (n = 115) had an immunocompromised CD4 status. Of these 
patients (n = 115), an average of 10 percent indicated physical health as a barrier, 23 percent 
indicated mental health as a barrier, 12 percent indicated substance use as a barrier, 9 percent 
indicated housing as a barrier, 17 percent indicated transportation as a barrier, and 16 percent 
indicated employment as a barrier. 
Comparatively, of the immunocompetent patients (n = 53), an average of 13 percent 
indicated physical health as a barrier, 26 percent indicated mental health as a barrier, 9 percent 
indicated substance use as a barrier, 15 percent indicated housing as a barrier, 25 percent 
indicated transportation as a barrier, and 19 percent indicated employment as a barrier. Overall, 
there was a ±3% difference between the average percent of barriers for immunocompromised 
and immunocompetent patients, with the exception of housing (-6%) and transportation (-8%). 
For HIV viral load, the majority of patients (n = 127) were virologically unsuppressed. Of 
these patients (n = 127), an average of 9 percent indicated physical health as a barrier, 25 percent 
indicated mental health as a barrier, 13 percent indicated substance use as a barrier, 10 percent 
indicated housing as a barrier, 16 percent indicated transportation as a barrier, and 17 percent 
indicated employment as a barrier. Comparatively, of the virologically suppressed patients (n = 
40), 15 percent indicated physical health as a barrier, 20 percent indicated mental health as a 
barrier, 5 percent indicated substance use as a barrier, 12 percent indicated housing as a barrier, 
24 percent indicated transportation as a barrier, and 15 percent indicated employment as barrier. 
When patients were virologically unsuppressed, the average percent of barriers was higher for 
mental health, substance use, and employment, when compared to patients who were 
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virologically suppressed. In contrast, when patients were virologically suppressed, the average 
percent of barriers was higher for physical health, housing, and transportation, when compared to 
patients who were virologically unsuppressed. 
Table 6 
Percent of Patients Classified by CD4 and Viral Load at Intake 
 CD4 at Intake 
N = 168 
 Viral Load at Intake 
N = 168 
 Compromised (%) 
n = 115 
Competent (%) 
n = 53 
 Unsuppressed (%) 
n = 127 
Suppressed (%) 
n = 40 
Physical Health 
 
10 13  9 15 
Mental Health 
 
23 26  25 20 
Substance Abuse 
 
12 9  13 5 
Housing 
 
9 15  10 12 
Transportation 
 
17 25  16 24 
Employment 16 19  17 15 
 
Data Analyses 
This section includes the results of the analyses for each research question. Logistic 
regression analyses were computed separately for the outcome variables to address the first two 
research questions. The third question uses and discusses the results of Chi-square analysis. 
Research Question A 
(a) How do biopsychosocial barriers (i.e., physical health, mental health, substance use, 
housing, transportation, and employment) and motivational interviewing predict antiretroviral 
medication adherence in people living with human immunodeficiency virus and acquired 
immune deficiency syndrome as measured by patients’ CD4 count cut score at week 21? 
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A multiple logistic regression analysis was conducted to determine if biopsychosocial 
barriers and motivational interviewing predicted medication adherence in PLWHA based on 
patients’ CD4 count cut scores at week 21. A 2x2 contingency table (crosstab) was analyzed to 
assure all cell frequencies were ≥ 1 and 80% or more of cells were > 5. A test of the full model 
versus a model with intercept only was not statistically significant at α = .05, χ2(7, N = 168), p = 
.513. The Hosmer-Lemeshow (H-L) goodness of fit test yielded a non-significant chi-square (p = 
.770) suggesting the model adequately fits the data. 
In addition to the H-L statistic, a classification table can describe the proportion of cases 
that have been classified correctly by the model. Table 7 shows how many patients’ observed 
values of CD4 cut scores were correctly predicted by the model at 21 weeks. The results show 
that 86.6 percent (n = 84) were correctly classified for the immunocompromised group, and 26.8 
percent (n = 19) were correctly classified for the immunocompetent group. Overall, 61.3 percent 
were correctly classified which is an improvement on the 57.7 percent correct classification with 
the constant model. This suggests that the model with predictors is a better model. 
Table 7 
Classification Table for CD4 Cut Scores at Week 21 
Observed 
Predicted 
CD4 cut score at Week 21 Percentage 
Correct Compromised Competent 
Step 1 CD4 cut score at 
Week 21 
Compromised 84 13 86.6 
Competent 52 19 26.8 
Overall Percentage     61.3 
Note. The cut value is .500 
 
The logistic regression equation for this model is log(p/1-p) = .996 - .125*physical health + 
.031*mental health + .028*substance use - .100*housing - .545*transportation - .586*employment - .455*MI intervention. 
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Table 8 shows the results of the logistic regression analysis, including the test of significance for 
each of the coefficients in the model. Specifically, the Wald statistic has a chi-square distribution 
and provides the significance of each predictor in the equation, holding constant the other 
predictors (Burns & Burns, 2008). Coefficients with a p-value less than .05 were considered 
statistically significant. Using the Wald statistic, none of the seven predictor variables 
demonstrated statistical significance at α = .05. This suggests that none of the predictor variables 
nor the use of motivational interviewing made a significant contribution to the prediction of 
medication adherence as measured by patients’ CD4 count cut scores at week 21.  
Table 8 
Multiple Logistic Regression Analysis for Variables Predicting Patients’ CD4 Count Cut Scores 
at Week 21 
 B S.E. Wald df Sig. Exp(B) 
PH -.125 .523 .057 1 .811 .883 
MH .031 .395 .006 1 .938 1.031 
SU .028 .519 .003 1 .957 1.029 
HO -.100 .545 .033 1 .855 .905 
TR -.545 .415 1.727 1 .189 .580 
EM -.586 .431 1.845 1 .174 .557 
MI -.455 .324 1.973 1 .160 .634 
Constant .966 .900 1.152 1 .283 2.627 
Notes. PH = physical health. MH = mental health. SU = substance use. HO = housing. TR = 
transportation. EM = employment. MI = motivational interviewing intervention. 
 
To control for differences in patients’ CD4 count cut scores at intake, patients’ intake 
CD4 count cut scores were added to the regression model. A second multiple logistic regression 
analysis was conducted to determine if biopsychosocial barriers and motivational interviewing 
predicted medication adherence in PLWHA based on patients’ CD4 count cut score at week 21 
while controlling for patients’ CD4 count cut scores at intake. A 2x2 contingency table (crosstab) 
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was analyzed to assure all cell frequencies were ≥ 1 and 80% or more of cells were > 5. A test of 
the full model versus a model with intercept only was statistically significant at α = .05, χ2(8, N = 
168), p < .001. The Hosmer-Lemeshow (H-L) goodness of fit test yielded a non-significant chi-
square (p = .305) suggesting the model adequately fits the data. 
In addition to the H-L statistic, a classification table can describe the proportion of cases 
that have been classified correctly by the model. Table 9 shows how many patients’ observed 
values of CD4 cut scores were correctly predicted by the model at 21 weeks while controlling for 
patients’ CD4 cut scores at intake. The results show that 93.8 percent (n = 91) were correctly 
classified for the immunocompromised group, and 66.2 percent (n = 47) were correctly classified 
for the immunocompetent group. Overall, 82.1 percent were correctly classified which is an 
improvement on the 57.7 percent correct classification with the constant model. This suggests 
that the model with predictors including patients’ CD4 cut scores at intake, is a better model. 
Table 9 
Classification Table for CD4 Cut Scores at Week 21, Controlling for Patients’ CD4 Count Cut 
Scores at Intake 
Observed 
Predicted 
CD4 cut score at Week 21 Percentage 
Correct Compromised Competent 
Step 1 CD4 cut score at 
Week 21 
Compromised 91 6 93.8 
Competent 24 47 66.2 
Overall Percentage     82.1 
Note. The cut value is .500 
 
The logistic regression equation for this revised model (i.e., controlling for patients’ CD4 
count cut scores at intake) is log(p/1-p) = 2.882 + .238*physical health + .202*mental health - .300*substance 
use + .430*housing - .633*transportation - .753*employment - .283*MI intervention – 3.463*CD4 cut scores at intake. Table 
10 shows the results of the logistic regression analysis, including the test of significance for each 
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of the coefficients in the model, while controlling for patients’ CD4 count cut scores at intake. 
This revised model suggests that patients’ CD4 count cut scores at intake contributed to the 
model’s prediction. Using the Wald statistic, patients’ CD4 count cut scores at intake (p < .001) 
demonstrated statistical significance at α = .05. This suggests that patients’ CD4 count cut scores 
make a significant contribution to the prediction of medication adherence as measured by 
patients’ CD4 count cut scores at week 21. 
Table 10 
Multiple Logistic Regression Analysis for Variables Predicting Patients’ CD4 Count Cut Scores 
at Week 21, Controlling for Patients’ CD4 Count Cut Scores at Intake 
 B S.E. Wald df Sig. Exp(B) 
PH .238 .695 .117 1 .732 1.268 
MH .202 .528 .147 1 .702 1.224 
SU -.300 .657 .208 1 .648 .741 
HO .430 .745 .333 1 .564 1.537 
TR -.633 .528 1.436 1 .231 .531 
EM -.753 .549 1.881 1 .170 .471 
MI -.283 .419 .455 1 .500 .754 
CD4-I -3.463 .511 45.834 1 .000* .031 
Constant 2.882 1.197 5.798 1 .016 17.845 
Notes. PH = physical health. MH = mental health. SU = substance use. HO = housing. TR = 
transportation. EM = employment. MI = motivational interviewing intervention. CD4-I = CD4 count 
cut scores at intake. 
 
Research Question B 
(b) How do biopsychosocial barriers (i.e., physical health, mental health, substance use, 
housing, transportation, and employment) and motivational interviewing predict antiretroviral 
medication adherence in people living with human immunodeficiency virus and acquired 
immune deficiency syndrome as measured by patients’ HIV viral load cut score at week 21? 
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A multiple logistic regression analysis was conducted to determine if biopsychosocial 
barriers and motivational interviewing predicted medication adherence in PLWHA based on 
patients’ HIV viral load. A 2x2 contingency table (crosstab) was analyzed to assure all cell 
frequencies were ≥ 1 and 80% or more of cells were > 5. A test of the full model versus a model 
with intercept only was statistically significant at α = .05, χ2(7, N = 168), p = .026. The Hosmer-
Lemeshow (H-L) goodness of fit test yielded a non-significant chi-square (p = .770) suggesting 
the model adequately fits the data. 
In addition to the H-L statistic, a classification table can describe the proportion of cases 
that have been classified correctly by the model. Table 11 shows how many patients’ observed 
values of viral load cut scores that were correctly predicted by the model at 21 weeks. In this 
study, 100.0 percent (n = 154) were correctly classified for the suppressed group, and 14.3 
percent (n = 2) correctly classified for the unsuppressed group. Overall, 92.9 percent were 
correctly classified, and this is an improvement on the 91.7 percent correct classification with the 
constant model. This suggests that the model with predictors is a slightly better model. 
Table 11 
Classification Table for Viral Load Cut Scores at Week 21 
Observed 
Predicted 




Step 1 Viral load cut 
score at Week 21 
Suppressed 154 0 100.0 
Unsuppressed 12 2 14.3 
Overall Percentage     92.9 
Note. The cut value is .500 
 
The logistic regression equation for this model is log(p/1-p) = .901 - .957*physical health + 
.666*mental health - 2.321*substance use - .414*housing - .767*transportation + .101*employment - .921*MI intervention. 
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Table 10 shows the results of the logistic regression analysis, including the test of significance 
for each of the coefficients in the model. Of the seven predictive variables, substance use 
contributed to the model’s prediction. Using the Wald statistic, the substance use predictor (p = 
.001) demonstrated statistical significance at α = .05. This suggests that the barrier substance use 
makes a significant contribution to the prediction of medication adherence as measured by 
patients’ HIV viral load. 
The Exp(B) column in Table 12 shows the odds ratio for each of the predictors. The 
Exp(B) value associated with substance use is 0.098. Hence, when controlling for the other six 
predictors and when substance use is not a barrier, patients become 0.098 times less likely to 
have an unsuppressed viral load. Taking the reciprocal (1/0.098 = 10.204), the odds ratio could 
be interpreted as patients become 10.2 times more likely to have an unsuppressed viral load 
when substance use is a barrier. 
Table 12 
Multiple Logistic Regression Analysis for Variables Predicting Patients’ Viral Load Cut Scores 
at Week 21 
 B S.E. Wald df Sig. Exp(B) 
PH -.957 .816 1.376 1 .241 .384 
MH .666 .767 .755 1 .385 1.947 
SU -2.321 .696 11.127 1 .001* .098 
HO -.414 .977 .180 1 .671 .661 
TR -.767 .675 1.292 1 .256 .464 
EM .101 .880 .013 1 .908 1.107 
MI -.921 .662 1.938 1 .164 .398 
Constant .901 1.373 .431 1 .512 2.463 
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Notes. *. Significant results with p-values less than .05 are shown in boldface. PH = physical health. 
MH = mental health. SU = substance use. HO = housing. TR = transportation. EM = employment. MI 
= motivational interviewing intervention. 
 
A 2x2 contingency table (crosstabs) was used to generate information about the bivariate 
relationship of the substance use predictor and viral load cut score at week 21. Table 13 provides 
the results of the crosstabulation. During intake, 11.3 percent (n = 19) of patients indicated that 
substance use was a barrier to treatment, while 88.7 percent (n =149) of patients did not. Of the 
total number of patients (n = 19) who indicated substance use as a barrier to treatment at intake 
68.4 percent (n = 13) were virologically suppressed at week 21. Comparatively, of the total 
number of patients (n = 19) who indicated substance use as a barrier to treatment at intake 31.6 
percent (n = 6) were virologically unsuppressed at week 21.  
The odds ratio for viral load cut score at week 21 was 8.135 with a 95 percent confidence 
interval of [2.447, 27.044]. This suggests that patients who did not report substance use as a 
barrier were eight times more likely to be virologically suppressed. Differences in odds ratio 
results from the logistic regression (OR = 10.204) and the crosstabulation results (OR = 8.135) 
are because the crosstabs function only examines one correlation to develop the odds ratio (i.e., 
substance use barrier by patients’ HIV viral load, while the logistic regression model calculates 
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Notes. VL = viral load. SU = substance use. 
 
To control for differences in patients’ viral load cut scores at intake, patients’ intake viral 
load cut scores were added to the regression model. A second multiple logistic regression 
analysis was conducted to determine if biopsychosocial barriers and motivational interviewing 
predicted medication adherence in PLWHA based on patients’ viral load cut score at week 21 
while controlling for patients’ viral load cut scores at intake. A 2x2 contingency table (crosstab) 
was analyzed to assure all cell frequencies were ≥ 1 and 80% or more of cells were > 5. A test of 
the full model versus a model with intercept only was statistically significant at α = .05, χ2(8, N = 
168), p = .036. The Hosmer-Lemeshow (H-L) goodness of fit test yielded a non-significant chi-
square (p = .614) suggesting the model adequately fits the data. 
In addition to the H-L statistic, a classification table can describe the proportion of cases 
that have been classified correctly by the model. Table 14 shows how many patients’ observed 
values of viral load cut scores were correctly predicted by the model at 21 weeks while 
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controlling for patients’ viral load cut scores at intake. The results show that 99.4 percent (n = 
153) were correctly classified for the virologically suppressed group, and 14.3 percent (n = 2) 
were correctly classified for the virologically unsuppressed group. Overall, 92.3 percent were 
correctly classified which is an improvement on the 91.7 percent correct classification with the 
constant model. This suggests that the model with predictors including patients’ viral load cut 
scores at intake, is a slightly better model. 
Table 14 
Classification Table for Viral Load Cut Scores at Week 21, Controlling for Patients’ Viral Load 
Cut Scores at Week 21 
Observed 
Predicted 




Step 1 Viral load cut 
score at Week 21 
Suppressed 153 1 99.4 
Unsuppressed 12 2 14.3 
Overall Percentage     92.3 
Note. The cut value is .500 
 
The logistic regression equation for this revised model (i.e., controlling for patients’ viral 
load cut scores at intake) is log(p/1-p) = 1.059 - 1.015*physical health + .666*mental health - 2.229*substance 
use - .478*housing - .812*transportation + .137*employment - .921*MI intervention – .594*viral load cut scores at intake. 
Table 15 shows the results of the logistic regression analysis, including the test of significance 
for each of the coefficients in the model, while controlling for patients’ viral load cut scores at 
intake. In this revised model, substance use still contributed to the model’s prediction. Using the 
Wald statistic, the substance use predictor (p = .001) demonstrated statistical significance at α = 
.05. Additionally, patients’ viral load cut scores at intake did not contribute to the model’s 
prediction (Wald χ2 = .503, p = .478). This suggests that patients’ viral load cut scores do not 
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make a significant contribution to the prediction of medication adherence as measured by 
patients’ viral load cut scores at week 21. 
Table 15 
Multiple Logistic Regression Analysis for Variables Predicting Patients’ Viral Load Cut Scores 
at Week 21, Controlling for Patients’ Viral Load Cut Scores at Intake 
 B S.E. Wald df Sig. Exp(B) 
PH -1.015 .829 1.499 1 .221 .362 
MH .666 .764 .761 1 .383 1.947 
SU -2.229 .701 10.116 1 .001* .108 
HO -.478 .968 .244 1 .622 .620 
TR -.812 .675 1.448 1 .229 .444 
EM .137 .886 .024 1 .877 1.147 
MI -.921 .664 1.924 1 .165 .398 
VL-I -.594 .837 .503 1 .478 .552 
Constant 1.059 1.397 .574 1 .449 2.882 
Notes. *. Significant results with p-values less than .05 are shown in boldface. PH = physical health. 
MH = mental health. SU = substance use. HO = housing. TR = transportation. EM = employment. MI 
= motivational interviewing intervention. VL-I = viral load cut scores at intake. 
 
Research Question C 
(c) Is there a statistically significant relationship between patients’ CD4 cut score at week 
21 and patients’ HIV viral load cut score at week 21 in predicting antiretroviral medication 
adherence? 
A chi-square test was used to determine the association between patients’ CD4 cut score 
at week 21 and patients’ HIV viral load cut score at week 21 in predicting antiretroviral 
medication adherence. Chi-square assumes: (a) variables are ordinal or nominal in nature, (b) 
data represents independent observations, and (c) all expected frequencies are > 5. All 
assumptions for chi-square analysis were met. Chi-square analysis results were χ2(1) = 1.173, p = 
0.279, which suggests that there was a non-significant association between patients’ CD4 cut 
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scores at week 21 and patients’ HIV viral load cut scores at week 21 in predicting antiretroviral 
medication adherence. A 2x2 contingency table (crosstabs) was used to generate information 
about the bivariate relationship of patients’ CD4 cut scores at week 21 and patients’ viral load 
cut scores at week 21. Table 16 provides the results of the crosstabulation. Phi is a chi-square 
based measure of association for nominal data (Burns & Burns, 2008). Phi test results support 
the non-significant chi-square analysis and show a very weak, negative association (φ = -.084) 
between the two variables.  
Table 16 
Patients’ CD4 Cut Scores at Week 21 by Patients’ Viral Load Cut Scores at Week 21 
Contingency Table 
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Note. SU = substance use. 
 
Chapter Summary 
This study examined the relationship between biopsychosocial barriers, motivational 
interviewing, and antiretroviral medication adherence. The sample was composed primarily of 
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African American men with an average age of 40 years. Multiple logistic regression analysis 
showed that no predictor variables made a significant contribution to the prediction of 
medication adherence as measured by PLWHA CD4 count. Comparatively, results showed a 
statistical significance for the barrier substance use when examining antiretroviral medication 
adherence in PLWHA as measured by patients’ HIV viral load. Further, a non-significant 
association between patients’ CD4 cut score at week 21 and patients’ HIV viral load cut score at 
week 21 in predicting antiretroviral medication adherence was found. The following chapter 
provides a review and interpretation of the study results as related to the purpose of the study and 
the literature introduced in previous chapters. The study’s limitations and future implications are 
also discussed.
 
CHAPTER FIVE: DISCUSSION 
Introduction 
Chapter One provided an in-depth background of human immunodeficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS) and common biopsychosocial threats 
to antiretroviral (ARV) medication adherence. In Chapter Two, the theoretical framework for 
this study was introduced and overarching concepts for self-determination theory and 
motivational interviewing were provided. Chapter Three presented the methods for the present 
study investigating the influence of biopsychosocial factors and motivational interviewing on 
antiretroviral medication adherence for people living with HIV/AIDS. Chapter Four described 
the results of statistical analyses used to address the research questions.  
The final chapter will synthesize the components from the first four chapters. 
Specifically, Chapter Five begins with a summary of the study including a review of the patients, 
data collection process, and study-specific variables. Next, limitations and implications of this 
study are examined. Additionally, this chapter provides a review and interpretation of the results 
as related to the purpose of the study, the literature introduced in the previous chapters and the 
SDT. This chapter will conclude with a discussion of the study’s limitations, implications, and 
suggestions for future research. 
Summary of the Study 
The purpose of this study was to explore the influence of biopsychosocial barriers and 
motivational interviewing on antiretroviral medication adherence to improve medication 
adherence for PLWHA. Specifically, this study analyzed how biopsychosocial barriers (i.e., 
physical health, mental health, substance use, housing, transportation, and employment) and 
motivational interviewing predicted antiretroviral medication adherence in PLWHA as measured 
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by patients’ CD4 count cut scores at week 21 and patients’ HIV viral load cut scores at week 21. 
This study also explored the association between antiretroviral medication adherence predicted 
by patients’ CD4 count cut scores at week 21 and antiretroviral medication adherence predicted 
by patients’ HIV viral load cut scores at week 21. To conceptualize statistical analyses, results 
were examined through the lens of self-determination theory. 
Based on the date of patient intake, a total of 627 patient records were identified for study 
inclusion. After an initial data cleaning procedure, 409 patients were identified as eligible for 
study inclusion. Of these, a stratified sample of 70 patients was collected from each of the three 
strata – Strata 1 – Year 1 (August 2013 – July 2014); Strata 2 – Year 2 (August 2014 – July 
2015); Strata 3 – Year 3 (August 2015 – July 2016). The strata represent one year before the 
motivational interviewing training, the year during the motivational interviewing training, and 
one year following the conclusion of the motivational interviewing training. After performing 
stratified sampling, the total sample included 210 patients. Using SPSS, frequency analysis was 
performed for each variable to detect missing values and unequal cell sizes. To create equal 
groups, an additional random sampling of 50 patients was collected from the Year 1 stratum. 
Additional procedures were performed to exclude cases with redundant CD4 counts and viral 
load.  
Demographic Data 
The final sample for this study was comprised of 168 patients. Descriptive statistics of 
demographic variables revealed a relatively homogenous sample. The sample consisted of 
mostly of African American (n = 128; 76%) males (n = 128; 76.2%) with an average age of 39.4 
years (SD = 13.25). Further, 41.7 percent (n = 70) of the patients were identified as having an 
HIV/AIDS diagnosis prior to coming to the Brody School of Medicine HIV (BSOMHIV) Clinic, 
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while the remaining 58.3 percent (n = 98) were identified as newly diagnosed. These results are 
consistent with patient demographics at the BSOMHIV Clinic (see Appendix A). Additionally, 
the demographic results reflect the previous literature regarding individuals of color, particularly 
African Americans, have higher rates of HIV infection in the United States (CDC, 2018a; 
Wawrzyniak et al., 2015). Given these statistics, providers of HIV/AIDS-related care in Eastern 
North Carolina should incorporate culturally sensitive approaches that is appropriate for 
individuals of color.  
Descriptive Data 
Predictor variables. For this study, predictor variables were categorical and included: 
physical health (comorbidity or no comorbidity), mental health (comorbidity or no comorbidity), 
substance use (comorbidity or no comorbidity), housing (stable or unstable), transportation 
(reliable or unreliable), employment (employed or unemployed) and motivational interviewing 
(before program implementation or after program implementation). Interestingly, the majority of 
patients did not indicate physical health (89.3%), mental health (76.2%), substance use (88.7%), 
housing (89.3%), transportation (80.4%), or employment (83.3%) as a biopsychosocial barrier to 
HIV/AIDS care. These numbers appear uncharacteristically low, particularly for mental health 
and substance use. For instance, DeLorenze, Tsai, Horberg, & Quesenberry (2014) found that 40 
percent of HIV-infected individuals engaged in illicit drug use, and more than 20 percent are 
diagnosed with a substance use disorder. However, research also suggests that barriers to care 
can be highly variable. For example, Pellowski (2013) found that transportation was a significant 
barrier to care for PLWHA in 9 of 11 studies. However, for this study’s sample, system level 
barriers were not problematic. This may be due to the case management policies in place at the 
BSOMHIV Clinic. Specifically, patients engaging in care first interact with a linkage retention 
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coordinator who performs a quick barrier assessment prior to patients’ intake day to ensure 
patients are able to maintain their scheduled intake appointment. The pre-intake screenings 
began in late 2012 and gradually expanded to include six new linkage retention coordinators over 
the last six years. With this in mind, patients entering the BSOMHIV Clinic at intake may have 
addressed larger, system-level barriers (e.g., transportation) through case management services 
received during pre-screening. 
Outcome variables. The outcome variables were patients CD4 count cut scores at week 
21 and HIV viral load cut scores at week 21. The dichotomized CD4 counts cut-off scores were: 
≥500 cells/mm3 (1 – immunocompetent) or <500 cells/mm3 (0 – immunocompromised). The 
number of immunocompromised patients in the sample decreased from 115 patients (68.5%) to 
97 patients (57.7%) between intake and week 21 post-intake. Additionally, the number of 
immunocompetent patients in the sample increased from 53 (31.5%) to 71 (42.3%). Furthermore, 
across the three years (strata) the average CD4 count for patients at intake was 358 cells/mm3. 
Comparatively, the average CD4 count for patients at week 21 was 471 cells/mm3. These 
findings are in keeping with past research which suggests that patients who are adherent to ARV 
medications can expect an increase in CD4 count (approximately 50 to 100 cells/mm3) within the 
first three months of treatment (AIDSInfo, 2018).  
The dichotomized HIV viral loads cut-off scores were: ≥1,000 copies/mL of blood (1 – 
virologically unsuppressed) or <1,000 copies/mL of blood (0 – virologically suppressed). At 
intake, 75.6 percent (n = 127) of the sample were virologically unsuppressed and expressed viral 
loads greater than 1,000 copies/mL of blood. Comparatively, only 8.3% (n = 14) of the sample 
was virologically unsuppressed at week 21, which suggested that the majority of patients were 
adherent to ARV medications. These findings are consistent with past research, which shows that 
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patients who adhere to ARV medication regiments and have no resistant mutations can expect to 
achieve viral suppression 8 to 24 weeks after ARV medication initiation (AIDSInfo, 2018).  
Interpretation of Statistical Analyses 
This section provides interpretation of multiple logistic regression and chi-square 
analyses presented in Chapter Four. Results of each research question are explored and compared 
to the previous literature reviewed in Chapter Two and the SDT. 
Multiple Logistic Regression Analyses 
Research Question A. How do biopsychosocial barriers (i.e., physical health, mental 
health, substance use, housing, transportation, and employment) and motivational interviewing 
predict antiretroviral medication adherence in people living with human immunodeficiency virus 
and acquired immune deficiency syndrome as measured by patients’ CD4 count cut score at 
week 21? 
Past research suggests that the relationship between CD4 and adherence to ARV 
medications is multifactorial (Ironson et al., 2005). In particular, biopsychosocial barriers such as 
mental health concerns can influence patients’ ability to adhere to ARV medications. Therefore, 
the current study explored the predictive values of biopsychosocial barriers on medication 
adherence as measured by patients’ CD4 counts. However, the results indicated that all seven 
predictor variables were non-significant. Further, motivational interviewing was not statistically 
significant in predicting patients’ CD4 counts. One possible reason for this finding is that patient 
CD4 counts may be better predictors of HIV/AIDS progression and be less effective in 
predicting an immediate response to ARV medications (Ironson et al., 2005). This suggests that 
changes in CD4 counts may require a longer period of time before statistically significant 
differences are observed. 
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Interestingly, the literature reveals mixed results regarding an effect of baseline CD4 
count on subsequent adherence to ARV adherence. Some studies report an association between 
higher baseline CD4 count and lower adherence (Diabaté, Alary, & Koffi, 2007; Pasternak, 
Bruin, Bakker, Berkhout, & Prins, 2015). Comparatively, other studies have found that high CD4 
at baseline was not associated with lower adherence (Paterson et al., 2000; Adakun et al., 2013). 
However, comparing results of previous studies is challenging due to differences in assessing 
ARV adherence and varying cutoffs for optimal versus suboptimal medication adherence. 
Furthermore, antiretroviral medication guidelines are changing. Specifically, CD4 counts 
are particularly useful before initiation of ARV medications as the measurement provides 
information about patients’ overall immune functioning (AIDSInfo, 2018). Along the same 
thread, this study found that adding patients’ CD4 cut scores at intake significantly contributed to 
the multiple logistic regression model. This suggests that patients’ CD4 counts before ARV 
medication initiation are an important determinant of medication adherence at week 21. 
Currently, most patients diagnosed with HIV start antiretroviral treatment regardless of their 
viral load or CD4 count, so the rationale for frequent CD4 monitoring is weaker than in the past 
(AIDSInfo, 2018). This underscores the importance of incorporate the use of both biological 
markers (i.e., CD4 and viral load) in routine clinical practice and HIV/AIDS outcomes related 
research. 
Another possible reason for this finding is that other biopsychosocial barriers may be 
better at predicting ARV medication adherence. Based on the literature review in Chapter One 
and Chapter Two, the following six factors – medical (i.e., physical health), mental health, 
substance use, housing, transportation, and employment concerns – were identified as variables, 
which may be predictive of medication non-adherence in PLWHA. However, there may be other 
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individual, interpersonal, structural, and societal barriers to care for PLWHA. For example, 
Langebeek and colleagues’ (2014) meta-analysis found that level of self-efficacy was a predictor 
of medication adherence in PLWHA (medium to large effect size). As a principle of motivational 
interviewing, self-efficacy helps enhance individuals’ self-confidence in their ability to create 
change in their lives. Furthermore, supporting individuals’ self-efficacy satisfies their need for 
competence, one of the basic needs for wellbeing identified in self-determination theory 
(Vansteenkiste & Sheldon, 2006). Future studies should explore possible predictor variables that 
satisfy the basic psychological needs of self-determination theory (i.e., autonomy, self-efficacy 
and social relatedness). 
Additionally, in the current study, all barriers were evaluated equally as categorical 
variables. However, some barriers may have had more influence than others. For example, Grau 
et al. (2017) suggest individual-level barriers, such as motivation and co-morbidity, require 
individuals to take action to overcome. Some individuals may not have the resources (internal 
and/or external), needed to address these concerns. When considering self-determination theory, 
the current study’s theoretical framework, case managers working with PLWHA who lack 
resources for change, should focus on increasing individuals’ basic psychological needs. 
Specifically, empowering patients with the knowledge (competence) necessary to be actively 
involved in the decisions about their care (autonomy) may prove beneficial. Furthermore, 
participating in HIV specific support groups would provide social relatedness. 
Research Question B. How do biopsychosocial barriers (i.e., physical health, mental 
health, substance use, housing, transportation, and employment) and motivational interviewing 
predict antiretroviral medication adherence in people living with human immunodeficiency virus 
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and acquired immune deficiency syndrome as measured by patients’ HIV viral load cut score at 
week 21? 
Results from multiple logistic regression analysis indicated that six predictor variables 
(i.e., physical health, mental health, housing, transportation, and employment) and motivational 
interviewing were non-significant. However, substance use as a barrier to care did demonstrate 
statistical significance (Wald χ2 = 11.127, p = 0.001, odds ratio = 0.098, 95% CI 0.025 – 0.384). 
This result aligns with meta-analysis research by Langebeek et al. (2014) that identified current 
substance use as associated with poor ARV medication adherence. As discussed previously, 
patients with substance use concerns were virologically unsuppressed, reported a statistically 
significant lower rate of medication adherence, and had an overall lower quality of life when 
compared to patients who are virologically suppressed (Wawrzyniak et al., 2015). 
One possible explanation for the significance of the substance use barrier in this sample is 
the difference in how the barriers were captured. Specifically, the Annual Risk Assessment 
Screening Tool (Appendix B) uses psychometrically sound screeners for substance use and 
mental health while the other barriers (i.e., physical health, housing, transportation, employment) 
are self-report. Utilizing self-report measures can introduce recall error as well as social 
desirability bias (DiIorio et al., 2003). For instance, one study found that patients with higher 
social desirability scores were more likely to decrease reporting of sexual risk behaviors (e.g., 
more than one sexual partner) or increase reporting of protective behaviors. That being said, 
social desirability bias may increase underreporting of biopsychosocial concerns. This potential 
bias underscores the importance of fostering a collaborative patient-provider relationship, as 
described in motivational interviewing. Specifically, utilizing the elements that comprise the 
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spirit of MI (i.e., partnership, acceptance, compassion, evocation) can create an environment in 
which patients may feel more comfortable sharing their biopsychosocial concerns. 
Unlike the other six predictor variables, substance use consistently appears in the 
literature as a potential barrier to care for PLWHA. This may be due to substance use being a 
major health concern, like HIV/AIDS, that affects individuals across all sociodemographics. 
Research suggests that PLWHA with co-occurring substance use concerns may have particular 
difficulty with utilizing positive coping skills, addressing comorbid conditions (e.g., mental 
health, hepatitis C), or obtaining the resources necessary to meet basic needs such as housing or 
transportation (Grau et al., 2017). Additionally, substance use can influence individuals’ self-
care beliefs and behaviors, in addition to ARV medication adherence (Remien et al., 2003). This 
underscores the importance of utilizing a multidisciplinary approach that includes substance use 
treatment for PLWHA. Furthermore, the application of SDT into a multidisciplinary approach 
may be of particular importance to PLWHA with substance use concerns. For instance, patients 
at the BSOMHIV clinic have access to programs designed to educate about the interplay of HIV 
and substance use (competence) while fostering relatedness through HIV specific support 
groups. 
Recall that the odds ratio was different for the multiple logistic regression (OR = 10.204) 
and the crosstabulation of the substance use predictor by patients’ viral load cut scores at week 
21 (OR = 8.135). The crosstabs function only examines one correlation to develop the odds ratio 
(i.e., substance use barrier by patients’ HIV viral load) while the logistic regression model 
calculates the odds ratio with the other predictors in the model. Although the other predictor 
variables were non-significant, it appears that one or more of these barriers is contributing to the 
influence of the substance use barrier. For instance, the substance use and mental health barrier 
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demonstrated a statistically significant relationship in this study. The mental health barrier may 
be influencing the statistical significance of the substance use barrier. Additionally, these results 
are reminiscent of Wawrzyniak et al. (2015) research, which suggests that co-occurring barriers 
are additively associated with increased HIV viral loads. Research also shows that being HIV+, 
along with having other physical or mental health concerns increases the likelihood that 
individuals will self-medicating with substances (Grau et al., 2017). The current findings 
reiterate the sentiments of past research by underscoring the need for strengths-based case 
management for PLWHA to address biopsychosocial barriers to care, particularly substance use 
concerns. 
Multiple logistic regression analyses findings. Of the two multiple logistic regression 
models used for this study, the model using viral load cut scores at week 21 was the preferred 
model. Specifically, the model using patients’ viral load was able to identify substance use as a 
statistically significant barrier to treatment, which had implications for ARV medication 
adherence.  
Motivational interviewing. From August 2014 to June 2015, clinical staff at the 
BSOMHIV Clinic were trained in the use of motivational interviewing. During this time frame, 
clinic staff received a two-day introduction training course followed by monthly booster sessions 
to reinforce learned motivational interviewing techniques. The goal of this intervention was to 
teach clinic staff how to integrate motivational interviewing into daily interactions with patients 
to identify biopsychosocial barriers and increase patient motivation for ARV medication 
adherence. Multiple logistic regression results revealed that motivational interviewing was not 
statistically significant for either model. One possible explanation for this is the BSOMHIV 
Clinic utilized a strengths-based case management model prior to the motivational interviewing 
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conversion. As previously discussed, strengths-based case management identifies and leverages 
patients’ strength to address individual-level barriers to care, and utilizes case managers to 
collaboratively overcome larger, system-level barriers (Wawrzyniak et al., 2015). Patient 
collaboration and strength identification are in keeping with the spirit of motivational 
interviewing (i.e., partnership, acceptance, compassion, and evocation). Research suggests that 
the spirit of motivational interviewing may be more important than the technical skills (Schoo, 
Lawn, Rudnik, & Litt, 2015). Thus, the similarities of the strengths-based case management 
model and the spirit of motivational interviewing may explain the non-significance of 
motivational interviewing as a predictor of ARV medication adherence. Furthermore, self-
determination theory suggests that supporting patients’ basic psychological needs for autonomy, 
encouraging competence through the evocation of patients’ beliefs about health care, and 
establishing relatedness through respectful collaboration between patients and healthcare 
professionals would support patients’ adherence to ARV medications. Thus, case managers 
following the strength-based case management model or utilizing motivational interviewing 
support patients’ basic psychological needs, which in turn may increase medication adherence. 
Another possible explanation for motivational interviewing’s lack of statistical 
significance may be that the case managers failed to use motivational interviewing consistently. 
In the study, motivational interviewing was treated as a categorical variable. Specifically, 
medication adherence was evaluated before program implementation of motivational 
interviewing and after program implementation of motivational interviewing. However, case 
managers’ motivational interviewing treatment fidelity was not evaluated. Treatment fidelity 
refers to the degree to which those trained in motivational interviewing adhered to the counseling 
behaviors, principles, and spirit of motivational interviewing (Allicock et al., 2017). Motivational 
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Interviewing skills can be assessed using the Motivational Interviewing Treatment Integrity 
(MITI) instrument. The MITI uses a coding system that measures how well clinicians/case 
managers are using motivational interviewing (Moyers, Manuel, & Ernst, 2014). The MITI 
focuses on global ratings (e.g., the spirit of motivational interviewing) and behavioral counts 
(e.g., open questions) and provides recommended proficiency and competency thresholds for 
each skill (Allicock et al., 2017). Future studies should use the MITI to determine the quality of 
the motivational interviewing intervention. 
Chi-Square Analysis 
Is there a statistically significant relationship between patients’ CD4 cut score at week 21 
and patients’ HIV viral load cut score at week 21 in predicting antiretroviral medication 
adherence? 
This question was interested in analyzing whether there was a relationship between CD4 
and viral load. Chi-square analysis revealed a non-significant difference between patients’ CD4 
cut scores at week 21 and patients’ HIV viral load cut scores at week 21 in predicting 
antiretroviral medication adherence (χ2 [1] = 1.173, p = 0.279). This suggests that CD4 and viral 
load are not measuring ARV medication adherence in the same way. One possible explanation 
for this finding may be due to the nature of CD4 and viral load. As previously discussed, CD4 
and viral load capture different components of antiretroviral medication adherence. Specifically, 
viral load measures the viral particles found in each milliliter of blood, while CD4 measures 
patients’ immunologic response to antiretroviral treatment (AIDSInfo, 2018). Additionally, there 
may be some concerns when measuring patients’ CD4 counts. For instance, research suggests 
that CD4 monitoring can have poor sensitivity and specificity when detecting treatment failure, 
especially when CD4 cell counts are high (i.e., healthy level of cells; WHO, 2016a). 
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Furthermore, CD4 cell counts are highly variable and can change based on the time of day the 
blood was drawn or the body’s exposure to other infections (HIV.gov, 2017e).  
Despite these challenges, research consistently identifies CD4 count and HIV viral load 
as the most commonly used marker of HIV/AIDS to determine disease progression and 
effectiveness of antiretroviral treatments (AIDSInfo, 2018). Additionally, this study found a 
negative association between patients’ CD4 count and their viral load (φ = -.084) which 
demonstrated that patients’ CD4 counts increased, their viral load decreased. This finding is 
consistent with the past research regarding the relationship between these two biological markers 
(Yu & Wu, 2017). Furthermore, changes in patients’ CD4 and viral responses are important in 
determining mortality due to a lack of ARV medication adherence. Specifically, research 
suggests that a significant predictor of later mortality is the failure to achieve recommended 
thresholds for either CD4 count or viral within three to nine months of ARV medication 
initiation (Moore et al., 2005).This underscores the importance of using both biological markers 
(i.e., CD4 and viral load) in routine clinical practice and HIV/AIDS outcomes related research. 
However, CD4 and viral load testing alone does not ensure linkage to care and sustained 
medication adherence. Furthermore, this data is not only important to HIV service providers in 
determining appropriate treatment services but for patients who use these markers to understand 
how HIV affects their bodies. As previously discussed, individuals’ belief that change is possible 
is enhanced through the support of self-efficacy (Treasure, 2004). In turn, supporting 
individuals’ self-efficacy likely satisfies their need for competence, an essential component of 
SDT that promotes overall wellbeing. For instance, Pasternak and colleagues (2015) suggest that 
CD4 counts may impact patients’ perception of ARV medication effectiveness. For some 
individuals, increased CD4 counts may encourage medication adherence because individuals 
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believe the medications are working. Comparatively, increased CD4 counts may decrease 
medication adherence because individuals see themselves as healthy and no longer needing the 
medications. Patients need to know the results of their CD4 and viral load tests (competence) as 
these results can have implications for how they choose to engage in their HIV treatment 
(autonomy). 
Study Limitations 
This section discusses the limitations of the current study including the research design 
and statistical analysis.  
Archival data. A limitation of the study is the use of archival data. More specifically, the 
data was not collected to address the research questions identified in this study. Data was 
gathered during the routine clinical intake process and then transformed to fit the research 
questions. Thus, limiting the variables of study (Cheng & Phillips, 2014). Another limitation of 
archival data analysis is that the lead researcher and those involved in data collection were not 
the same individuals (Cheng & Phillips, 2014). More specifically, patients’ responses to the 
Annual Risk Assessment Screening Tool were collected by medical case coordinators. Staff 
changes, reorganization of staff roles, and changes in clinic procedures which may have resulted 
in missing data, were not in the lead researcher’s control. Despite these limitations, using 
archival data for this study was expeditious and cost-efficient. 
Cross-sectional design. Another limitation of this study is the use of a cross-sectional 
design, which captures a specific point in time and may not accurately reflect participant long-
term barriers or medication adherence. More specifically, because the current study examined 
patients’ barriers only at intake, the effect of the barriers on patients’ antiretroviral medication 
adherence over time is unknown. Grau and colleagues (2017) suggest that substance use often 
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increases after an HIV diagnosis as a coping mechanism. Additionally, substance use concerns 
for PLWHA can create other sources of instability (e.g., housing insecurity, financial), which 
may have confounded the influence of the barriers. Future research should explore the 
relationship between barriers and medication adherence at intake as well as over time. For those 
with substance use concerns, it may be important to determine if and how other predictive 
variables may be influencing (moderating) the strength of the relationship. Future research may 
benefit from utilizing a longitudinal perspective and examining biopsychosocial barriers and 
ARV medication adherence at multiple intervals of time. Moreover, qualitative research may 
provide a richer narrative for understanding patients’ perspectives on how various barriers affect 
their ability to engage and maintain antiretroviral medication adherence. 
Study sample. Because this study describes a cross-section of the current patients at the 
BSOMHIV Clinic during a specific range of time, there is no information about individuals who 
were not actively in care. Out of the initial 627 patient records identified based on patients’ 
intake date, only 409 were considered for study inclusion. This study did not capture information 
for patients who had fallen out of care between intake and week 21. Furthermore, Colasanti et al. 
(2017) found that patients who were not retained in care had more unmet needs when compared 
to those who were continuously retained in care. Excluding individuals who are not enrolled in 
care or had fallen out of care introduces bias, as comparisons between current patients and 
individuals who are not currently in care were not made. For example, patients’ who are in care 
may be more motived (or self-determined) to engage in the treatment process when compared to 
those who are currently out of care. Future studies may expand this study’s reach and explore the 
barriers to antiretroviral medication adherence for out-of-care patients diagnosed with 
HIV/AIDS. 
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Hanna, Selik, Tang, and Gange (2012) suggested that there are state-specific contextual 
barriers to care for PLWHA. The sample for this study comes from a 30-county catchment area 
of eastern North Carolina. This geographic area is considered predominately rural with 12 to 33 
percent of the residents living at or below the poverty level. Similar to the study by Wawrzyniak 
et al. (2015), this study was conducted at a clinic where patients typically represent a lower 
socioeconomic status. Because of patients’ socioeconomic status, the sample may inherently 
have more barriers, including those that were not considered in this study’s design (e.g., financial 
concerns). This, in turn, limits the interpretation of the study’s results to patients from eastern 
North Carolina who fit a specific sociodemographic profile. To increase generalizability, future 
research should increase the sample size to include patients that cross-cut an array of 
sociodemographics. 
Study variables. This study chose to examine six factors (physical health, mental health, 
substance use, housing, transportation, and employment concerns) as well as motivational 
interviewing as predictors of ARV medication adherence. While substance use was found as a 
predictor of ARV medication adherence as measured by patients’ HIV viral load, this study 
acknowledges that there may be other individual and system-level barriers to ARV medication 
adherence for PLWHA. Additionally, the BSOMHIV Clinic utilized screening tools for 
substance use and mental health while the other barriers were self-report. This may have 
introduced recall error as well as social desirability bias.   
Antiretroviral medication adherence was measured using patients’ CD4 cut scores at 
week 21 and HIV viral load cut scores at week 21. However, this study acknowledges that CD4 
and viral may be capturing ARV medication adherence differently. Furthermore, research 
suggests that in clinical trials with short follow-up periods, viral load is often treated as an 
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endpoint, while CD4 count is viewed as a covariate (Yu & Wu, 2017). Future studies may 
consider treating viral load as a response variable and adding CD4 to the model as a covariate. 
Yu and Wu (2017) suggest that interpretation error can occur in HIV/AIDS research due 
to measurement errors, outliers, and missing data. Although the current study dichotomized data 
to reduce the influence of outliers, the archival study design did present instances of missing 
data. Absent observations on study variables decreased the final sample size and weakening the 
statistical power of the results. Despite missing data, this study was able to use stratified, random 
sampling which increases generalizability. 
Statistical analysis. A limitation of logistic regression is the loss of information due to 
reducing variables to dichotomous levels (Ranganathan, Pramesh, & Aggarwal, 2017). Although 
this study’s dichotomous cutoffs for patients’ CD4 counts and HIV viral loads were in keeping 
with past research, this study was unable to explore the amount of change in each outcome 
variables and if changes occurred in one or more of the predictive variables. Future research 
should consider using multiple linear regression to explore the relationship between patients’ 
CD4 count, HIV viral load and one or more explanatory variables (e.g., alcohol use). Further, 
multiple linear regression would allow for CD4 counts and HIV viral loads to be analyzed as a 
continuous variable. 
Another limitation of logistic regression is equations derived for a specific sample may 
not apply to other samples (Ranganathan et al., 2017). For this study, logistic regression models 
may only be applicable to samples with similar sociodemographic variables. Future studies may 
consider using repeated measures, which allows for multiple measurements of each 
subject/patient (Moore et al., 2009). Repeated measures would also assist in controlling for 
factors that cause variability between subjects, resulting in a more statistically powerful analysis. 
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Even with these limitations, logistic regression was still considered an appropriate statistical 
analysis for this study. Specifically, logistic regression provides model percentages and makes 
meaningful predictions of biological variables (Zhao, Chen, & Schaffner, 2001). 
Implications for Healthcare Professionals, Counselors, and Counselor Educators 
The results of this study have implications for healthcare professionals, counselors, and 
counselor educators. More specifically, finding substance use as a barrier to medication 
adherence supports previous research that underscores the need for healthcare professionals and 
counselors to address substance use concerns in PLWHA. For example, Grau et al. (2017) found 
that PLWHA with co-occurring substance use disorders were more likely to acquire 
opportunistic infections and experience disease progression than PLWHA without-occurring 
substance use disorders. Self-determination theory may provide an explanation for this trend. 
Specifically, those with substance use concerns may experience more difficulty attending to 
basic needs (e.g., housing, financial stability), which can diminish individuals’ capacity to attend 
to higher-order psychological concerns (i.e., autonomy, competence, and relatedness) that ensure 
overall wellbeing. However, utilizing a multidisciplinary approach may alleviate these concerns 
by addressing basic needs while concurrently supporting patients’ ability to attend to higher-
order concerns. For instance, patients may present with concerns related to housing and the 
subsequent stress of homelessness. In this situation, case managers may link patients to 
temporary housing while behavioral health specialists provide psycho-education regarding the 
interplay of stress and HIV and suggest effective coping skills. 
Furthermore, research recommends screening for substance use should be standard 
practice when treating PLWHA (Kader, Govender, Seedat, Koch, & Parry, 2015). Again, the 
current findings that substance use as a predictor of ARV medication non-adherence supports 
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this suggestion. Additionally, cross-training among health care providers and addiction 
counselors would assist in the identification and treatment of substance use concerns which in 
turn may improve medication adherence (Kader et al., 2015). Specifically, cross-training would 
consist of psychoeducation concerning the link between substance use and HIV and how to refer 
patients appropriately to different levels of substance use treatment within (e.g., smoking 
cessation sessions with an on-site behavioral health specialist) or beyond HIV clinics (e.g., 
inpatient substance abuse treatment facility). The Annual Risk Assessment and Screening Tool 
(Appendix B) used by healthcare professionals at the BSOMHIV Clinic is an example of how to 
incorporate substance use screening into the routine of clinical practice. 
Healthcare professionals and counselors may utilize SDT as a theoretical framework for 
conceptualizing patients’ motivation and innate tendency towards growth in supportive 
environments. From an SDT perspective, healthcare providers and counselors may understand 
how essential patients’ motivation is for obtaining HIV/AIDS-related health goals (e.g., getting 
better, maintaining virological suppression).  
In the current study, no difference was found when the BSOMHIV Clinic moved from a 
strength-based case management approach to a motivational interviewing approach. That is, 
medication adherence was high regardless of the approach used. Strength-based case 
management or motivational interviewing may offer healthcare providers and counselors with 
the clinical tools needed to help facilitate health-related behavioral changes including ARV 
medication adherence. Furthermore, recent research suggests that motivational interviewing 
training is most effective in altering the relational component (i.e., the patient-centered 
orientation) of trainees (Beach et al., 2018). Thus, the adoption of a patient-centered approach 
found in both strength-based case management and motivational interviewing may be the key to 
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healthcare professionals and counselors engaging PLWHA in the treatment process. 
Additionally, strengths-based case management, motivational interviewing, and SDT have many 
conceptual overlaps and promote similar themes to elicit change within supportive environments. 
Given the number of individuals currently living with HIV/AIDS as well as the 
presentation of co-occurring psychosocial concerns (e.g., substance use, mental health, social 
stigma), it is likely that counselors are or will works with individuals who have a seropositive 
status (Rose, Sullivan, Hairston, Laux, & Pawelczak, 2015; Owen-Pugh & Baines, 2014). As 
such, counselors need an awareness of the unique counseling concerns that arise when working 
with PLWHA. This awareness begins during counselors’ formal education. Counselor educators 
prepare students to serve as competent counselors who are capable of working with different 
populations (e.g., substance use, mental health) in an array of clinical settings (Council for 
Accreditation of Counseling and Related Educational Programs [CACREP], 2015). Research 
suggests that many clinicians do not receive adequate preparation during their graduate training 
to work with PLWHA (Joe & Foster, 2017).  
One of the challenges counselor educators face is balancing the demands of accreditation 
standards for general counseling-related content, while also providing learning opportunities for 
special topics such as HIV/AIDS. While professional development and continuing education 
opportunities with an HIV/AIDS focus exist, there is no guarantee that counselors use these 
opportunities to obtain knowledge and skills needed to work effectively with PLWHA (Joe & 
Foster, 2017). Furthermore, counselor education programs with a clinical mental health or 
addictions focus may not incorporate strength-based case-management into their curriculum. As 
discussed previously, a strengths-based case management approach can be essential for PLWHA 
with biopsychosocial barriers to care.  
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Despite these challenges, counselor educators have the framework necessary to 
incorporate HIV/AIDS-specific learning. For instance, many courses in counselor education 
programs do include biopsychosocial case conceptualization (CACREP, 2015). This provides 
opportunities for counselor educators to engage students in case conceptualization activities that 
incorporates and discusses biopsychosocial concerns unique to PLWHA. As well, Section 2 of 
CACREP’s (2015) 2016 standards of accreditation suggests “strategies for identifying and 
eliminating barriers, prejudices, and processes of intentional and unintentional oppression and 
discrimination” (p. 9) should be incorporated into the counseling curriculum. Counselor 
educators acting as supervisors for students have an opportunity to support students’ self-
exploration of their perceptions, attitudes, and biases regarding PLWHA. Finally, counselor 
educator can expand their experiential courses (i.e., practicum and internship) to include clinical 
settings in which counselors-in-training gain supervised exposure to working with PLWHA.  
Recommendations for Future Research 
This study provides a new understanding of the influence of biopsychosocial barriers and 
motivational interviewing to ARV medication adherence. Furthermore, this study found that 
patients with a substance use barrier are 8 to 10 times more likely to be virologically 
unsuppressed. Though the other five biopsychosocial variables were not significant, the results 
suggest that one or more of these barriers contribute to the influence of the substance use barrier 
on viral load. Further research on these variables is recommended. For instance, statistical 
analysis may treat barriers to physical health, mental health, housing, transportation, and 
employment as covariates that explain the influence of the substance use barrier. Additionally, as 
discussed previously future research should explore the relationship between barriers and 
medication adherence at intake as well as over time. 
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An emerging concept called syndemics is being discussed in HIV/AIDS-related literature. 
Specifically, syndemics refer to when two or more endemics or epidemics occur simultaneously 
and act synergistically (WHO et al., 2017). This suggests that HIV and other major 
biopsychosocial concerns (e.g., co-occurring sexually transmitted infections, substance use) do 
not occur in isolation and must be addressed comprehensively. For example, there is a growing 
rise in the number of individuals with opioid use concerns across the United States. Future 
research may consider looking at the regional biopsychosocial concerns (e.g., substance use) that 
may be synergistically influencing the effective treatment of HIV. 
Finally, to determine the validity and reliability of the current study’s results, replication 
is needed. Because this study used a secondary analysis of data collected, interpretation of results 
as applied to the research questions were limited. Specifically, there may be other important 
variables such as patients’ self-reported adherence or patients’ self-efficacy that were not 
available for the analysis. Additionally, as discussed previously, the data collected during this 
study was transformed to fit the research questions. Future studies should include primary data 
collection procedures that explore the relationship between biopsychosocial barriers, 
motivational interviewing and ARV medication adherence. 
Conclusion 
Adherence to antiretroviral medications is a complex issue for PLWHA. Research 
supports the success of antiretroviral medications for the management of HIV as a chronic illness 
(Palmisano & Vella, 2011). However, the effectiveness of ARV medications is contingent on a 
strict medication adherence regimen (HIV.gov, 2017a). Self-determination theory provides a 
theoretical framework that explains how healthcare professionals can work collaboratively 
(relatedness) with patients and empower them with the knowledge (competence) necessary to be 
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actively involved in the decisions about their HIV treatment (autonomy). However, PLWHA 
may be unable to attend to these psychological needs due to unmet basic human needs. To foster 
medication adherence with PLWHA, research encourages the use of non-judgmental, case 
management model to address biopsychosocial concerns that may pose as barriers to HIV/AIDS 
care (Broeckaert & Challacombe, 2015). 
HIV/AIDS-related research is an ever-growing body of knowledge. The results provided 
in this study illuminates one piece of a much larger paradigm. While statistical significance was 
not found for many of the barriers, the current findings begin the discussion as to what the 
barriers are for PLWHA. Specifically, substance use is an important barrier that warrants further 
research for PLWHA with similar sociodemographics. Further, barriers to HIV/AIDS-related 
care do not exist in isolation. Rather, they are interconnected. The results of the current study 
suggest that the interconnectedness of barriers may be particularly true for PLWHA with 
substance use concerns. This reiterates the importance of integrating multidisciplinary care into 
HIV/AIDS treatment services, particularly in rural areas where access to healthcare may be 
difficult or limited. Future research exploring substance use treatment and ARV medication 
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East Carolina University-Brody School of Medicine HIV Program (ECU-BSOMHIVP) proposes to use 
supplemental Ryan White part D (RWPD) funding to train staff involved in treatment adherence in 
motivational interviewing technique (MIT) to promote treatment adherence.  Fifteen staff members will 
be trained to include: medical care coordinators; medication adherence clinical pharmacist; substance 
use/mental health counselor; and some nurses and medical care providers.  The target population will be 
women (in particular Black/African American women who represent 80% of our female population) and 
young men >18 to <25 years of age receiving primary HIV medical care at BSOMHIVP.  The primary 
goal of the intervention is to increase our staff ability to use an evidence-based communication approach 
to identify barrier to retention and what will motivate clients towards retention in care.    
The MI training will be done at the BSOMHIV clinic and facilitated by staff from ECU Department of 
Additions and Rehabilitation Studies certified in MI technique training.  This project will train existing 
personnel to integrate MI into their communication with clients on an everyday basis.  The staff will use 
MI to promote retention by helping clients to keep two-provider appointments/CD4/VL twice in a 12 
month monitored period, to take their medication as prescribed and substance use reduction or abstinence.  
Promoting retention in care is one of the National HIV/AIDS Strategies to Increasing Access to Care and 
Improving Health Outcomes for people living with HIV:  By 2015, increase the proportion of Ryan White 
HIV/AIDS Program clients who are in continuous care (at least 2 visits for routine HIV medical care in 
12 months at least 3 months apart) from 73 percent to 80 percent (1). Our quality management data 
indicates that our WICY clients are not meeting this national standard.  MI training will help our staff to 
gain the ability to use open ended questions and listening skills to identify barriers to retention in care and 
to help identify what will motivate clients to set treatment adherence goals and medication adherence.         
II. Needs Assessment 
Description of Burden  
The ECU-BSOMHIVP is located in Greenville, NC, which is approximately 90 miles east from Raleigh, 
NC and 100 miles west of the Outer Banks, NC.  This includes a 30-county catchment area of eastern 
North Carolina (ENC), which is predominantly rural, with limited to no public transportation, and 12% to 
33% of residents live at or below poverty level (2).  BSOMHIVP provides comprehensive primary HIV 
medical care to the predominately rural area of eastern North Carolina (ENC).   BSOMHIVP is a ‘One 
Stop’ clinic that provides several core and support services:  primary HIV medical care, substance use and 
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mental health counseling, medical care coordination/medical case management; medication adherence 
clinical pharmacist counseling; gynecology care for all non-pregnant women; peer- led prevention for 
positives support groups; RW transportation assistance and 340b prescription assistance program.  MI 
training will be integrated within the existing infrastructure of the BSOMHIVP and is an efficient use of 
resources.  
 
In 2013 BSOMHIVP provided care for 1,455 unduplicated HIV positive people living with HIV (PLWH) 
disease.  Our quality management data for WICY clients in calendar years 2012 and 2013 identified gaps 
in retention in care:  In 2012, 44% and in 2013, 52% of women had one medical visit in each 6-month 
period (at least 60 days apart) of the 24 months monitored period and young men (>18 - < 25 years) over 
the same period it was 16% and 35% respectfully.  Other retention in care gaps include: for women 63% 
(2012) and 72% (2013) had two CD4/VL labs 90 days apart; and for men 50% and 60% (respectfully).   
Some of our client’s demographic include: 77% (n = 1,119) were Black/African American, 4% (n = 56 
were Hispanic; 64% (n = 932) were male and 36% (n = 519) were women (80% Black/African 
American); 66% (n = 977) live at or below 100% Federal Poverty Level (FDL) and 21% (n= 311) 
between 100% and 200% of FDL; 55% (n = 805) had Medicaid or Medicare, 17% (n = 142) had other 
private insurance, 41% (n=595) were uninsured and 35% (n=514) received AIDS drug assistance program 
(2013 BSOMHIVP RSR).   The table below provided data on our program specific to WICY clients from 
January 1, 2012 to December 31, 2013 
 
ECU-BSOMHIVP HIV Care Continuum Data – January 1, 2012 to December 31, 2013  
Stages  Measurement Periods 
 
Calendar Year  2012 
  
Calendar Year 2013 
  
Number of HIV infected WICY 
persons in care 1 
551 97.70 % In care  573 97.12 % in care 
  564   590   
Number of WICY newly diagnosed 
with HIV 2 
37  6.56% Newly Dx. 39 6.6% Newly Dx.  
564   590   
Number of WICY linked to HIV 
care within 90 days of diagnosis 
TOTAL 3 
35  Linked to care  35  Linked to care 
37 94.59% 39 89.74% 
Number of WICY linked to HIV 
care within 90 days of diagnosis - 
WOMEN 3 .1  
24   17   
25 96.00% 19 89.47% 
Number of WICY linked to HIV 
care within 90 days of diagnosis 
MEN 18-24 3.2 
11   18   
12 91.67% 20 90.00% 
Number of WICY retained in care 
TOTAL  4 
169 Retained in Care 236  Retained in 
Care 
407 41.52% 451 52.33% 
Number of WICY retained in care  
WOMEN4.1 
162   209   
369 43.90% 405 51.60% 
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Number of WICY retained in care  
Men 18-244.2 
6   16   
38 15.79% 46 34.78% 
Number of WICY prescribed 
antiretroviral therapy TOTAl:5 
515 WICY on ART 541  Prescribed 
ART 
551 93.47% 573 94.42% 
Number of WICY prescribed 
antiretroviral therapy WOMEN5.1 
456   475   
483 94.41% 501 94.81% 
Number of WICY prescribed 
antiretroviral therapy MEN 18-245.2 
47   53   
68 69.12% 72 73.61% 
Number of WICY with virologic 
suppression Total6 
392  Virally Suppressed 447  Virally 
Suppressed 
551 71.14% 573 78.01% 




402   
483 73.29% 501 80.24% 
Number of WICY with virologic 
suppression Men 18-246.2 
38 
 
34   
68 55.88% 72 47.22% 
Number of WICY who received 2 
CD4 labs 90 days apart in 
measurement year TOTAL 7 
320 2 CD 4 Labs 90 
Days Apart 
376 2 CD 4 Labs 90 
Days Apart 
505 63.37% 522 72.03% 
Number of WICY who received 2 
CD4 labs 90 days apart in 
measurement year WOMEN 7.1 
286   341   
450 63.56% 522 65.33% 
Number of WICY who received 2 
CD4 labs 90 days apart in 
measurement year Men 18-24 7.2 
28   28   
55 50.91% 47 59.57% 
Number of WICY who received 2 
VL labs 90 days apart in 
measurement year TOTAL 8 
319 2 Viral Load Labs 
90 Days Apart 
373 2 Viral Load 
Labs 90 Days 
Apart 
505 63.17% 522 71.46% 
Number of WICY who received 2 
VL labs 90 days apart in 
measurement year WOMEN 8.1 
286 
 
338   
450 63.56% 475 71.16% 
Number of WICY who received 2 
VL labs 90 days apart in 
measurement year Men 18-24 8.2 
27 
 
35   





1. Numerator - Total number of WICY Infected with HIV and in care during the measurement year.                                                                                                                                                                                                                                    
Denominator - Total number of WICY with an HIV diagnosis during measurement year  
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2. Numerator - Total number of WICY newly diagnosed with HIV during measurement year 2012                                                                                                                                                                                                                   
Denominator - Total number of WICY with a HIV diagnosis during measurement year  
3. Numerator - Total number of HIV infected WICY in care during measurement year                                                                                                                                                    
Denominator - Total number of WICY newly  diagnosed with HIV  during measurement year  
3.1  Numerator - Total number of HIV infected Women in care during measurement year                                                                                                                                                    
Denominator - Total number of Women newly  diagnosed with HIV  during measurement year  
3.2 Numerator - Total number of HIV infected Men 18-24 in care during measurement year                                                                                                                                                    
Denominator - Total number of Men 18-24 newly  diagnosed with HIV  during measurement year  
4. Numerator - Number of WICY patients in the denominator who had at least one medical visit in each 6‐
month period of the 24‐month measurement period with a minimum of 60 days between first medical visit in 
the prior 6‐month period and the last medical visit in the subsequent 
6‐month period                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Denominator - Total number of  WICY, regardless of age, with a diagnosis of HIV with at least one medical 
visit in the first 6 months of the 24‐month measurement period 
4.1 Numerator - Number of Female patients in the denominator who had at least one medical visit in each 6‐
month period of the 24‐month measurement period with a minimum of 60 days between first medical visit in 
the prior 6‐month period and the last medical visit in the subsequent 
6‐month period                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Denominator - Total number of  Females regardless of age, with a diagnosis of HIV with at least one medical 
visit in the first 6 months of the 24‐month measurement period 
4.2 Numerator - Number of Men 18-24 in the denominator who had at least one medical visit in each 6‐month 
period of the 24‐month measurement period with a minimum of 60 days between first medical visit in the prior 
6‐month period and the last medical visit in the subsequent 
6‐month period                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Denominator - Total number of  Men 18-24,  with a diagnosis of HIV with at least one medical visit in the first 
6 months of the 24‐month measurement period 
5. Numerator - Number of WICY patients from the denominator with an HIV diagnosis and prescribed ART in 
the 12 month measurement period                                                                                                                                                                                                                                    
Denominator - Total Number of WICY patients with an HIV diagnosis with at least one O/A visit in the 12 
month measurement period. 
5.1  Numerator - Number of Female patients from the denominator with an HIV diagnosis and  prescribed 
ART in the 12 month measurement period                                                                                                                                                                                                                                    
Denominator - Total Number of Female patients  with an HIV diagnosis with at least one O/A visit in the 12 
month measurement period. 
5.2 Numerator - Number of Men 18-24 from the denominator with an HIV diagnosis and prescribed ART in 
the 12 month measurement period                                                                                                                                                                                                                                    
Denominator - Total Number of Men 18-24 with an HIV diagnosis with at least one O/A visit in the 12 month 
measurement period. 
6. Numerator - Number of WICY in the denominator with and HIV diagnosis with a viral load <200 
copies/mL at last test in the 12 month measurement period                                                                                                                                                                                                                                                              
Denominator - Total Number of WICY patients  with an HIV diagnosis with at least one O/A visit in the 12 
month measurement period. 
6.1 Numerator - Number of Females in the denominator with and HIV diagnosis with a viral load <200 
copies/mL at last test in the 12 month measurement period                                                                                                                                                                                                                                                              
Denominator - Total Number of Female patients  with an HIV diagnosis with at least one O/A visit in the 12 
month measurement period. 
6.2 Numerator - Number of Men 18-24 in the denominator with and HIV diagnosis with a viral load <200 
copies/mL at last test in the 12 month measurement period                                                                                                                                                                                                                                                              
Denominator - Total Number of Men 18-24  with an HIV diagnosis with at least one O/A visit in the 12 month 
measurement period. 
7. Numerator - Total Number of WICY who had at least 2 CD 4 Labs at least 3 months Apart                                                                                                             
Denominator - Total number of HIV Infected WICY who had at least one medical visit during the 
measurement year 
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7.1  Numerator - Total Number of Women who had at least 2 CD 4 Labs at least 3 months Apart                                                                                                             
Denominator - Total number of HIV Infected Women who had at least one medical visit during the 
measurement year 
7.2 Numerator - Total Number of Men 18-24 who had at least 2 CD 4 Labs at least 3 months Apart                                                                                                             
Denominator - Total number of HIV Infected Men 18-24 who had at least one medical visit during the 
measurement year 
8. Numerator - Total Number of WICY who had at least 2 Viral Load Labs at least 3 months Apart                                                                                                             
Denominator - Total number of HIV Infected WICY who had at least one medical visit during the 
measurement year 
8.1 Numerator - Total Number of Women who had at least 2 Viral Load Labs at least 3 months Apart                                                                                                             
Denominator - Total number of HIV Infected Women who had at least one medical visit during the 
measurement year 
8.2 Numerator - Total Number of Men 18-24 who had at least 2 Viral Load Labs at least 3 months Apart                                                                                                             




Advances in the HIV treatment over the past decade have led to improved outcomes and longer, higher 
quality of life for PLWH. This has been accomplished, in part, due to the Ryan White Care Act, which 
provides primary HIV medical care and support services.  Given the chronicity of successful HIV care, 
successful interventions will need to provide sustainable improvement in linkage and retention and must 
address the range of barriers faced by people living with HIV/AIDS, especially among harder to reach 
populations like women, communities of color and young MSM. Some of these barriers include 
competing needs, poverty, decreased educational achievement, gender imbalance, stigma, mental illness 
and substance use, among other factors. These barriers and others (joblessness, homelessness, denial, 
racism, discrimination, disclosure and confidentiality concerns and religious/cultural beliefs  (alternative 
medicines and prayer) have been shown to be competing concerns to health care (3, 4).   
 
The interplay between these barriers makes for a complex matrix that contributes to the vulnerability of 
women and young men living with HIV disease.    These barriers also interfere with timely entry into 
primary HIV medical care after diagnosis and the subsequent retention of clients in care and remain 
significant challenges. Previous evaluations of interventions aimed at addressing these barriers, in 
particular those outlined in the HRSA publication “Making the Connection: Promoting engagement and 
retention in HIV medical care among hard-to-reach populations,” have been encouraging. The programs 
described in the publication targeted a wide range of populations and used a variety of interventions 
aimed at engaging and retaining harder to reach populations. These programs also highlighted the creative 
use of existing personnel and highlighted the need to seamlessly insert new interventions within the 
framework of existing operations and the importance of ongoing quality assurance measures to provide 
periodic improvements to the intervention (5).  
 
Proposed Intervention:  
Motivational interviewing (MI) is a client-centered counseling style for eliciting behavior change by 
helping clients to explore and resolve ambivalence.  Providers trained in MI use a specific approach in 
conversation with clients to help them develop the motivation to initiate and sustain behavioral change.  
MI was first developed in connection with substance use treatment and is now used in a range of 
behavioral health applications (smoking cessation, medication adherence, and weight management).  
Research has shown that MI can produce significant change in client health behavior in general (6).  In 
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HIV care, MI can be used to address risk behaviors to help people better manage their HIV and improve 
health outcomes.  MI has been used in a variety of Health Resources and Services Administration, 
HIV/AIDS Bureau (HAB), Special Projects of National Significance (SPNS) demonstration projects (6).  
At BSOMHIVP clinic, MI will be used to foster retention in care, medication adherence, and 
subsequently VL suppression.   
 
Training ECU-BSOMHIVP staff in MI will provide the staff with an evidence-based tool to identify 
barriers to treatment adherence and to help motivate clients to choose behaviors that support retention in 
care. This new intervention will train staff in the use of open-ended questions and listening skls.  We 
intend to train a variety of our team members who are involved in different aspect of treatment adherence 
(medical care coordinators, medication adherence clinical pharmacist, substance use-mental health 
counselor, nurses and medical provider).  The cross-sectional staff will use MI to promote client center 
goals related to the provider’s sub-specialty and within our multidisciplinary group settings.  The medical 
care coordinators will use MI training to communicate with clients with open-ended questions and 
listening skills to identify client’s barriers and what will motivate client to address barriers identified.  
The medication adherence clinical pharmacist will use MI to identify barriers to medication adherence.  
The substance use-mental health counselor can use MI to motivate client towards realistic achievable goal 
of substance use reduction or abstinent.  Nurse and providers can use MI to identify barriers to treatment 
adherence and the need for referring clients to one of our support providers: medical case manager, 
medication adherence clinical pharmacist, and substance use-mental health counselor.  Each team 
member interacts with our clients and has unique opportunity to gather information from the client about 
their barriers to treatment adherence and what may motivate a client towards treatment adherence.  
Clients information collected form many providers will be shared at one of our two multidisciplinary 
meeting:  Monday Morning Case Conference where clients’ treatment plans are reviewed and all new/re-
engaging clients for that week are discussed; and Monthly Treatment Adherence Team (TAT) meeting 
where client’s with complex issues are discuss and individualized treatment care plans are developed.  
 
MI training is aimed at improving our staff competency in the use of MI to gather information from 
clients and motivate clients to set goals to be compliant with provider visit and getting CD4 and VL 
studies done twice a year which will promote retention in care. Our intervention approach has the 
following primary objectives:  
• 90% of the staff identified for the training will complete the beginning intense training 
and participate in the ‘Learning Community’ phase of the program to enhance 
participants’ skill level to that of ‘Competency’.  
• Increase the percent of women and young men (>18 - <25 years) with one medical visit 
in each 6-month period (at least 60 days apart) of the 24 months monitored period to 65% 
for women from 52% and  50% for young men from 35%  
• Increase the percent of WICY that have two CD4/VL 90 days apart in 12 month monitor 




The target population include women (in particular Black/ African American women who represent 80% 
of our female population) 18 years and older and young men > 18 years and < 25 year of age.   All clients 




Project CARE will be a clinic-based initiative that will train staff at ECU-SOMHIVP to use MI to help 
motivate clients to be treatment adherent.   The medical care coordinators will serve as the main contact 
for clients and will follow clients for the duration of the intervention.  Other staff that is involved in 
treatment adherence will also be trained to include: medication adherence clinical pharmacist who is 
directly involved in medication adherence; substance use/mental health counselor; and some nurses and 
medical care providers.   
 
Motivational Interviewing training will be offered by a team trained in MI at Department of Addictions 
and Rehabilitation Studies at East Carolina University (ECU).  Dr. William ‘Leigh’ Atherton is an 
Assistant Clinical professor, Director of the Navigate Counseling clinic and Field Site Coordinator for 
MS Programs at ECU’s Department of Addiction and Rehabilitation Studies.  He has over 10 years of 
clinical experience in the mental health substance use field.  He has been a member of the Motivational 
Interviewing Network of Trainers (MINT) since 2008 and has conducted over 2500 hours in MI training.  
Dr. Paul Toriello is an Associate Clinical Professor at Department of Addictions and Rehabilitation 
Studies at ECU.  He has been a MIT trainer since 1995 to include advanced MI trainer, trainer of MI 
integrity coding system and did the MI advanced training curriculum.  A doctoral candidate, to be 
announced, will also work on the program to assist Drs. Atherton and Toriello with the implementation of 
the program over the grant year.    
 
The MI training will be provided over one year to include an intense introduction to MIT and the 
development of Learning Community groups. The intense introduction phase aims to enhance 
participants’ initial skill level to that of ‘Beginning Proficiency’.  The Learning Community groups will 
engage participants in follow-up continuous learning, focused skill building sessions and coaching 
facilitated by MIT experts. The aim of the ‘Learning Community’ phase is to enhance participants’ skill 
level to that of ‘Competency’.   The facilitators will use the learning-to-learn model in which the 
emphasis is on the spirit of MI to reflect understanding and practice of the MI approach. It is the goal that 
participants in the MI training will be able to identify client’s responses that indicate a good response to 
MI and not-so-good responses.  Research have identified that MI is an evidence-supported clinical 
method to promote behavioral change to support health care, that it can be disseminated in to practice, 
and feedback and/or coaching improves MI retention and proficiency after an intense clinical workshop 




1. Understand Spirit and Principles of MI 
2. Develop skill and comfort with Reflective Listening 
3. Exchange information and advice provision within a MI style 
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4. Recognize, evoke, and respond to change and sustain talk language 
5. Develop hope and confidence using MI 
6. Strengthen commitment to change 
7. Negotiate effective change plans 




I. Introduction (1 full day training) 
a. MI Primer 
b. Individualized MI Training goal development 
c. Introduce MI interventions for specific target behaviors 
i. HIV Testing and Linkage to Care 
ii. Engagement and Retention in Care 
iii. Adherence to Antiretroviral Therapy 
II. Motivational Interviewing Knowledge (two 4-hour trainings) 
a. Spirit & Principles 
b. Styles of communication 
c. Introduction to Motivational Interviewing Treatment Integrity (MITI) coding system 
III. Learning Community (multiple 4-hour skill building and coaching sessions) 
a. Engaging:  
i. Opening Strategies & Rolling with Resistance 
ii. Coaching and Coding 
b. Focusing and Evoking 
i. Elicit and Respond to Change Talk 
ii. Coaching and Coding 
c. Planning and Integration  
i. Change Plan  
IV. Internal Champion Coaching (bi-weekly 1-hour advanced coaching/train-the-trainer session 
a. Train-the-Trainer skill building 
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i. Training, coaching, and coding MI 
b. Development of a sustainable training/coaching plan 
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*Champions will get intense MI training to be able provide MI support after the project ends 
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living with HIV 
disease 
 
Young men >18 
- <15 years of 
age living with 
HIV disease 
• 90% of the staff identified for the training 
will complete the beginning intense training 
and participate in the ‘Learning Community’ 
phase of the program to enhance participants’ 
skill level to that of ‘Competency’.  
• Increase the percent of women and young 
men (>18 - <25 years) with one medical visit 
in each 6-month period (at least 60 days apart) 
of the 24 months monitored period to 65% for 
women from 52%  and  50% for young men 
from 35%  
• Increase the percent of WICY that have two 
CD4/VL 90 days apart in 12 month monitor 
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 period: women to 80% from 75% and young 
men (>18 - <25 years) to 70% from 60%. 
 
IV. Evaluation:  
Evaluation is critical to determining programmatic success. We will measure the effectiveness of the staff 
to use MIT by qualitative and quantitative methods. Quantitative evaluation will include pre and post staff 
survey on knowledge of MI and chart review of clients that do not met HAB performance for provider 
visits, CD4/VL, and VL suppression.  Data collected in RWY 2014-2015 on these performance indicators 
will be compared with 2012 and 2013 data.  The qualitative measure will include observation of staff-
client interviews and feedback from staff members trained in MI.  Further, MI skill proficiency will be 
assessed through the use of the Motivational Interviewing Treatment Integrity (MITI) 3.0 coding system. 
Staff will submit audio recordings representing their use of MI, which will be coded by MI experts using 
the MITI coding system. MI proficiency standards range from ‘Beginning Proficiency’ to ‘Competency’. 
MI experts will develop an initial individualized training plan with each staff, which will be continuously 
reviewed and updated based on the staff’s level of progress with MI skills. The following table depicts the 
MITI 3.0 coding system and benchmarks. 
 





Global Clinician Ratings Average of 3.5 Average of 4 
Reflection to Questions Ratio 1:1 2:1 
Percent Open Questions 50% 70% 
Percent Complex Reflection 40% 50% 
Percent MI-Adherent 90% 100% 
 
The overall evaluation outcomes, lessons-learned, and recommended best-practices resulting from the 
program will be summarized and reported to the Ryan White project officer at regular intervals.  Findings 
will be used to make policy recommendations to improve retention in care between women and young 
men, to reduce barriers that will allow clients to participate in long-term HIV treatment 
 
Brief Biography of Motivational Interviewing Trainers 
William “Leigh” Atherton, PhD, LPC, LCAS, CRC, CCS  
Dr. Atherton currently holds the position of Clinical Assistant Professor, Director of Navigate Counseling 
Clinic, and Field Site Coordinator for MS programs within East Carolina University’s Department of 
Addictions and Rehabilitation Studies. He has over 10 years of clinical experience in the mental health 
and substance use field, serving as a clinician, supervisor, and educator. He has been a member of the 
Motivational Interviewing Network of Trainers (MINT) since 2008, and has conducted over 2500 hours 
of training specific to Motivational Interviewing. His extensive experience with Motivational 
Interviewing (MI) includes:  
 
• *Practicing and supervising MI since 2004,  
• *Training in Advanced MI from William Miller, the co-creator of MI, and Theresa Moyers,  
• *Training by Dr. Miller and Theresa Moyers as a MI Trainer,  
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• *Training in “MIA: STEP” (MIA:STEP is a MI clinical supervision curriculum),  
• *Membership with the international Motivational Interviewing Network of Trainers since 2008  
• *MI interventionist for NIDA R01 funded Project Safe through Boston Medical Center   
emergency department.  
 
Paul Toriello, PhD, CRC, LCAS, CCS 
Dr. Toriello is an Associate Professor in the Department of Rehabilitation Studies at East Carolina 
University (ECU). Before coming to ECU, Dr. Toriello served for several years as the Training Director 
and then the Clinical Director of a 108-bed residential facility serving adjudicated adolescents with 
behaviors disorders and substance use issues. His extensive experience with Motivational Interviewing 
(MI) includes: 
• Practicing and supervising MI since 1995,  
• Training in Advanced MI, 
• Training as a MI Trainer,  
• Training in the Motivational Interviewing Treatment Integrity coding system, 
• Training as a “MIA:STEP Trainer (MIA:STEP is a MI clinical supervision curriculum), and 
• Membership with the international Motivational Interviewing Network of Trainers since 2003. 
 
For his MI research 2005, Dr. Toriello won an American Rehabilitation Counseling Association Research 
Award. He has conducted over 2000 clock hours of MI training with a broad spectrum of professionals. 
Finally, in the role of Principal Investigator or Research Consultant, Dr. Toriello has participated in grant 
projects funded by the National Institute on Drug Abuse, National Institute on Alcohol Abuse and 
Alcoholism, Center for Substance Abuse Treatment, and other national funding organizations.  
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APPENDIX D: Qu’Nesha Hinton – Curriculum Vitae  





East Carolina University (ECU) 
Ph.D., Rehabilitation Counseling and Administration Expected May 2018 
 
M.S., Substance Abuse and Clinical Counseling August 2014 
Certificate in Rehabilitation Studies (CRC Eligible) 
 
University of North Carolina at Chapel Hill 
B.A., Psychology May 2012 
Anthropology minor 
 
PROFESSIONAL LICENSURE & CERTIFICATIONS 
 
National Certified Counselor (NCC #811372) February 2018 
 
North Carolina Board of Licensed Professional Counselors – Associate (LPCA #A11830) September 2015 
 
North Carolina Licensed Clinical Addictions Specialist – Associate (LCASA #20587) September 2014 
 
PUBLICATIONS IN PRESS  
 
Tate, T.T., Hinton, Q.S. (2016). Preparing service members for the civilian workforce: A test review of 
the Military-to-Career Transition Inventory (MCTI). 
 
Hinton, Q.S., Goodwin Jr., L.R. (2016). Barriers to wellness for counseling students. VISTAS Summer 
2016. Retrieved from http://www.counseling.org/knowledge-center/vistas  
 
PRESENTATIONS AT PROFESSIONAL MEETINGS 
 
Hinton, Q.S. (2017, April). STIs 101. Presentation at the local fourth annual Community Health Fair of 
Goldsboro High School, Goldsboro, North Carolina. 
 
Meola, C., Hinton, Q.S. (2017, March*). Addressing Counselor Wellness through Equine Assisted 
Learning. Poster session at the national conference of the American Counseling Association 2017 
Conference and Expo, San Francisco, California. *Proposal accepted. 
 
Hinton, Q.S., Meola, C., Sias, S. (2016, July). Unique Supervision Needs for Counselors Working with 
People Living with HIV/AIDS. Poster session at the national conference of the 40th Anniversary American 
Mental Health Counselors Association Annual Conference, New Orleans, Louisiana. 
 
Hinton, Q.S., Gilbert, G. D., Williams, P. (2016, April). HIV and STDs 101. Presentation at the local 
third annual Community Health Fair of Goldsboro High School, Goldsboro, North Carolina. 
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Hinton, Q.S., Sanders, M. (2016, April). Effective Treatment for People Living with HIV/AIDS (PLWHA) 
and Co-Occurring Substance Use Disorders (SUDs) for Community Care Providers. Presentation at the 
state conference of the University of North Carolina – Chapel Hill Horizons 2016 Annual Conference, 
Chapel Hill, North Carolina.  
 
Sanders, M., Hinton, Q.S. (2016, April). Using the BESI with clients from an economically depressed 
background. Presentation at the state conference of the North Carolina Vocational Evaluation and Work 
Adjustment Association and North Carolina Vocational Evaluation and Career Assessment Professionals 
Training Conference, Atlantic Beach, North Carolina. 
 
Atherton, W.L., Hinton, Q.S., Meola, C. (2016, March). Clinical Supervision: Fundamentals in 
addictions and rehabilitation counseling. Presentation at the national conference of the Professional 
Association of Rehabilitation Counselors (PARC) 2016 Annual Conference, Atlantic Beach, North 
Carolina.  
 
Hinton, Q.S. (2015, July). Living with HIV/AIDS and co-occurring mental health and substance use 
disorders. Presentation at the Safe Spaces Program, Greenville, North Carolina. 
 
Hinton, Q.S., Montgomery-Lee, E. (2014, December). Fetal alcohol spectrum disorders. Presentation at 
the Pitt County Coalition on Substance Abuse Town Hall Meeting, Greenville, North Carolina. 
 
Hinton, Q.S., Harris, J.D. (2014, April). Co-occurring body dysmorphic disorder and substance use 
disorder: Considerations for racial and sexual minorities. Poster session at the state conference of the 8th 
Annual Rehabilitation of Racial and Ethnic Minorities with Behavioral Addictions (REMBA) 
Conference, Greensboro, North Carolina. 
 
Bell, A. M., Hinton, Q.S., Gilbert, G. D. (2014, February). Navigate – Pregnancy and Recovery Clinic: 
Using motivational interviewing in an integrated healthcare program. Poster session at the state 
conference of the Jean Elaine Mills 10th Annual Health Symposium, Greenville, North Carolina. 
 
Tate, T.T., Hinton, Q.S. (2013, October). Preparing service members for the civilian workforce: A test 
review of the Military-to-Career Transition Inventory (MCTI). Poster session at the state conference of 
the 1st Annual Military and Trauma Counseling Conference, Greenville, North Carolina. 
 
Harris, J.D., Hinton, Q.S. (2013, September). Fitness and recovery. Poster at the Pitt County Coalition on 






ECU Navigate Counseling Clinic Greenville, NC 
Clinician – II & Clinic Coordinator August 2014 – December 2015, May 2017 – August 2017 
Clinician – I (master’s level practicum) August 2013 – December 2013 
 
ECU Center for Counseling and Student Development Greenville, NC 
Brief Alcohol Screening and Intervention for College Students (BASICS) Counselor September 2016 
– April 2017 
  
168 
ECU Beginnings – Pregnancy and Recovery Clinic (PARC) Greenville, NC 
Group Leader & Perinatal Educator August 2014 – July 2015, May 2016 – August 2016 
Group Co-leader (master’s level practicum/internship) August 2013 – July 2014 
 
ECU Physicians – Division of Infectious Diseases and International Travel Health  Greenville, NC 
Behavioral Health Specialist (master’s level internship) January 2014 – July 2014 
 
ECU Career Center Greenville, NC 




ECU Department of Addictions and Rehabilitation Studies (DARS) Greenville, NC 




Teaching Assistant Fall 2017 
ECU ADRE 2003 (undergraduate level) Alcohol and Drug Abuse: Health and Social Problems 
 
Teaching Assistant Fall 2017 
ECU ADRE 4796 (undergraduate level) Contemporary Issues for Addictions 
 
Teaching Assistant Fall 2017 
ECU ADRE 6796 (master’s level) Contemporary Issues for Addictions 
 
Guest Lecture, Applications of the Barriers to Employment Success Inventory April 2016 
ECU ADRE 6401 (master’s level) Assessment in Clinical, Addictions, and Rehabilitation Counseling 
 
Guest Lecture, Finding Your Balance July 2015 
ECU ADRE 6010 (master’s level) Introduction to Clinical, Addictions, and Rehabilitation Counseling 
 
Guest Lecture, Ethical Issues in Community Work June 2015 
ECU ADRE 6050 (master’s level) Ethics and Legal Aspects in Clinical, Addictions, and Rehabilitation 
Counseling 
 
Guest Lecture, Values and the Helping Relationship June 2015 
ECU ADRE 6050 (master’s level) Ethics and Legal Aspects in Clinical, Addictions, and Rehabilitation 
Counseling 
 
Guest Lecture, Family Mapping February 2015, October 2014 
ECU ADRE 6320 (master’s level) Family Treatment in Substance Abuse Rehabilitation  
 
Guest Lecture, Beyond the Initial Interview November 2014 





ECU DARS  Greenville, NC 
CACREP Accreditation Committee September 2015 – present 
 
ECU DARS & Division of Infectious Diseases and International Travel Health Greenville, NC 
Motivational Interviewing Research Assistant August 2014 – August 2015 
 
ECU College STAR Greenville, NC 
Research Assistant, Graduate Assistantship May 2014 – July 2014 
 
ECU Beginnings – Pregnancy and Recovery Clinic (PARC) Greenville, NC 




Pitt County Coalition on Substance Abuse February 2014 – November 2017 
Executive Board Secretary, April 2016 – November 2017 
Student Board Member, February 2014 – April 2016 
 
Licensed Professional Counselors Association of North Carolina January 2017 – October 2017 
Graduate Student Representative, January 2017 – October 2017 
 
Professional Association of Rehabilitation Counselors March 2016 – March 2017 
Division President – General Counselors 
 
Chi Sigma Iota International Honor Society February 2013 – January 2017 
President, March 2013 – April 2014 
 
Student Addictions and Rehabilitation Association August 2012 – May 2014 
President, May 2013 – May 2014 
Social Committee Co-Chair, August 2012 – April 2013 
 
The College of Allied Health Sciences Student Leaders Council February 2013 – May 2013 
Department of Addictions and Rehabilitation Studies Student Representative 
 
ADDITIONAL WORK EXPERIENCE 
 
ECU Walter and Marie Williams STEPP Program Greenville, NC 
Biology Tutor, Graduate Assistantship August 2014 – December 2014 
Mentor and Academic Support, Graduate Assistantship August 2013 – May 2014 
 
ECU Department of Health Services and Information Management Greenville, NC 
Graduate Assistantship January 2013 – August 2013 
 
ECU Department of Athletics/Office of Student Development Greenville, NC 
Graduate Assistantship August 2012 – July 2013 
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HONORS & AWARDS 
 
American Counseling Association 2016-2017 Graduate Student Ethics Competition – Third Place 
Team Winner at the Doctoral Level  
 
Licensed Professional Counselors Association of North Carolina’s Nancy Howell Scholarship 
Award – Doctorate recipient for the 2016 award year 
 
UNC Campus Scholarship for Doctoral Students – Awarded for 2016-2017 & 2017-2018 academic 
years 
 
ECU DARS Doctoral Student Stipend and Financial Assistance Package – Awarded for 2014-2015, 
2015-2016, & 2016-2017 academic years 
 
Elizabeth “Beth” Lambeth Memorial Scholarship – Awarded for the 2013-2014 academic year 
 
PROFESSIONAL MEMBERSHIPS AND AFFILIATIONS 
 
Collegiate Recovery Community Ally September 2015 – Present 
 
Licensed Professional Counselor Association of North Carolina – Student Member September 2014 – 
Present 
 
American Counseling Association – Student Member August 2012 – Present 
 
American Mental Health Counseling Association – Student Member July 2016 – July 2017 
 
Professional Association of Rehabilitation Counselors – Student Member March 2016 – March 2017 
 
RELEVANT TRAININGS  
 
North Carolina Intervention (NCI) – A Training July 2016 
 
Mental Health First Aid October 2014 
 
Rapid HIV & Hepatitis Testing Training March 2014 
 
Rethink: Psychiatric Illness Training  November 2013 
 
HIPAA, Bloodborne Pathogens, and Tuberculosis Trainings August 2013 
 
Stewards of Children Child Sexual Abuse Recognition, Response & Prevention Training June 2013 
 
REAL Crisis Center Volunteer Crisis Counselor Training October 2012 
 
